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Abstract 
 
 Retinal diseases are personally debilitating and expensive, yet many early disease 
mechanisms leading to their onset and progression remain poorly understood. The 
harlequin mouse is a model of human mitochondrial dysfunction and parainflammation 
leading to subsequent cerebellar and retinal degeneration. Diagnosis of retinal 
degeneration can be tracked in vivo and is associated with AIF dysfunction. Here, retinal 
dysfunction in the harlequin mouse was first quantified using electroretinography 
followed by assay of blood-retinal-barrier integrity and transcriptome alterations in young 
adulthood. Nonmetric multidimensional scaling of oscillatory potentials provided a 
novel, comprehensive assessment of inner-retinal health and can detect shifts in OP 
parameters. Barrier integrity ruled out confounding exogenous antigens and confirmed an 
endogenous source of retinal tissue malfunction. In addition, transcriptome alterations 
support the necessity of the hq retina to maintain metabolic demands. Alternative 
metabolism pathways are hypothesized to be important for hq complex I mitochondrial-
dysfunction associated retinal degeneration.  
  
 
Keywords: harlequin, Apoptosis-inducing factor, retinal degeneration, mitochondrial 
dysfunction, electroretinography, oscillatory potentials, nonmetric multidimensional 
scaling, blood retina barrier, Evans Blue, ATP deficiency, quantitative gene expression, 
glycerol metabolism. 
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Chapter 1. Introduction  
1.1 Increased prevalence of neurodegenerative disorders in an increasingly aged 
population 
 Neurodegenerative diseases are characterized by progressive functional deficiencies 
and cell death of neurons resulting in nervous system dysfunction. Medical advances in 
cardiovascular diseases, cancers and other common illnesses have increased human 
longevity and thereby increased prevalence of neurodegenerative disorders.
1
  
Predispositions from familial and environmental risk factors may also play a role in 
neurodegenerative disease onset and progression, however, the highest propensity of 
disease risk occurs with age.
2
 Despite high prevalence and extreme negative 
consequences to quality of life, the causes and early disease mechanisms of such diseases 
remain unknown.  
 In Canada, it is expected that within 25 years the number of seniors will double to 
well over 9.9 million people and surpass the age demographic of  0-14 year olds for the 
first time in Canadian history (Population Projections for Canada, Provinces and 
Territories. 2009-2036).
3
 Common retinal degenerative diseases such as: age-related 
macular degeneration (AMD), diabetic retinopathy (DR) and open-angle glaucoma 
(OAG)  affect well over 1.75 million Canadians and the prevalence of such diseases is 
expected to rise proportionally (CNIB Report, 2009).
4
 These three diseases fall under the 
umbrella term of “vision loss” and have the highest direct healthcare costs of any disease 
in Canada at $8.6 billion annually.
4
 Despite this high level of expenditure, little is known 
about early disease mechanisms and prevention leaving the diseases personally 
debilitating and expensive. Vision research remains critical for increasing the quality of 
2 
 
 
 
life of affected individuals and also for reducing expenditures as the increasingly aged 
population brings alarming financial demands. 
 
1.2 Mechanisms of common retinal degenerative diseases remain unclear  
  As the Canadian population shifts towards an older demographic cohort, the 
prevalence of common retinal degenerative disorders is expected to rise.
4
 These common 
diseases are progressive and require continual and enhanced treatment as the disease 
advances. Retinal degenerative disorders can lead to losses of central, peripheral, and 
even complete vision in the later stages of disease progression.  Unfortunately, disease 
mechanisms and triggers leading to neuronal death are numerous and little is known 
about initiating mechanisms that cause retinal degeneration.  
 Age-related macular degeneration (AMD) is a prevalent retinal degenerative 
disorder affecting over one million Canadians and is the leading cause of irreversible 
blindness in the developed world.
4,5
 AMD begins with the deposition of acellular protein 
and lipid debris, known as drusen, in the space behind the retina around the macula.
6
 The 
macula contains the highest density of cone photoreceptors in the primate eye and is 
responsible for the central vision acuity that we appreciate as human beings.
7
  Excess 
drusen can cause damage to the retina and lead to hypoxia. Hypoxia induces the 
expression of angiogenic cytokines, such as vascular endothelial growth factor (VEGF), 
causing neovascularization in the macula and leading to subsequent central vision loss.
5
  
 Diabetic retinopathy (DR) is the second-most prevalent retinal degenerative 
disorder affecting over 500,000 Canadians.
4
 It is a common complication of diabetes 
caused by hyperglycemia, hypoxia and neovascularization.
8
 The exact mechanisms by 
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which DR causes neovascularization and progressive retinal degeneration remain poorly 
understood.   
 Open-angle glaucoma (OAG) is the third-most prevalent retinal degenerative 
disorder affecting over 250,000 Canadians.
4
 Glaucoma is often caused by an increase in 
intraocular pressure leading to optic neuropathy.
4
 Increases in intraocular pressure caused 
by reduced aqueous humor drainage lead to progressive retinal neuron axon loss, 
particularly along the optic nerve.
9
 Mechanisms that drive retinal cell loss remain 
unknown and lead to peripheral vision loss with no preventative treatment available.
10
 
 The progressive symptoms associated with these common retinal degenerative 
diseases are clearly characterized and various treatments are available in the later 
advancements of the disease. However, early mechanisms and triggers leading to retinal 
degenerative disorders are poorly understood and treatment is only available after cell 
damage has already begun. Therefore, to increase the quality of life, an understanding of 
early disease mechanisms is critical to limit disease onset and progression.        
 
 
1.3 The physiology and anatomy of a healthy retina is complex 
 The retina is one of the most complex structures of the vertebrate eye and a key 
component of the visual pathway (Figure 1.1A). The retina is a light-sensitive tissue that 
lies in the posterior region of the vertebrate eye and is divided into two regions known as 
the neural retinal and retinal pigmented epithelium (RPE) (Figure 1.1B).
7
 These two 
anatomical regions develop from the embryonic forebrain and undergo complex 
differentiation and ultimately function as an outcropping of the central nervous system.
11
 
4 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
Figure 1.1 A cross-section of the mouse eye and retina stained with Hemotoxylin and 
Eosin. (A) A C-cut section of the mouse eye demonstrates similar anatomical features of 
the human eye including the cornea, lens, pupil, iris, retina, scalera and optic nerve. 
Representative wild-type mouse eye adapted from MacPherson (2009).
19
 (B,C) A cross-
section of the mouse retina indicates the distinct retinal cells layers. Light must transverse 
all layers of the retina prior to excitation of the photoreceptors which are positioned in the 
outer segment (OS). The retinal pigment epithelium (RPE) lies at the base of the retina 
and absorbs any stray photons of light not absorbed by photoreceptors. In addition, the 
RPE separates the retina from the posterior choroid and acts as a nutrient shuttle. 
Phototransduction begins in the OS as the electrochemical signal is conveyed through the 
outer nuclear layer (ONL) and synapses through the outer plexiform layer (OPL) onto the 
horizontal cells and bipolar cells of the inner nuclear layer (INL). The electrochemical 
signal is then relayed to the amacrine and ganglion cells of the ganglion cell layer (GCL) 
through the inner plexiform layer (IPL). The electrochemical signal leaves the GCL via 
the optic nerve where it is transmitted to the visual cortex for interpretation.  
 
 
 
 
 
 
 
 
 
  
6 
 
 
 
 The design of the mammalian retina is counter-intuitive in nature because light 
must cross all neural retinal layers prior to the excitation of photoreceptors. Thereby, 
photoreceptors are positioned at the most posterior region of the neural retina, only 
posteriorly superseded by the RPE (Figure 1.1B).
12
 This is due to the fact that the RPE 
continuously supplies nutrients to the highly metabolic photoreceptors.
11
 The RPE is a 
monolayer of pigmented cells that separates the internal choroid from the neural retina 
and acts as a nutrient shuttle, providing a steady stream of 11-cis retinal, glucose, and 
fatty acids from the choroid to the outer segment of the photoreceptors.
13–15
 The RPE also 
plays an essential role in the recycling of all-trans retinal back into 11-cis retinal once it 
has been isomerized by light.
14,13
 The RPE is highly pigmented, containing a high 
proportion of melanin granules that absorb stray photons of light in the retina to enhance 
vision acuity and reduce exposure to light radiation.
7
  In addition, the RPE creates an 
outer blood-retinal-barrier (BRB) through epithelium tight junctions which maintains 
optimal homeostatic conditions for retinal neurons.
15
   
 Anterior to the RPE lies the neural retina composed of six differentiated layers 
(posterior to anterior) (Figure 1.1B,C). The outer segment (OS) contains the familiar rod 
and cone photoreceptors responsible for the initial absorption of light and relay of 
electrochemical signal.
7
  All vertebrate retinas contain both rod and cone photoreceptors 
which differ by their absorption wavelength and cell morphology. Rods are thin, rod-
shaped structures that are highly sensitive to blue-green light (500 nm) and are densely 
packed with the visual surface photopigment rhodopsin. Rods are generally used for low-
light vision (scotopic vision) and make up 95-97% of all photoreceptors in the 
mammalian eye (human 95%).
7,16
  Cones are large, conical structures that are densely 
7 
 
 
 
packed with opsin photopigments and are sensitive to daylight and bright colours 
(photopic vision). Three types of cones with different associated opsin photopigments 
exist in the human retina, each responsible for the absorption of a different wavelength of 
light: red (559 nm), green (431 nm) or blue (419 nm).
16
 This provides the trichromatic 
vision that we appreciate as humans. The inner segment (IS) contains the cell bodies of 
the photoreceptors and is responsible for maintaining metabolism.
16
  In the outer nuclear 
layer (ONL) lie the nuclei of the photoreceptors. The outer plexiform layer (OPL) is a 
thin region of synaptic connections between the photoreceptors and the neural cells of the 
inner nuclear layer (INL). The outer plexiform layer (OPL) is a region densely populated 
with axons from the rod and cone photoreceptors and neurites of bipolar and horizontal 
cells.
11
 Eleven types of human bipolar cells exist in the INL, the most common being 
bipolar cells connecting photoreceptors with ganglion cells through the release of 
glutamate.
11
 Horizontal cells have a large lateral extension across the retina and synapse 
back onto rod and cone photoreceptors in an inhibitory manner.
17
 This provides a level of 
local gain in the retina and allows image processing to begin through inhibiting light-
saturated photoreceptors to prevent scattering of light in the retina.
18
 The INL also 
contains the nuclei of amacrine cells which mediate the effect of the ON-,OFF- bipolar 
cells on ganglion cells through the release of neurotransmitters, glycine and gamma-
aminobutyric acid (GABA).
18
 These mechanisms assist with the early building of images 
in the retina.
7
 Synapsis of bipolar and amacrine with ganglion neurons occurs in the inner 
plexiform layer (IPL). The innermost layer of the retina is the ganglion cell layer (GCL) 
which contains both the axons and nuclei of the ganglion cells and is responsible for 
relaying electrochemical signals to the visual cortex via the optic nerve.  
8 
 
 
 
1.4 Phototransduction is compromised in retinal degeneration  
 Phototransduction is the process in which photons of light excite photopigments in 
the photoreceptor cells to generate an electrical response.
20
 First, light must travel 
through all layers of the retina and will only activate photoreceptors in the field of 
reference.  In rod photoreceptors, rhodopsin is the primary photopigment and is 
covalently linked to the chromophore, 11-cis retinal.
21
 During the absorption of light, 11-
cis retinal is converted to all-trans retinal through photoisomerization.
20
 Conformational 
changes of rhodopsin are capable of activating photoreceptor-specific G-protein, 
transducin.
20
 Transducin stimulates the activity of cGMP phosphodiesterase, resulting in 
a reduction of cytoplasmic cGMP concentration and subsequent closure of cGMP gated 
channels.
22
 Closure of the cGMP channels results in a decrease of Na
+
 and Ca
2+
 influx 
triggering membrane hyperpolarization and reduced release of synaptic neurotransmitter, 
glutamate.
20
 Glutamate is the principal neurotransmitter involved in electrochemical 
transmission in the retina.
7
 Unlike common nerve cell function, photoreceptors release 
glutamate in the dark as Na
+
 and Ca
2+
 flow freely across the phospholipid membrane.
20
 
Upon light stimulus, glutamate release is hindered in photoreceptors and leads to 
subsequent depolarization of bipolar, horizontal and amacrine cells of the INL.
22
 This 
signal is further processed by the GCL before travelling to the visual cortex via the optic 
nerve. Phototransduction occurs in a similar fashion in cone photoreceptors, however, 
opsin proteins vary slightly in their optimal absorption wavelength. Phototransduction is 
imperative to normal retinal function and vision. Common retinal degenerative diseases 
can lead to damage of the photoreceptors and phototransduction pathway by various 
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disease factors including: age, light toxicity, diabetes, hypertension, genetic mutations, 
vitamin A deficiency, angiogenesis, parainflammation and mitochondrial dysfunction.
23,24
  
 
1.5 Neuronal homeostasis is maintained by glial cells of the retina 
 Three types of resident glial cells reside in the retina and are essential for retinal 
function and homeostasis, these include Müller cells, astroglia, and microglia cells. 
Müller cells are the most abundant glia of the retina and provide architectural support 
across all neural layers.
25
 Müller cell bodies sit in the INL and perform a variety of 
functions including: the breakdown of glycogen for anaerobic metabolism,
26
 removal of 
excess neurotransmitters from the subretinal space,
27
 assistance with phagocytosis of 
apoptotic neurons and neuronal debris,
28
 assistance with the formation of the BRB
29
 as 
well as maintaining ionic homeostasis in the retina by recycling K
+
.
30
 Astroglia are the 
supportive glia that originate in the optic nerve head and are subsequently present in the 
GCL.
31,32
 Similar to Müller cells, they assist with the formation of barrier properties by 
vascular endothelial cells,
29,33,34
  the breakdown of glycogen for neuron nutritive 
support,
26
 and regulation of ionic homeostasis
30
 as well as GABA metabolism.
25
 The 
resident macrophage of the retina is the microglial cell. The retina is a region of immune 
privilege protected by the BRB to hinder the movement of pathogens and microbes into 
the highly sensitive neural retina. Microglia cells act as part of the innate immune system 
and partake in immune survelliance
35
, neuronal support
36
 and phagocytosis of cellular 
debris and pathogens.
37
 Under necrotic or apoptotic pathways, cellular debris such as 
ATP, uric acid and other alarmins are released and stimulate the innate immune system.
38
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Microglial cells become activated and elicit an inflammation response to clear cytotoxic 
debris from the retina. Together, these three types of glial cells all play a vital and distinct 
role in the retina to maintain homeostasis and proper retinal function.  
 
1.6 Retinal neurons rely heavily of oxidative phosphorylation for ATP generation 
 Neurons of the retina require high amounts of ATP to maintain ionic potentials 
through the active transport of Na
+
 influx and K
+ 
 efflux by Na
+
K
+
ATPases.
39
 In addition, 
the continuous recycling of neurotransmitters places additional metabolic pressure on the 
cell.
40
 Neurons do not store glycogen and suppress the enzymatic machinery to 
synthesize glycogen and therefore rely on the constant flow of oxygen and glucose from 
the vasculature in order to maintain their high metabolic rate.
41,42
 Dendrites, regions of 
frequent membrane hyperpolarizations/depolarizations and ion mobility, are the most 
energetically consuming region of the neuron. Consistent with their great metabolic rate, 
neurons rely heavily on glucose oxidative phosphorylation (OXPHOS) for ATP 
production.
43–45
 Glial cells, on the other hand, are highly glycolytic. In addition, glia also 
have the ability to store glycogen and convert it to glucose 6-phosphate when glucose 
supply to the retina is diminished.
44
  Glial cells can provide lactate and other metabolites 
to the neurons of the retina via Monocarboxylate transporters (MCT) when glucose 
supply is diminished.
40
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1.7 Nourishment in the retina is maintained by a healthy blood-retinal-barrier  
 Glucose is supplied to the retina through the choroid (located posterior to the RPE) 
and the retinal capillaries.
7
 Glucose must first traverse the epithelial barrier of the RPE 
(outer BRB) or the retinal capillary endothelial vasculature (inner BRB) which controls 
the exchange of metabolites and waste products between the vasculature and neural 
retina.
46
 The inner BRB supplies nutrients and oxygen to the ONL, INL, and GCL, 
whereas the outer BRB is responsible for neuronal support of the inner and outer 
segments of the photoreceptors.
46
 Pericytes surround the endothelial cells and secrete 
angiopoietin 1 to induce tight junction protein expression.
47
 Both the inner and outer 
BRB develop junctional complexes between the vascular endothelial/epithelial cells to 
allow limited movement of ions and solutes into the neural retina.
46,48
 Tight junctions are 
made up of transmembrane proteins known as, claudins, occludin and the junctional 
adhesion molecules which are linked to the cytoskeleton of the adjacent cells.
46
 Tight 
junctions lead to the fusion of two adjacent endothelial or epithelial cells and limit 
intracellular space to reduce diffusion of ions, pathogens, lipids, proteins, reactive oxygen 
species (ROS) and foreign substances into the sensitive neuronal space. Epithelial cells of 
the RPE act as a regulatory interphase between the choroid and outer retina. The basal 
surface of the RPE contains many invaginations to enhance selective transport and 
secretion along the vasculature.
15
 Due to the continual active transport of substrates 
across the RPE and vasculature barrier, cells are highly metabolic and subsequently 
require high levels of ATP to maintain efficient transport. The endothelial/epithelial 
structure of the BRB is considered to be the first line of defence to protect the neural 
retina from invasion of pathogens as they can engulf foreign antigens.
15
 In addition, 
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epithelial cells of the RPE can excrete various cytokines to initiate an inflammatory 
response.
49
 Dysfunctions of the BRB are associated with DR as the dysfunction leads to 
pathological changes such as chronic inflammation and hypoxia triggering retinopathy 
progression.
50,51
 In addition, the outer BRB harbours the choroid vasculature and limits 
neovascularization in the retina. A loss of integrity also leads to AMD and subsequent 
vision loss.  
 
1.8 Electrophysiological examination can assess health of the visual system in vivo 
 Electroretinography can be used to assess the integrity of phototransduction in the 
retina. The electroretinogram (ERG) is a massed, retinal response measured by corneal 
electrodes following a light stimulation. The major components of the ERG include, the 
a-wave and the b-wave with high-frequency oscillations known as oscillatory potentials 
(OP) on the ascending limb of the b-wave (Figure 1.2).
11
 The initial output wave, known 
as the a-wave, is associated with photoreceptor hyperpolarization.
52
 The secondary wave, 
known as the b-wave, is associated with the depolarization of bipolar cells and Müller 
cells.
53
 The exact origin of the oscillatory potentials remains unknown, although they are 
believed to be generated by interactions between amacrine, bipolar and ganglion cells.
54–
56
 Electroretinography can be used to assess the function of both rod- and cone-based 
systems. “Dark-adaptation” of the subject prior to the assay will result in rod 
hyperpolarization following a light stimulus.
57
 “Light-adaptation” of the subject prior to 
the assay will result in hyperpolarization of the cone photoreceptors as the rods will be 
saturated.
57
 Electroretinography performed under scotopic conditions assesses the 
functionality of rod photoreceptors and can be used to examine the inner retinal pathways  
13 
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Figure 1.2. A schematic representation of a trace electroretinogram elicited by a 
healthy, dark-adapted mouse retina following a light stimulus of 30 cd•s/m2 (Flash 
11). All major characteristic components of the electroretinogram are evident. The a-
wave represents the initial hyperpolarization of the photoreceptors and is the initial 
negative deflection. This is followed by the intermediate oscillatory potentials (OP) peaks 
1-4 (OP1, OP2, OP3, OP4) on the ascending limb of the b-wave. It is apparent that early 
OP peaks are correlated with the function of the photoreceptors whereas late OP peaks 
are indicative of ganglion and amacrine negative feedback in the outer retina.
56
 The final 
component, the b-wave, represents the depolarization of the bipolar and Müller cells, and 
is the cumulative response of the retina.  
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and mechanisms rods initiate. Since the mouse retina is composed of well over 97% rods 
58
 ERGs performed under scotopic conditions provide a more general, comprehensive 
analysis of retinal function and health. The ERG provides the only non-invasive, in vivo, 
diagnostic tool that can be used to quantify retinal health by testing functionality of 
photoreceptors and neural cells of the retina. 
 
1.9 Oscillatory potentials can provide early in vivo examination of INL and GCL 
function  
 Oscillatory potentials (OPs) are the low amplitude, high-frequency oscillations that 
are found on the ascending limb of the b-wave.
11
 The exact origin of OPs remains 
unknown and their interpretation remains difficult, however attritional changes are 
associated with diseases of the retina particularly retinopathy and retinal degeneration. 
Early OPs are believed to be associated with the hyperpolarization of the photoreceptors 
and intermediate OPs with action-potential (graded) independent neurons such as 
horizontal cells and bipolar cells.
56
 Later OPs however, are associated with more 
proximal retinal responses, that of action-potential dependent mechanisms of amacrine 
and ganglion cells.
56
 Due to the fact that OPs appear as oscillations on the leading edge of 
the b-wave, it has been suggested that OPs may be the result of neurons with large lateral 
mobility in the IPL i.e. amacrine cells.
54,59
 Additionally, the interplexiform cell which 
spans the OPL and IPL may also generate radial current (feedback) from lateral synapses 
and may be responsible for the oscillations.
54,55
 OPs have been used previously, to study 
the function of the inner retina and have been useful in the diagnosis of a variety of 
progressive retinal eye diseases including; increased intraocular pressure, diabetic  
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retinopathy, retinal vascular occlusions, and retinopathy of prematurity.
59–66
 OPs have 
been useful in the diagnosis of DR prior to any structural cell loss or ocular symptoms in 
both human and animal models.
59,62,65
 Therefore OPs can be used as a versatile, disease 
tracking, diagnostic tool prior to any structural and noticeable changes. 
 There is little consensus on the most appropriate method for extracting oscillatory 
potentials from the ERG. Signal conditioning is the first step that must be performed for 
isolation of OPs from the ERG trace. Current recommendations set by the International 
Society for Clinical Electrophysiology of Vision (ISCEV) suggest a simple band-pass 
filter applied at 75 to 300 Hz to remove any a-wave contribution or high-frequency 
noise.
67
 In mice, these cut-offs discard most of the rod-driven OPs and are therefore 
rarely followed.
68–70
 The most common method of OP isolation involves a pre-
conditioning waveform to remove any photoreceptor contribution
68,71–74
 followed by a 
fifth order Butterworth transformation with a band-pass of 65 to 300 Hz (Figure 2.2).
68–
70,75
 The amplitude and latency of each OP wavelet can be analyzed individually or as a 
sum in the time domain; or through a fast Fourier transform in the frequency domain. 
 The underlying goal of any OP examination is to surmise physiological origins of 
the parameters or to identify a clinically relevant, diagnostic parameter that may infer 
disease mechanisms prior to disease onset.
76
 In the time domain (Figure 2.3), analysis of 
individual OP amplitudes is advantageous because the amplitudes offer implicit 
information about associated retinal regions given retinal layers and signal transduction 
through the retina.
60
 Summed amplitude of all OPs encompasses a full inner retinal 
response of the INL and GCL. Initial latency is a measure of synapsis timing and 
periodicity of the INL/GCL retinal response.
77
 Decreases in both OP summed amplitude 
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and initial latencies have found in retinopathy,
66,78,79
 diabetic retinopathy,
63,65
 and 
glaucoma.
61
 The time domain analysis of OPs contains relevant information in regards to 
individual components and mechanisms occurring in the retina, however until an exact 
understanding of OP generation is established only qualitative interpretations can infer 
disease.  The frequency domain (Figure 2.3) analysis of the extracted OP waveform 
following application of a fast Fourier transform is advantageous because it provides a 
holistic examination of the OP waveform, particularly when signal-to-noise ratio is 
low.
66,76
 In addition, the frequency domain analysis is much more objective as it does not 
require the subjective identification of individual OPs which may become troublesome 
when signal response is low or noise is high.
80
 Since both time- and frequency-domain 
analysis provide distinct information about OP parameters and general health of the 
retina, they were both examined in our investigation to identify an early diagnostic 
feature of retinal degeneration.  
 
1.10 Nonmetric multidimensional scaling as a method for understanding OP 
waveform changes  
 In general, the mammalian ERG contains five OP wavelets existing on the leading 
edge of the b-wave, each with its own characteristic period (latency) and amplitude.
54
  OP 
profiles depend on the intensity of the light stimulus, with increasing intensity leading to 
increased OP amplitude and decreased latency until retinal phototransduction saturation 
occurs.
66,74,78
  Examination of the OPs occurs following a single high-intensity flash and 
subsequent comparisons of latencies and amplitudes of each OP between a disease model 
and a healthy control. In addition, summed OP amplitude is useful for understanding 
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whole retinal response in the time domain.
76,78
 Examination of OPs at a single flash-
intensity has limitations since it may not be useful for understanding complete waveform 
changes across multiple stimuli intensities where disease mechanisms may be evident in 
retinal neurons only activated under low light intensity.  The frequency domain provides 
a much more holistic approach to whole OP waveform interpretation; however, similar to 
the time domain, this approach can only be examined at a single flash intensity to 
examine differences in frequency, power, and energy between a disease model and a 
healthy control.
66,80,81
 
 To understand whole OP waveform changes, a comprehensive nonmetric 
multidimensional scaling (NMDS) of OP parameters across multiple flash intensities can 
be applied. NMDS is a monotonic, numeric, ordination technique that involves spatial 
representation of observed variables to fitted distances.
82–84
 The method involves the 
assignment of derived coordinates for every sample and mandates that rank order may 
not be changed but observed proximities can be adjusted.
82–84
  In this way, many 
variables can be examined for each sample and modelled into a previously selected 
explicit number of axes, provided that the original rank order is not changed.
82
 Stress is a 
measure of how well the ordination fits the observed distances among samples and the 
error associated with modelling.
85
 Stress increases with the number of samples and the 
number of variables fit into the ordination.    
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1.11 Mitochondrial dysfunction is a common theme in retinal degeneration 
 The mitochondrion is the organelle responsible for oxidative phosphorylation 
(OXPHOS). In highly metabolic tissues, the density of mitochondria tends to be much 
higher to keep up with the energetic demands of the cell.
86
 The visual pathway is amongst 
the most energetically demanding processes in the body, as it requires continual 
movement of ions across membranes for maintenance of resting potentials in addition to 
the continual recycling of neurotransmitters.
87,40
  Due to the persistent energetic demands 
of the retina, it has the highest relative oxygen consumption of any tissue in the body, 
necessary to facilitate OXPHOS.
88,89
 Therefore, adequate and consistent delivery of 
oxygen is vital to retinal homeostasis and any deviations can lead to mitochondrial 
dysfunction and subsequent oxidative stress. Mitochondrial dysfunction is a common 
theme in retinal degenerative diseases and has been implicated in AMD, OAG, and DR 
due to oxidative damage of photoreceptors.
90
   
 
1.12 The mouse is a valuable model organism for vision research 
 The use of animal models continues to be vital as an ethical means to investigate 
fundamental biological principles.  Mouse models are amongst the most common due to 
their short life cycle, quick sexual maturity, large litter size, and similar physiological and 
genetic composition to humans.
91
 In addition, isogenic, inbred strains reduce variation 
amongst individuals and allow complex diseases to be studied with smaller sample sizes 
while achieving higher power to detect significant differnces.
11
 Many similarities exist 
between the human and mouse eye; including a large cornea and lens’ as well as 
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analogous retinal nerve layer physiologies and cell types.
92
 The mouse retina is quite 
similar to the human retina with only minor differences in the visual pathway. For 
example, mice have a higher proportion of rod photoreceptors (over 97%)
58
 which makes 
their retinas much more effective in scotopic light. Another major difference is the 
presence of a macula in the human retina. The macula is a dense, cone-rich area in the 
central region of the retina responsible for central vision acuity.
7
 In mice this is replaced 
with a central region of highly concentrated rod photoreceptors.
58
 While humans possess 
three types of cone photoreceptors, mice only have two; green- and blue-sensitive.
7
 This 
property, although a major difference, assists researchers because mouse “dark-adapted” 
experiments can be performed in red-light. While subtle differences do exist between the 
mouse and human retina, common physiologies, genetics and cell types as well as the 
progression of similar diseases make mice an excellent mimic for human retinal disease 
mechanisms and subsequently vision research.
92
 
 
1.13 The harlequin (hq) mouse is a model of mitochondrial dysfunction and 
neurodegenerative disease 
 The harlequin (hq) mouse (X
hq
X
hq
, X
hq
Y or X
hq
X) is a model of mitochondrial 
dysfunction associated with neurodegenerative disease of the retina and cerebellum.
93
 
The term “hq” refers to the hqY genotype unless otherwise specified. Characteristic 
markers of the hq phenotype include; low body mass, a patchy coat, ataxia, low 
subcutaneous fat reserves as well as characteristic retinal and cerebellar degeneration.
93
 
These phenotypic characteristics are the result of a spontaneous proviral insertion into 
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intron 1 of the X-linked Apoptosis-inducing factor (Aif) gene which encodes a 
mitochondrial flavin adenine dinucleotide-dependent oxidoreductase.
94
 Since the proviral 
insertion is in a suspected regulatory region of intron 1, there is an overall global 
downregulation of AIF by nearly 80% in most tissues.
93
 
 As described previously, AIF is located on the human X-chromosome in the Xq25-
26 region.
94
 The gene is syntenic in the mouse and is also located on the X-chromosome 
in the A6 region.
94
 The AIF amino acid sequence is highly conserved in both organisms, 
sharing 92% sequence homology of the active domain as well as an amino-terminal 
mitochondrial-localization sequence.
94
 Upon translocation to the intermembraneous space 
of the mitochondrion, the localization sequence is cleaved leaving a functional 57 kDa 
flavoprotein.
94
 AIF is ubiquitously expressed across most tissues in mice
95
 with 
demonstrated embryonic lethality at day 9 in a complete Aif mouse knockout.
96
 This 
indicates AIF’s vital role in development as well as cell life and death. 
 The function of AIF was first characterized as a mitochondrial bound caspase-
independent death effector protein that translocates to the nucleus and aids with 
chromatin condensation and DNA fragmentation when apoptosis is induced.
94,97
 
However, recent investigations have led to the description of multiple functions of AIF.  
AIF’s primary role in vivo may be linked to OXPHOS efficiency, particularly that of 
NADH dehydrogenase (complex I). Aif-knockdowns have displayed limited formation of 
complex I in vivo indicating its role in maintenance and facilitation of complex I 
formation.
98
 hq mice have an overall decrease in mitochondrial complex I efficiency, 
particularly that of the retina (~30% of normal function) and brain (~60% of normal 
function).
95
 Although Aif causes a decrease in complex I function, no changes in the 
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transcriptome or proteome indicate dysfunction of complex I subunits post-
translationally.
98
 Further analysis of AIF indicates that it shares sequence similarities
94
 
and similar crystal structure
99,100
 with bacterial oxidoreductases and may function as a 
mitochondrial scavenger of free-radicals including ROS. hq mice demonstrate elevated 
oxidative stress in dying neurons of the retina and cerebellum.
93
 However, this function 
of AIF remains controversial because mitochondria isolated from brain of hq mice show 
no traces of increased ROS production as a result of Aif deficiency.
101
  
 
1.14 Timeline of the hq disease progression 
 Since Aif is mapped to the X-chromosome, affected hq males are hemizygous for 
the proviral insertion. Females can either be homozygous or heterozygous for the proviral 
insertion. Homozygous females demonstrate a severe, early-onset disease phenotype, 
similar to that of hemizygous males.
93
 Heterozygous females however, show delayed 
onset, moderate disease progression and moderate disease phenotype,
102,103
 likely due to 
random X-inactivation.   
 The progression of the hq disease (homozygous and hemizygous) is well 
characterized in both the retina and the cerebellum. The hq disease is an ageing-
associated retinal degeneration with primary structural losses occurring as early as three 
months of age in amacrine and ganglion cells.
93
  The progression of the hq disease is 
quite rapid with histological analysis indicating significant losses in the INL and ONL by 
four months of age.
19,93
 Examination of the IPL and OPL in the hq retina indicate losses 
of neurites, particularly that of dendrites.
93
 Functional deficits precede structural losses in 
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the hq retina with electroretinography showing rapid functional deficits in ERG a-wave 
amplitudes at three months and b-wave at two months of age.
19
 By ten months of age, hq  
mice elicit no functional response of the retina.
93
 Physiological changes begin as early as 
1.8 months in the hq  retina, consistent with a loss of homeostasis and activation of 
microglial cells in the IPL
104
. This is indicative of an inflammatory response and may 
contribute to the early structural and functional losses observed. Chronic activation of 
microglial cells continues through hq disease progression and leads to microglial 
migration into the ONL and GCL by four months of age, consistent with cell losses 
observed previously.
93,104
  
 The degeneration of the hq cerebellum occurs with a much slower progression in 
comparison to the retina.
102
  Early histological analysis indicates apoptosis in the hq 
cerebellum as early as four months of age in granule cell nuclei leading to smaller total 
cerebella by seven months.
93,105
 Loss of over 50% of granule cells was observed by 
twelve months of age.
93
 Purkinje cell loss in the hq cerebellum occurs later in comparison 
to granule cell loss initiating at seven months of age.
93,105
 Characteristic markers of 
microglia activation in the hq cerebellum have yet to be tracked in situ. 
 
1.15 Deficiencies in OXPHOS lead to neuronal malfunction and ATP deficiencies   
 It is well established that OXPHOS is the major source of ATP for all cells, in 
particular neuronal cells of the brain and retina. Energetic failure of OXPHOS in 
neuronal cells has been linked with Alzheimer’s disease,106 Parkinson’s disease,107 
Huntington’s disease,108 amyotrophic lateral sclerosis109 and other neurodegenerative 
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disorders. Neuronal cells maintain consistent internal ATP concentrations and minimal 
energy gradients by axonally transporting mitochondria  via microtubules to regions of 
high energy consumption.
110
 The presynaptic compartment of the neuron, responsible for 
neurotransmitter release, is the region of highest energy consumption.
110,111
 High amounts 
of ATP are required for continuous neurotransmitter recycling as well as ion pumping to 
maintain membrane potentials.
111
 Deficiencies in OXPHOS particularly affect the 
presynaptic cleft and other highly metabolic regions leading to neurite loss and synaptic 
degeneration.
111,112
   
 In addition to being “the powerhouse of the cell,” the mitochondrion is also an 
intracellular regulator of calcium. Mitochondrial dysfunction as a result of OXPHOS 
deficiency causes mitochondrial overload of Ca
2+
, leading to
 
opening of the 
mitochondrial permeability transition pore and Ca
2+
 release.
113,114
 This furthers induces 
ATP deficiency, successive glycolytic ATP dependency, reduced mitochondrial mobility, 
release of ROS and subsequent activation of the caspase execution cascade leading to 
apoptosis and cell death in the tissue.
114–116
     
  
1.16 OXPHOS deficiencies in the hq mouse 
 The variability associated with the hq disease phenotype is large, with timing of 
disease onset and progression occurring differently across individuals.
95
 Additionally, the 
effect of the Aif proviral insertion is also not equivalent across tissues of the hq mouse. 
Western blotting reveals that AIF expression in hq mice, in comparison to controls, was 
approximately 20-40% in the cerebellum, spinal cord, cortex, skeletal muscle, and 
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kidney.
95
 AIF reaches almost 60% expression levels in the liver, with minimal to nil 
expression in the retina.
95
  
 In association with decreased AIF expression, compromised OXPHOS efficiency 
was found in all regions of the brain and retina however no OXPHOS deficiency was 
evident in the heart or the liver.
98
 A complete knockout of Aif  in the mouse heart does 
however lead to reduced OXPHOS activity indicating the buffering threshold of the Aif 
knockout may be organ specific.
117
  Tissue specific Aif knockout for liver, muscle and 
heart leads to increased glucose uptake (via glucose transporter 1 and 4) as well as a 
reduction in overall ATP levels and high NADH/NAD+ ratios and lactate production. 
This suggests the switch towards glycolytic metabolism and generation of anaerobic 
ATP.
117,118
 In addition, hq mice demonstrate similar characteristics of increased insulin 
sensitivity and glucose uptake/tolerance with reduced predisposition to obesity on a high 
fat diet.
118
  
 The complete Aif  knockout in embryonic stem cells identifies consistent 
consequences leading to high levels of lactate production.
98
 The addition of 2-D-
deoxyglucose, an inhibitor of glycolysis, increases apoptosis in these Aif-deficient 
embryonic stem cells and indicates high dependency on glycolytic ATP and glucose as a 
primary metabolite.
98
  Taken together, this thorough examination of AIF dysfunction 
indicates a metabolic change towards anaerobic and lactate ATP production in Aif-
deficient cells particularly in tissues of mesodermal and ectodermal origin.  
 The knockout or knockdown of Aif predisposes embryonic stem cells, muscle, liver 
and heart cells to mitochondrial OXPHOS deficiency and reduces overall ATP 
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generation. Aif–deficient cells must compensate and switch their metabolic processes 
towards a glycolytic pathway of ATP production and promote high glucose uptake and 
metabolism. Glycolysis is the conversion of a glucose molecule into pyruvate in a 1:2 
ratio with the reduction of two NAD
+
 molecules to NADH and the net overall production 
of two ATP molecules. The switch to glycolysis allows for ATP production when 
OXPHOS is an inefficient source of energy production and provides the necessary energy 
for metabolic need. Unlike other cell types and tissues, glycolysis is intrinsically 
repressed in neurons and the central nervous system to maintain low oxidative stress.
45,119
 
Therefore they do not  have the ability to increase glycolysis when OXPHOS integrity is 
interrupted.
45
 PFKFB3 enzymatically produces fructose-2,6-bisphosphate (a strong 
glycolytic activator) and is down-regulated in neurons. Its overexpression leads to 
oxidative stress and cell death in vivo.
45
 Since neurons of  the central nervous system rely 
almost completely on OXPHOS-generated ATP, they are highly vulnerable to decreases 
in ATP generation.
120
 In the hq mice, this is evident due to the severe and irreversible 
onset of retinal and cerebellar degeneration.  
 
1.17 Parainflammation is a chronic response in the hq retina 
 Inflammation is the biological response to maintain homeostasis following a 
negative insult in vivo. Inflammation is commonly the product of a tissue injury or 
infection
121
 and solicits the homeostatic response of the innate immune system and the 
adaptive immune system. The recognition of pathogens by the innate immune system 
begins with the specific binding of the pathogen-associated molecular patterns (PAMPs) 
expressed by microbes via Pattern Recognition Receptors (PRP)
122
. Following binding, 
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immune cells (macrophages) are recruited and the pathogen is destroyed and removed. 
The adaptive immune response is triggered for the selection of an antibody to better 
target the pathogen during future insult. In the event of a tissue injury, the innate immune 
system must respond to cellular damage of an endogenous injured cell and therefore 
PRPs are not present. The response to these injuries is facilitated by endogenous 
molecules known as alarmins that are released during non-programmed cell death and 
recruit the innate immune response.
123,124
  One such example is that of architectural 
chromatin protein, High Mobility Group Box 1 (HMGB1).
125
 Under apoptotic conditions 
HMGB1 binds irreversibility to nucleosomes and elicits no immune response, however 
under necrotic conditions HMGB1 is released into the extracellular space and becomes a 
potent activator of inflammation.
125
 
 In addition, alternative endogenous mechanisms beyond necrosis can induce 
inflammation. The formation of advanced glycation end-products (AGEs) begins under 
hyperglycemic or oxidative conditions and catalyzes the interaction of glucose with 
protein amino acids and lipids.
126
 Once formed, they bind with the receptor for advanced 
glycation end-products (RAGEs) which can induce a pro-inflammatory response through 
the secretion of Tumor necrosis factor α (TNF-α) and stimulation of T-cells.126 Under 
oxidative conditions; proteins, lipids and DNA can be oxidized. Lipids are oxidized into 
highly reactive aldehydes which in turn induce macrophage secretion of TNF-α and elicit 
an inflammatory response.
127
 Finally, inflammatory cytokines released by activated 
macrophages can further induce inflammatory responses. Chronic cytokine release by 
macrophages causes further tissue damage and the potential breakdown of blood 
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barriers.
121
 Inflammatory cytokines can alter the functionality of the endothelial/epithelial 
tight junctions leading to barrier degradation.
128
  
 Microglial cells are the resident macrophages of the retina and cerebellum that are 
responsible for the innate immune response during an inflammatory stimulus.
12
 Resting, 
dormant microglia cells generally take on a ramified cellular morphology with many 
protrusions as a means to monitor their microenvironment as well as clearing any 
metabolic waste and tissue debris.
129
 Microglial cells become activated during neuronal 
injury, stress and infection changing their cell morphology to an amoeboid macrophage. 
The surface membrane, G-coupled purinergic membrane receptor P2Y12 can detect small 
changes of ADP and ATP concentrations in the extracellular space released by stressed or 
necrotic neurons and prompts microglial activation.
130
 Activated microglia become 
highly mobile and exhibit strong phagocytic ability and further induce the release of 
cytokines to enhance microglia recruitment to mediate tissue repair.
121
 During healthy 
conditions, this is generally a low-grade tissue adaptive response known as basal 
inflammation. In contrast, chronic activation of microglia cells as a result to neuronal 
stress can lead to a state of parainflammation. Parainflammation is an intermediate 
response between overt-inflammation and non-inflammatory removal of apoptotic 
cells.
121
 Chronic microglial activation is associated with the release of tissue damaging  
ROS, nitric oxide, proteases, and further cytokines causing exaggerated recruitment of 
microglial cells and retinal degeneration.
131
 Parainflammation and chronic microglial 
activation have previously been observed in the hq retina as early as 1.8 months of age as 
a result of AIF downregulation. Chronic microglial activation may be the cause of 
subsequent structural losses in the hq retina. The exact triggers leading to chronic 
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microglial activation has yet to be defined and may be the result of a continuous 
endogenous stress (tissue stress) or the breakdown of a retinal barrier allowing chronic 
influx of exogenous pathogens into the sensitive retinal space (Figure 1.3).  
 
1.18 Central hypothesis  
 I hypothesize that since the hq mouse is hypomorphic for AIF function in oxidative 
phosphorylation, health of the inner retina is compromised without loss of blood-retinal-
barrier integrity and evidence of compensatory ATP production mechanisms exist. 
 
1.19 Experimental Aims 
 The first experimental aim is to determine if electroretinogram oscillatory 
potentials can infer early mechanisms of retinal degeneration, particularly operational in 
the inner retina. The use of OPs as a non-invasive diagnostic feature could infer 
physiological changes as well as the health of the inner retina prior to any cell losses. The 
rapid onset of the hemizygous hqY disease leads to functional losses as well as later 
structural losses. OPs have been used to track disease progression prior to any 
symptomatic functional losses in a variety of retinal diseases as OP features infer the 
health of various neural networks in the retina. It is therefore predicted that OPs can be 
used to diagnose early functional changes in the hq retina prior to any structural losses. 
To track and examine disease progression, OP from hq mice were analyzed monthly from 
two months of age to ten months of age. This provides long term disease progression 
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information and functional retinal documentation at a later age. To complement the 
examination of OPs in the severe and rapid disease phenotype, the investigation of the 
heterozygote phenotype can provide valuable information regarding disease progression. 
Female heterozygotes demonstrate a longer timeframe to observe disease mechanisms 
prior to cell death and were examined at three months, eleven months and fifteen months 
of age.   
 The second experimental aim is to assess RPE (outer BRB) and inner retina 
endothelial vasculature barrier (inner BRB) integrity to ascertain the potential for 
exogenous triggers of microglial activation and subsequent retinal degeneration (Figure 
1.3). This examination is instrumental in determining if the metabolic deficiency 
associated with hq neurons compromises the functionality of the highly metabolic RPE 
and inner retina endothelial vasculature barrier. Metabolic deficiency in the hq retina may 
result in the degradation of tight junctions and lead to vascular endothelial/epithelial 
leakage into the sensitive inner retinal space and thereby elicit microglial activation. 
Alternatively, it can be hypothesized that microglial activation in the hq retina is the 
consequence of endogenous photoreceptor and inner retinal neuron cell stress due to ATP 
deficiency triggering chronic microglial activation. To examine the integrity of the BRB, 
injections of Evans Blue followed by a complete vascular perfusion assesses diffusion of 
albumin-bound Evans Blue into the inner retina and potential breakdown of the BRB. 
Two age groups of mice were examined for both wild-type and hq mice: a younger age 
group (< 4 month) prior to ONL losses, and an older age group (> 7 months) 
corresponding to chronic microglial activation at 1.8 months.  It is hypothesized 
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Figure 1.3. Activation of retinal microglia may be the result of blood-retinal-barrier 
breakdown (exogenous) or inner retinal dysfunction (endogenous). (A) Microglia 
activation (ramified to amoeboid) may be a consequence of BRB breakdown causing 
diffusion of harmful exogenous antigens into the sensitive retinal space. Highly metabolic 
epithelial and endothelial cells of the BRB may malfunction due to intracellular ATP 
deficiency. (B) Alternatively, microglia activation may be the result of internal neuronal 
malfunction due to AIF downregulation and ATP deficiency leading to cell stress, 
apoptotic and necrotic conditions thereby inducing parainflammation and chronic 
microglia activation.  
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that microglial activation in the retina is the result of endogenous ATP deficiency leading 
to cellular stress and apoptotic neurons rather than a compromised BRB inducing 
microglial activation.  
 The third and final aim is to confirm retinal transcriptome changes consistent with 
mitochondrial dysfunction and subsequent metabolic disease during the onset and 
progression of hq retinal and cerebellar degeneration. The downregulation and reduced 
expression of AIF leads to alternative metabolism in mesodermal tissues. It was predicted 
that similar compensating mechanisms were expected to transpire in the hq retina and 
cerebellum. Although glycolysis is unlikely to be upregulated in hq neurons, alternative 
pathways of ATP production such as lactate production, glycerol metabolism and glucose 
uptake are predicted to be upregulated. To confirm transcriptome changes consistent with 
alternative metabolism three ages were examined corresponding to disease onset and 
progression (two, three and four months of age).  Since the cerebellum is not as ATP 
demanding as the retina
40
 and histological changes occur later in the hq cerebellum it is 
expected that metabolic changes in the hq mouse are not as evident by four months of 
age.  
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Chapter 2. Materials and Methods 
2.1 Animal care and housing 
The Canadian Council on Animal Care and The Animal Use Subcommittee of 
The University Council on Animal Care approved all protocols prior to the 
commencement of any experimental work (Appendix A). Mice (B6:CBACaA
w-J
/A-
Pcdc8
hq/J
, 97% CBA/CaJ genetic background) [Jackson Laboratories, Bar Harbor, ME] 
were housed at a constant temperature of 21 ± 1
o
C with a relative humidity of 44% to 
60% and a light/dark cycle of 14/10 hours. The mice received a standard diet [PMI 
Foods, St. Louis, MO] and water ad libitum.  
 
2.2 Genotyping of the hq allele 
A tri-primer polymerase chain reaction (PCR) was used to determine the presence 
of the Aif hq allele.
93
 Tissue samples for genotyping were taken as ear-notches when mice 
were approximately 12 days old. DNA was amplified using the Terra
TM
 PCR Direct 
[Clontech, Mountain View, CA] standard protocol. Amplified DNA was subjected to gel 
electrophoresis through a 1.5% agarose gel stained with SYBR
®
 Safe DNA Gel Stain 
[Life Technologies Inc., Burlington, ON]. The presence of a 725 bp amplicon indicated 
the Aif hq disease allele and the presence of a 537 bp amplicon indicated a wild-type Aif 
allele. Female heterozygous mice show both a 537 bp and a 725 bp amplicon. PCR 
primer sequences used for Aif genotyping are provided in Appendix B (Table B.1). 
Reference to the hq phenotype refers to the hqY genotype unless otherwise specified. 
Wild-type (WT) mice refer to male (XY) mice with a functional Aif.  
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2.3 Collection of trace electroretinograms  
 Repeated electroretinogram (ERG) analyses were performed on cohorts of wild-
type mice and hqY mice at two, three, four, five to seven and eight to ten months of age 
to assess retinal function and severe disease progression (Figure 2.1A,B).
132
 Additionally, 
ERG analyses were performed on female carrier mice (hqX) along with an age-matched 
wild-type cohort at three, eleven and fifteen months to assess moderate disease 
progression of the hq carrier disease (Figure 2.1B).
102,103
 Electroretinography was 
performed with a Colordome Stimulator [Diagnosys, Lowell, MA] on both dark-adapted 
(scotopic) eyes through a series of eleven flashes of increasing intensities (0.001 – 25 
cd•m/s2).  
 
2.4 Processing of trace electroretinogram for waveform modelling 
 Original exported ERG trace files contained only data corresponding to parameters 
of the a-wave and b-wave components. A thorough review of the ERG user manual was 
performed and allowed for export of all raw data corresponding oscillatory potential 
components. A macro written into Excel [Microsoft, Redmond, VA] known as 
“MLTRIM” automatically sorted the original trace file into averaged neuronal responses 
for each eye and presented them as µV across all flash intensities.
133
 In addition, 
MLTRIM was used to convert ERG trace data into a format readable by MATLAB [The 
MathWorks, Natick, MA].  
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Figure 2.1.4Experimental design and cohort sizes for oscillatory potential analysis. 
(A) The complete experimental design for the severe disease progression hqY analysis.
132
 
A single mouse may appear multiple times due to repeated measures at multiple ages. (B) 
Repeated measures of the severe disease progression experiment were removed randomly 
to allow study of hqY mice without repetition.  (C) The complete experimental design for 
the moderate disease progression hqX experiment.
103
 No repeated measures were present 
in this study.  
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2.5 Signal conditioning and oscillatory potential waveform extraction  
Scripts (Appendix C, MATLAB Script A,B) were written into MATLAB [The 
MathWorks, Natick, MA] to model and extract relevant oscillatory potential waveforms 
(Figure 2.2).
133
 To limit contribution of photoreceptor hyperpolarization, the a-wave was 
digitally modelled and subtracted from the original trace (Figure 2.2A).
66,68,69,71–74
 
Additional high frequency and low frequency noise were removed by processing the 
waveform through a fifth-order Butterworth filter with a band pass of 65-300 Hz (Figure 
2.2C).
69,70
  Previous literature suggests a lower band pass limit of 40 Hz for 
characterization of mouse rod photoreceptor oscillatory potentials, however 65 Hz was 
chosen to avoid interference by the 60 Hz line noise as previously described.
69,70
 The 
remaining bandwidth made up the final OP waveform, herein known as the “extracted 
waveform”.  
 
2.6 Parameter analysis of the extracted waveform 
The extracted waveform was first analyzed in the time-domain. The amplitude 
(µV), initial latency (ms) and interpeak distance were determined for OP2, OP3, OP4, 
and OP5 (Figure 2.3A). Following waveform extraction, OP1 was typically present, 
however due to inconsistencies OP1 was not included in further analysis. Amplitude of 
each OP was defined as the difference between the trough and the peak immediately 
preceding it (Figure 2.3A). Initial latency was defined as the time from stimulus to the 
onset of OP2 (Figure 2.3A). Interpeak distance was the measurement of time (ms)  
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Figure 2.25Signal conditioning of oscillatory potentials from the ERG trace 
waveform. (A) A digital subtraction of photoreceptor contribution (dashed line) was 
performed by a mathematical fitting and subtraction of the a-wave from the initial ERG 
(solid line). (B) The ERG waveform following complete a-wave digital subtraction. (C) 
The final waveform was passed through a fifth order Butterworth transformation (65-300 
Hz) to remove any low or high frequency noise resulting in the final “OP extracted 
waveform” (solid line).  
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Figure 2.3.6Measurement of individual Oscillatory Potential features in the time-
domain and frequency-domain. (A) Following waveform extraction, measurements of 
OP latency (ms) and amplitude (µV) were taken for OP2, OP3, OP4, and OP5. 
Amplitude of each OP was defined as the difference between the trough and the peak 
immediately preceding it. Initial latency was defined as the time from stimulus to the 
onset of the OP2 peak. Interpeak distance was the measurement of time (ms) between 
adjacent peaks. OP1 was not measured due to inconsistencies and the potential for a-
wave contamination. (B) A fast Fourier transform (FFT) was applied to the extracted OP 
waveform and gave a single-sided smoothed frequency power spectrum (dotted Line). 
The single-sided smoothed frequency power spectrum was fitted to a two-term Gaussian 
envelope (solid line) and measurements of peak power (Ppeak), peak frequency (Fpeak) and 
total energy (waveform integration) were taken.   
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between adjacent peaks (i.e. OP2 and OP3) (Figure 2.3A). Total OP response in the time 
domain was measured as the summation of OP2-OP5 amplitudes. 
 
2.7 Fast Fourier Transformation (FFT) of the extracted waveform 
The frequency spectrum of the extracted waveform was also analyzed by a Fast 
Fourier Transformation (FFT) to provide a holistic frequency waveform interpretation.
54
 
Scripts (Appendix C, MATLAB Script C) written in MATLAB [The MathWorks, Natick, 
MA] performed this operation and converted the frequency-power spectra to a single-
sided smoothed frequency power spectrum. To avoid “powers of two” problems, only the 
first 128 samples of the extracted waveform (contained entire OP waveform) were 
applied to the FFT.
66
 To calibrate the output of the FFT, a sine wave of known periodicity 
and amplitude was subjected to the algorithm. These produced a single peak indicative of 
a properly calibrated FFT algorithm. To avoid the problem known as ‘overspill’ the FFT 
output was fit to a two-term Gaussian envelope with the following equation: 
66,75
  
 ( )  (     )   
 
 (
       
 )
 
  
where P is the power associated with the frequency response (F, Hz). Fpeak is the 
frequency at the peak of the Gaussian envelope, and Ppeak is the corresponding power 
(Figure 2.3B). Major frequency (Fpeak) was determined as the dominant frequency of the 
Gaussian frequency-power spectrum and is related to OP periodicity. S indicates the 
width of the time distribution. The area under the original frequency power spectrum 
(Total energy) was calculated by integration of the original frequency-power spectrum 
(Figure 2.3B).  
44 
 
 
 
2.8 Non-Metric Multidimensional Scaling (NMDS) of oscillatory potential 
parameters  
The longitudinal nature of the hqY study does not allow simple statistical testing 
(Figure 2.1). Approximately five mice were euthanized at the end of each age cohort age 
(2, 3, 4, 5-7, 8-10 respectively) and the attrition associated does not allow the application 
of a simple repeated-measures two-way ANOVA. In addition, OPs contain a wealth of 
information across multiple flash intensities and a comprehensive analysis was pursued 
as described in the introduction. A clustering method known as Non-metric 
Multidimensional Scaling (NMDS) was used in R Statistical Software [R Core Team, 
Vienna, Austria] (Appendix D, NMDS R-code A) to model every variable from each 
respective OP peak at all four flash intensities (Flash 8-11). This resulted in a total of 32 
variables being analyzed in the time domain and 12 variables in the frequency domain 
(Figure 2.4). Each variable was first converted into a z-score using the following 
equation: 
         
   
 
 
where x is each value in the dataset, µ is the mean of the dataset and σ is the standard 
deviation of the dataset. The Euclidean distance between all mice was calculated 
encompassing all variables and a dissimilarity matrix was computed to demonstrate the 
absolute distances between mice.
82
 A NMDS was then applied to model data in a two-
dimensional ordination plot such that rank order matches the order of dissimilarity 
between mice. Stress is indicative of the best rank order of agreement between the 
dissimilarities as well as fitting the data to a monotonic regression (Shepard plot). Lowest  
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Figure 2.4.7Total number of measurements taken from a single mouse across four 
flash intensities. (A) A total of 32 parameters are measured in the time-domain, eight 
measurements for each flash intensity. (B) A total of 12 parameters are measured in the 
frequency-domain, three for each flash intensity.  
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stress was found at the global optima following 100 iterations. Stress below 20% is 
deemed fair.
82
 For NMDS axis interpretation a Pearson’s correlation coefficient was used 
to interpret the axis in relation to various time domain and frequency domain parameters. 
 
2.9 Experimental design for Blood-Retinal-Barrier (BRB) integrity phenotyping 
Male hqY mice and age-matched wild-type controls were selected at two age 
cohorts of two-to-four months of age and seven months of age. The number of mice in 
each cohort was between three and five individuals. Evans Blue dye [Sigma Aldrich, St. 
Louis, MO]  dissolved in 1X Phosphate Buffered Saline (PBS) (50µL) [Santa Cruz 
Biotechnology, Dallas, TX] was intravenously injected over 15 seconds through the tail 
vein at a concentration of 45 mg/kg.
134,135
 Following injection, the dye was allowed to 
circulate through the vasculature for a period of 30 minutes. During this period the mouse 
turned visibly blue particularly in the extremities, confirming the uptake and distribution 
of the dye.
136
 The mouse was then euthanized via CO2
 
inhalation and the chest cavity was 
opened. A transcardial perfusion with 60 mL 1X PBS was performed until all blood was 
removed from the vasculature. Tissue was stored at -80
o
C until further processing.  
 
2.10 Generation of a standard curve to estimate Evans Blue tissue concentrations 
 A standard curve was generated to calculate concentrations of EB in respective 
tissues. Serial dilutions of EB in formamide were made from 10000 ng/mL to 250 ng/mL 
and background-subtracted absorbances (620 nm - 740 nm) measurements were made in 
triplicate. Standards were prepared on different days by three different individuals. 
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2.11 Evans Blue Extravasation 
 Immediately following PBS perfusion, eyes were enucleated and the retinas were 
carefully microdissected away and rinsed with PBS. Liver, cerebellum and cerebrum 
tissue were also harvested and rinsed with PBS. Tissues were flash frozen in liquid 
nitrogen and stored at  -80
o
C until further processing.  
 The wet weight of tissues was determined and they were then homogenized using a 
blunt homogenizer. The approximate weight of a mouse retina was 1 milligram and 
therefore approximately 1 mg of liver tissue was also processed as a technical control. EB 
was extracted from liver and retinal tissue by incubating in 100 µL of formamide [Sigma 
Aldrich, St. Louis, MO] for 24 hours at 75
o
C.
134
 Cellular debris was removed by 
centrifugation at 4000 rpm for 45 minutes. Approximately 1 µL of supernatant was used 
for triplicate spectrophotometric measurements using the NanoDrop ND-1000 
Spectrophotometer [Thermo Scientific, Wilmington, DE]. A background-subtracted 
absorbance was determined with measurements at 620 nm and 740 nm, known 
absorbance maximum and minimums for EB dye.
134
 The concentration of the dye in the 
extracts was determined using the standard curve and was normalized to liver 
concentrations from the same animal to account for technical variation such as albumin 
dye uptake and injection efficiencies. Statistical significance was determined using a two-
way ANOVA.  
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2.12 Examining daily food consumption in the hq mouse 
Four-month-old hqY (n = 4) and age-matched, wild-type (n = 4) mice participated 
in a feeding study to determine average daily food consumption (grams of food 
consumed/ grams of body mass/ day) differences in hq mice. Food intake (mass) and 
mouse mass were measured every-other-day over a two-week period to determine daily 
food consumption. At the end of the two-week period, average daily food consumption 
for each mouse was determined and divided by the mouse mass. Statistical significance 
was determined by a repeated-measures ANOVA.  
 
2.13 Microarray pathway analysis 
 To identify early triggers and mechanisms of retinal degeneration, gene expression 
microarray [Affymetrix, Mouse Gene 1.0 ST Array, Santa Clara] data were analyzed 
extensively. The microarray data were obtained by Alex Laliberté with 4-month-old hq 
and age-matched wild-type mice.
103
 To determine early mechanisms of retinal 
degeneration selection criterion were set; at a significant change of p < 0.05 and a 
threshold fold change (mRNA transcript level) of at least ± 1.75. Canonical pathway 
analysis was performed using KEGG Pathway Analysis [Kyoto University, Kyoto, Japan] 
and Ingenuity Pathway Analysis [Ingenuity Systems Inc., Redwood City, CA]. A 
thorough literature review of Aif function complemented this pathway analysis and 
indicated a loss of Aif function leads to increased glucose metabolism, lactate 
metabolism, as well as glycerol and fatty acid metabolism.
98
 Due to the specific nature of 
retinal degeneration markers and multiple genetic isoforms used in the retina, gene 
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ontology databases did not provide a thorough review of microarray data. Therefore 
grouping and annotation of differentially-expressed genes was performed manually and 
based on extensive literature survey on above pathways in NCBI [National Institute of 
Health, Bethesda, MD] (Appendix E). Multiple genes (>1.75 fold change, p < 0.05) from 
each above stated pathway were selected for confirmation of transcriptome changes via 
quantitative PCR (qPCR).  
 
2.14 Tissue harvest for gene expression assays  
Cohorts of hqY mice aged two-, three-, and four-months of age and age-matched 
wild-type mice (n = 5 per cohort) were euthanized via CO2 inhalation according to 
Animal use Protocol (AUP) 2009-033 (Appendix A). Eyes were enucleated and retinas 
were microdissected and cleaned with 1X PBS in an RNase-free environment. 
Cerebellum, cerebrum and liver tissues were also harvested. Extracted retinas and 
cerebella were flash frozen in liquid nitrogen and stored at -80
o
C. All tools involved in 
microdissection were baked overnight at 200
o
C or treated with RNaseZAP [Sigma 
Aldrich, St. Louis, MI] to ensure an RNase-free environment and RNA integrity.  
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2.15 Retinal RNA extraction 
Retinal samples (~1 mg) were homogenized and lysed using a sand 
homogenization protocol as previously described.
137
 Ottawa Sand (20-30 mesh) [Fisher 
Scientific, Fair Lawn, NJ] was rinsed through multiple, serial washes of ddH2O, 0.5M 
NaOH and 0.5M HCl and baked overnight at 200
o
C. Following homogenization, RNA 
was isolated using the Qiagen
®
 RNeasy Mini Spin Columns Kit [Qiagen Canada Inc., 
Montreal, QC]. This included binding of total RNA to a silica membrane within the spin-
column. A series of subsequent RPE
®
 and RW1
®
 washes were performed to clean the 
RNA and increase efficacy of RNA binding to the silica column membrane. An on-
column Qiagen
®
 RNase-Free DNase [Qiagen Canada Inc., Montreal, QC] step was 
performed to remove genomic DNA (gDNA) contamination. RNA was resuspended in 
nuclease-free ddH2O and stored at -80
o
C.  
 
2.16 Cerebellar RNA extraction  
Cerebellar samples (30 mg) were lysed with Qiazol
®
 Lysis Buffer [Qiagen 
Canada Inc., Montreal, QC] and were homogenized by 20 strokes in a 7 mL Type A 
Glass Dounce Homogenizer [Wheaton Science Products, Millville, NJ]. Following 
homogenization, total RNA was isolated using the standard protocol for the Qiagen
®
 
RNeasy Mini Spin Column Kit [Qiagen Canada Inc., Montreal, QC] as described above. 
An additional on-column RNase-Free DNase step was added and RNA was resuspended 
in nuclease-free ddH2O and stored at -80
o
C.  
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2.17 Assessment of RNA purity and quality 
Retinal and cerebellar RNA quality was first assessed with a NanoDrop ND-1000 
Spectrophotometer [Thermo Scientific, Wilmington, DE] to determine A260/A280 ratios 
(>1.9). Cerebellar samples were then subjected to gel electrophoresis and electrophoresed 
through a 1.5% agarose gel to determine the presence, integrity and ratios of the 18S and 
28S rRNA subunits. This quality assurance stage was not performed with the retinal 
samples as the total amount of RNA isolated was considerably lower and not sufficient to 
perform gel electrophoresis. However, to ensure RNA purity, both cerebellar and retinal 
samples (1 µL) were assessed with the Agilent 2100 Bioanalyzer [Agilent Technologies 
Inc., Palo Alto, CA] to determine RNA integrity (RNA Integrity Number - RIN > 8). 
 
2.18 cDNA synthesis 
Mouse retinal RNA samples were selected for single-stranded, complementary 
DNA (cDNA) synthesis from concentrations ranging from 15 ng/µL to 72 ng/µL. Mouse 
cerebellar samples were selected for cDNA synthesis from concentrations ranging from 
84 ng/µL to 354 ng/µL. In each age cohort, the lowest concentration was selected as the 
rate-limiting sample, indicating the highest total RNA (µg) that could be added to the 
cDNA synthesis reaction based on the final volume of 16 µL. cDNA synthesis was 
performed using the Superscript
®
 VILO
TM
 cDNA Synthesis Kit [Life Technologies, 
Burlington, ON] and its associated standard protocol. A negative control did not contain 
any RNA and ddH2O was used as a substitute. Following synthesis, cDNA was diluted to 
100 µL to increase downstream throughput and stored at -20
o
C.   
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2.19 Taqman
®
 gene expression experimental design 
 qPCR was performed using Taqman
®
 probes [Life Technologies, Burlington, ON]. 
Probes that spanned exon junctions were selected to avoid the possibility of false 
amplification due to gDNA contamination. Genes were assayed in a block design for 
each age cohort (Appendix B, Figure B.1). Each gene of interest was assayed in three 
technical replicates including triplicate No-Template Controls (NTC). Biological 
replicates were assayed in parallel to avoid the possibility of additional technical 
variation (n = 4). For each reaction; 5µL of Taqman
®
 Fast Advanced MasterMix [Life 
Technologies, Burlington, ON], 0.5 µL of Taqman
®
 probes [Life Technologies, 
Burlington, ON], 2.5 µL of nuclease free water and 2 µL of cDNA were added to a final 
volume of 10 µL per reaction well. The assay was performed using the ViiA
TM
 7 Real-
Time PCR System [Life Technologies, Burlington, ON]. qPCR cycling conditions began 
with a 2 minute hold at 50
o
C for Uracil N Glycosylase incubation, a 20 second hold at 
95
o
C for complete cDNA denaturation, followed by 40 cycles of 1 second at 95
o
C for 
denaturation and 20 seconds at 60
o
C for primer annealing and polymerase extension. 
Two reference genes, 18S Ribosomal RNA (Rn18s) and Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) were selected as normalizer genes due to their documented high 
and consistent expression levels in all tissues.
138,139
 Rn18s was selected to ensure 
expression of Gapdh was consistently expressed between hq and wild-type mice. Upon 
confirmation of high, consistent uniform expression of Gapdh across genotypes, Gapdh 
was selected as the primary normalizer. Aif was assayed across all cohorts to ensure a 
downregulation in hq mouse retina and cerebellum.  
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2.20 Statistical analysis of Taqman
®
 gene expression changes 
 The ΔΔCt relative quantification method was used to determine fold-changes 
across genotypes.
140
 ΔCt values were determined as the difference between the measured 
average amplification cycle of the gene of interest and the average amplification cycle of 
Gapdh. Significance was determined with a one-way ANOVA in Excel [Microsoft, 
Redmond, VA] comparing ΔCt values between hq and wild-type mice in each cohort.  To 
calculate fold-change the hq ΔCt values were subtracted from wild-type ΔCt values to 
yield a ΔΔCt value which was then input in to the following equation to determine fold 
change: 
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Chapter 3. Results  
3.1 Mouse phenotyping and Aif PCR genotyping confirmed the presence or 
absence of an Aif proviral insertion 
 Characteristic phenotypic hq markers such as a patchy coat, ataxia and low body 
mass were consistently observed among X
hq
X
hq
 and X
hq
Y mice. Genotypes of mice used 
in this study were confirmed by PCR using the tri-primer method. A 725 bp amplicon 
indicated the presence of an Aif hemizygous males (hqY)  proviral insertion whereas the 
presence of a 537 bp amplicon indicated a wild-type Aif allele (Figure 3.1).  Female 
heterozygotes (hqX) showed amplification of both 537 bp and 725 bp amplicons (Figure 
3.1).  
 
3.2 hqY mice show longer latency as early as three months and progressive 
decreases in OP summed amplitude  following a 10 cd•s/m2 stimulus 
 Time-domain analysis of ERG OPs revealed no early (two month) delays of initial 
OP latency in hq disease mice when compared to the wild-type mice (Figure 3.2A). 
However, by three months of age hq mice demonstrate a significant delay (p = 0.005, 
Figure 3.2A) of initial OP latency by 24.6%. This is indicative of neural retinal feedback 
delay between the photoreceptors, INL and GCL of the retina. The trend of OP delayed 
response continues at four months and is significantly delayed at five to seven months (p 
= 0.0115, Figure 3.2A). Summed OP amplitudes demonstrated no significant changes at 
two or three months of age in the hq mice indicating normal INL and GCL function  
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Figure 3.1.8PCR amplification confirmed Aif genotype. Aif genotyping PCR 
amplicons were electrophoresed through a 1.5% agarose gel and stained with SYBR
®
 
Safe DNA Gel Stain (Invitrogen, Burlington, ON). A 100 bp DNA ladder (FroggiaBio 
Inc, Toronto, ON) was used as a size standard (STD) to estimate amplicon size. A single 
537 bp amplicon indicated a wild-type Aif allele (XY) while a single 725 bp amplicon 
indicated the presence of an Aif proviral insertion.
93
 Heterozygote, hq carriers 
demonstrated the presence of both 537 bp and 725 bp amplicons. A no DNA control 
(NC) was created with water prior to amplification and added to the PCR mastermix to 
eliminate the possibility of a false positive.    
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(Figure 3.2B). However by four months of age, a significant deterioration of summed OP 
amplitudes (p = 0.0222) by 26.5% occurred in hq mice resulting in reduced INL and GCL 
function (Figure 3.2B). The largest effect on summed OP amplitudes occurred at five to 
seven months with a significant reduction (p = 0.003, Figure 3.2B) by 54.4%. No 
statistical conclusions can be made about initial OP latency or summed OP amplitudes at 
eight to ten months of age as the hq cohort only contains two mice, although general 
trends appear to continue (Figure 3.2A,B).  
  
3.3 Frequency-domain analysis of ERG OPs show early frequency changes in hqY 
disease mice followed by later changes in OP power and energy (10 cd•s/m2 -
stimulus) 
 hqY OP frequency demonstrated early, two-month changes with a significant 
reduction  by nearly 14% in comparison to the wild type. Significant reductions were also 
present at three (p = 0.0015, 26.6%) and four months (p = 0.0248, 25.9%) of age (Figure 
3.3A). This is indicative of delayed periodicity and reduced neural feedback mechanisms. 
hqY overall OP power showed no early significant changes at two, three, or four months 
in comparison to the wild type (Figure 3.3B). This indicated adequate uniform retinal 
response of the INL and GCL of the hq mice. However by five to seven months of age, 
overall OP power demonstrated a significant reduction (p = 0.0028) by nearly 54.5% in 
comparison to the wild type (Figure 3.3B). Total OP waveform energy, indicative of total 
retinal INL, GCL and retinal response across the entire retina, demonstrated no early 
changes at two or three months of age in hqY mice (Figure 3.3C). A significant decline  
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Figure 3.2.9Electroretinography demonstrates delayed retinal responses and 
decreases in initial OP latency followed by subsequent reductions in summed OP 
amplitudes in the hq retina following a 10 cd•s/m2 stimulus. (A) Initial latency of OP2 
indicates the functional response of the INL and GCL cells to photoreceptor 
hyperpolarization. Delayed initial latency of OP2 is evident at three months in hq mice 
with a significant delay of nearly 24.6% in comparison to the wild type. The delay in hq 
initial OP response is also evident at five to seven months with an overall delay by 
30.8%. (B)  Summed amplitude is indicative of the overall retinal response and continuity 
of neural feedback of the INL and GCL. Significant reductions in hq OP summed 
amplitude are first apparent at four months of age resulting in an overall reduction by 
nearly 26.5%. In five-to-seven-month-old hq mice, the disease reduces summed OP 
amplitudes by 54.5%. The effect of age on genotype was also examined for all measured 
variables (data not shown, Appendix B, Table B.6A) Sample size per cohort can be found 
in Figure 2.1B. Asterisks indicate statistical significance (* p < 0.05, ** p < 0.005) and 
error bars represent ± 1 standard error of the mean.    
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Figure 3.3.10hqY mice have changes in OP waveform frequency as early as two 
months of age, followed by subsequent reductions of OP power and energy following 
stimulus of 10 cd•s/m2. (A) Significant OP frequency reductions were evident 
immediately at two months of age with a 14% decline in comparison to the wild type. OP 
frequency continued to decline in hqY mice at 3 (26.6% reduction) and four months 
(25.9% reduction) of age in comparison to the wild type. This was indicative of a 
prolonged INL and GCL periodicity. (B) OP power is a measure of uniform retinal 
response of the INL and GCL. OP power showed a significant reduction of 54.5% by five 
to seven months in hq mice and continued to decline until eight to ten months. (C) OP 
energy is the summation of total OP retinal energy and was not significantly different at 
two or three months of age in hq mice. However, by four months of age hq mice show a 
significant reduction of OP energy by nearly 28.3% which progresses to a nearly 52.3% 
reduction by five to seven months of age. This indicates progressive disease in the hq 
retina particularly in the INL and GCL response. The effect of age on genotype was also 
examined for all measured variables (data not shown, Appendix B, Table B.6B)  Sample 
size per cohort can be found in Figure 2.1B. Asterisks indicate statistical significance     
(* p < 0.05, ** p < 0.005) and error bars represent ± 1 standard error of the mean. 
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(p = 0.029) is evident at four months of age resulting in a 28.3% reduction of OP energy 
(Figure 3.3C). The decline in OP energy continues as the hq disease progresses and by 
five to seven months an overall significant reduction (p = 0.0006) by 52.3% is apparent 
(Figure 3.3C). No statistical conclusions can be made about OP frequency, power or total 
energy at eight to ten months of age as the hq cohort only contains two mice, although 
general trends appear to continue (Figure 3.3A, B,C).   
 
 
3.4 Time-domain analysis of OPs indicate decreased summed amplitude in hq 
carrier mice as early as eleven months of age following a 10 cd•s/m 2 stimulus 
 Initial latency of OP2 revealed no significant changes across all ages of the hqX 
heterozygote when compared to the wild type (Figure 3.4A). Summed amplitude, a 
measure of total inhibitory feedback mechanisms of the INL and GCL demonstrated no 
significant changes at three months when compared to the wild type. In the eleven- 
month cohort, a significant reduction of summed OP amplitude was evident (p = 0.011; 
Figure 3.4B) at nearly 40.6%. Similarly, a significant reduction of 70.9% was observed in 
summed OP amplitudes at fifteen months (p = 0.0341; Figure 3.4B) indicating overall 
INL and GCL dysfunction and progression of the hq disease.  
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Figure 3.4.11OP2-5 summed amplitudes indicates progressive loss of functional 
feedback mechanisms of the hq carrier retina following a 10 cd•s/m2 stimulus. (A) 
Initial latency of OP2 is indicative of the initial neural response between photoreceptors 
and bipolar and horizontal cells of the INL and GCL. Although not statistically 
significant at any age it is apparent that hqX may have a lengthened initial latency in 
comparison to the wild type. (B) Summed amplitude of all OPs is indicative of the health 
of the neural retina and the continuity of feedback mechanisms of the INL and GCL. 
Significance is evident at eleven months of age with a 40.6% reduction in overall 
summed amplitude. INL and GCL function continued to decline as demonstrated by a 
significant reduction of OP summed amplitude by 70.9% at fifteen months. The effect of 
age on genotype was examined for all measured variables (data not shown, Appendix B, 
Table B.6C) Sample size per cohort can be found in Figure 2.1C. Asterisks indicate 
statistical significance (* p < 0.05) and error bars represent ± 1 standard error of the 
mean.    
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3.5 OPs of hq carrier mice indicate early functional periodicity deficits and 
subsequent reductions in retinal response continuity following a 10 cd•s/m 2 
stimulus 
 OP frequency, a measure of response of periodicity and neural feedback 
mechanisms across the INL and GCL, showed early functional deficits in hq carrier mice 
at three months of age (p = 0.049) with an overall reduction of 10.9% (Figure 3.5A). 
However, at eleven and fifteen months of age hq carrier mice showed no significant 
difference in overall OP frequency (Figure 3.5A). Overall power, a measure of uniform 
retinal response, showed no significant changes in hq carrier mice when compared to the 
wild type at three months of age (Figure 3.5B). By eleven months of age, retinal 
continuity in hqX mice is significantly reduced (p = 0.013) by 43.7% and progressive 
decreases lead to a significant (p = 0.0047) 62.9% reduction by fifteen months (Figure 
3.5B). OP total energy, a summation of total retinal response and analogous to OP 
summed amplitude demonstrated no significant differences at both three and eleven 
months of age in the hq carrier mice (Figure 3.5C). A significant difference was observed 
in retinal OP total energy at fifteen months with a significant reduction (p = 0.002) of 
66.3% (Figure 3.5C).   
 
66 
 
 
 
 
 
67 
 
 
 
Figure 3.5.12Frequency-domain OPs expose early functional differences of 
periodicity in three-month-old hq carrier mice and subsequent losses of OP power 
and energy following a stimulus of 10 cd•s/m2. (A) Frequency of OPs is indicative of 
periodicity of feedback inhibitory mechanisms of the INL and GCL. Significance in OP 
frequency response changes in the hq carrier mice at three months, with the hqX mice 
demonstrating a significantly lower OP frequency response. (B) OP Power is a measure 
of uniform retinal response of the INL and GCL. Statistical significance is evident in hq 
carrier mice at eleven months of age with an overall reduction of OP power by 43.7%. 
OP power and INL and GCL function continued to decline in comparison to the wild type 
leading to an overall reduction by 62.9% by fifteen months of age. (C) Energy of the OP 
waveform is the summation of the total OP response and was not statistically significant 
in three- and eleven- month-old hq carrier mice when compared to the wild type. 
However by 15 months of age, OP energy was significantly reduced by 66.3% in hq 
carrier mice indicting the progressive nature of the hq disease on INL and GCL function. 
The effect of age on genotype was also examined for all measured variables (data not 
shown, Appendix B, Table B.6D) Sample size per cohort can be found in Figure 2.1. 
Asterisks indicate statistical significance (* p < 0.05, ** p < 0.005) and error bars 
represent ± 1 standard error of the mean.    
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3.6 NMDS of time-domain hqY OP parameters indicate functional differences in 
OP latencies and amplitudes as early as two months of age  
 The stress associated with modelling all 32 time-domain variables from the severe 
hqY disease progression study into a two-dimensional axis was 11.31%. Pearson’s 
correlation coefficients were used for axis interpretation following NMDS of hqY OP 
time-domain parameters (Appendix B, Table B.2). The x-axis (Coordinate 1) is highly 
correlated to OPs with shorter latencies, particularly initial latencies of OP2 and OP3 at 
all flash intensities (Figure 3.6). The x-axis is also positively correlated with increasing 
OP amplitudes particularly amplitudes of OP4 and OP5 at all flash intensities. The y-axis 
(Coordinate 2) is positively correlated to decreasing OP amplitudes across all flash 
intensities (Figure 3.6). Young hqY and wild-type mice cluster distinctly at two months 
of age with hqY mice demonstrating decreased OP amplitudes in comparison to the wild 
type (Figure 3.6A). Aging of the hqY mice is associated with a sharp decline in OP 
amplitudes and latencies between two and three months of age indicative of reduced INL 
and GCL function (Figure 3.6A). The disease appears to be progressive, leading to 
further reductions of OP latencies and amplitudes as the hqY mice age (Figure 3.6A). 
Inter-animal variation is much higher in the hqY mice, likely due to variation in the 
severity of retinal degeneration occurring in the hqY mice (Figure 3.6A). Wild-type mice 
show little OP amplitude change and slight decreases in OP latencies through time 
(Figure 3.6A).      
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Figure 3.6.13hqY time-domain OP parameters indicate early (two months) losses of 
INL and GCL periodicity and reduced retinal continuity at later ages.  (A) Young 
hqY mice cluster distinctly from young, wild-type mice at two months of age as a result 
of reduced OP amplitudes and OP latencies. Progression of the hq disease leads to 
continued loss of OP amplitude (particularly OP4 and OP5) and latencies across all other 
age groups (months) resulting in severe losses of INL and GCL function. hq retina 
degeneration shows great inter-animal variation. Young, wild-type mice at two months 
demonstrate high OP amplitudes and short OP latency responses indicative of healthy 
retinal responses and have marginal declines from ages two through seven months. By 
eight to ten months, wild-type retinal function begins to decline with delayed OP latency 
and decreasing OP amplitudes. (B) The average coordinates for each cohort were plotted 
to assist with interpretation of NMDS clustering.  Error bars represent ± 1 standard error 
of the mean. Stress is equal to 11.31%.  
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3.7 NMDS of frequency-domain OP parameters reveal distinct clustering of young 
hqY mice associated with decreased OP power, energy and frequency  
 The stress associated with modelling all 12 frequency-domain variables from the 
severe hqY disease progression study into a two-dimensional scale was 5.67%. Pearson’s 
correlation coefficients were used for axis interpretation following NMDS of hqY OP 
frequency-domain parameters (Appendix B, Table B.3). Coordinate 1 is highly correlated 
with decreasing energy and frequency and slightly correlated with decreasing power at all 
flash intensities (Figure 3.7). Coordinate 2 is highly correlated to decreasing power and 
highly correlated to increasing OP frequencies at all flash intensities (Figure 3.7). Wild-
type and hqY mice cluster distinctly at two months of age with hqY mice demonstrating 
immediate lower total OP power, energy and frequency (Figure 3.7A). Distinctive hqY 
clustering continues across all ages with progressive reductions of OP frequency, power 
and energy (Figure 3.7A). Inter-animal variation is much higher in the hqY mice, likely 
due to variation in the severity of retinal degeneration occurring in the hqY mice (Figure 
3.7A). Young, wild-type mice cluster with high OP energy, power and frequency and 
with only marginal reductions in any parameter with age (Figure 3.7A).  
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Figure 3.7.14hqY frequency-domain OP parameters reveal distinct loss of overall 
retinal periodicity and continuity of the INL and GCL response as early as two 
months. (A) Young hqY and wild-type mice cluster distinctly demonstrating an 
immediate reduction in overall OP frequency, power and total energy and loss of retinal 
function. Aging of hqY mice (three-ten months) leads to progressive loss of all 
frequency-domain OP parameters. Severe losses in OP energy and frequency are most 
prominent between two and three months of age in hqY mice. Young, wild-type mice 
(two months) cluster with high OP frequency, power and total energy and have slight age 
related decreases (three to ten months). Progression of aging in wild-type mice shifts 
NMDS parameters similar to that of young hqY mice (two months).  (B) The average 
coordinates for each cohort were plotted to assist with interpretation of NMDS clustering. 
Old wild-type mice cluster similarly with young hq disease mice.  Error bars represent ± 
1 standard error of the mean. Stress is equal to 5.67%. 
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3.8 NMDS of hq heterozygote time-domain parameters expose distinct clustering at 
eleven and fifteen months of age  
 The stress associated with modelling all 32 time-domain variables from the 
moderate hqX disease progression study into a two-dimensional scale was 9.84%. 
Pearson’s correlation coefficients were used for axis interpretation following NMDS 
(Appendix B, Table B.4). The x-axis (Coordinate 1) is highly correlated to short OP 
latencies, particularly of OP2 and OP3 as well as high OP3 and OP4 amplitudes (Figure 
3.8). The y-axis (Coordinate 2) is highly correlated to decreasing OP amplitudes across 
all flash intensities (Figure 3.8). Young hq carrier and wild-type mice (three months) 
cluster together with long OP latencies and intermediate amplitudes (Figure 3.8A). 
However by eleven months, hq mice shift towards decreased OP amplitudes and shorter 
latencies indicative of enhanced periodicity but loss of continuity of neural feedback 
response. By fifteen months of age hq carrier mice demonstrate a large delay in OP 
latencies with small OP amplitudes resulting in overall decreased retinal function (Figure 
3.8A). Aging of wild-type mice (eleven and fifteen months) is associated with marginal 
decreases in OP amplitudes and enhanced OP latencies (Figure 3.8A). 
 
3.9 NMDS of frequency-domain hq carrier mice OP parameters demonstrate 
progressive loss of OP power and energy at eleven and fifteen months  
 The stress associated with modelling all 12 frequency-domain variables from the 
moderate hqX disease progression study into a two-dimensional scale was 3.84%. 
Pearson’s correlation coefficients were used for axis interpretation following NMDS of  
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Figure 3.8.15hq carrier time-domain OP parameters demonstrates distinct 
clustering at 11 and fifteen months associated reduced initial INL/GCL response 
and decreased continuity of overall retinal response. (A) Young hq carrier and wild-
type mice cluster similarly with reduced OP initial latency and intermediate amplitudes at 
three months of age. This is indicative of reduced photoreceptor and INL and GCL 
periodicity and continuity of INL and GCL function at a young age. By eleven months of 
age, hq carrier mice demonstrate distinct clustering associated with delayed initial OP 
latency and a reduction in OP amplitudes when compared to age-matched wild type. As 
the hq disease progresses, further reductions are evident in both OP initial latency and 
amplitudes at fifteen months and as a result of incomplete retinal function. Aging of wild-
type mice is associated with marginal decreases in OP amplitude and increases in OP 
latencies and ultimately little change in retinal function. (B) The average coordinates of 
each age cohort were plotted to assist with interpretation of NMDS clustering. Error bars 
represent ± 1 standard error of the mean. Stress is equal to 9.84%. 
 
 
 
 
 
 
 
77 
 
 
 
 
78 
 
 
 
Figure 3.9.16Frequency-domain OP parameters of hq carrier mice indicates distinct 
clustering associated with INL and GCL dysfunction at eleven and fifteen months. 
(A) Young (three months) hqX and wild-type mice cluster similarly based upon high OP 
power and energy and low frequency. hq disease progression at eleven months is 
indicative of large reductions in total OP power and energy as well as increased OP 
frequency. Further reductions of OP power and energy are evident at fifteen months with 
additional reduced OP frequency. Aging of wild-type mice is associated with increases in 
OP frequencies and minimal reductions in overall OP total power and energy. (B) The 
average coordinates for each cohort were plotted to assist with interpretation of NMDS 
clustering. Error bars represent ± 1 standard error of the mean. Stress is equal to 3.84%. 
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hqX OP frequency-domain parameters (Appendix B, Table B.5). The x-axis (Coordinate 
1) is highly negatively correlated to both OP total energy and power across all flashes 
while the y-axis (Coordinate 2) is highly positively correlated to frequency across all 
flashes (Figure 3.9).  hq carrier and wild-type mice cluster similarly at three months of 
age with hqX mice demonstrating slightly lower OP frequency, power and energy (Figure 
3.9A). By eleven months of age, hq carrier mice cluster distinctly with higher OP 
frequency and significantly reduced OP power and energy (Figure 3.9A). This general 
trend progresses as hq carrier mice progress to older ages with further reductions in OP 
power and energy indicative of reduced continuity of INL and GCL retinal response 
(Figure 3.9A). Aging of wild-type mice is associated with increases in OP frequency and 
marginal decreases in OP power and energy (Figure 3.9A).  
 
3.10 hq mice maintain blood retinal barrier integrity at both a young and old age  
 To estimate concentrations of the Evans Blue (EB) dye in tissue, a standard curve 
was created through a series of dilutions of EB in formamide. EB dye dissolved in 
formamide maintain a linear relationship between 250 to 10000 ng/mL (Figure 3.10A, r
2
 
= 0.999, y = 7.87 x10
-6
x
 
+ 0.002). The liver is a region of full vascularization and 
therefore no blood endothelial barrier is present. To infer sensitivity of the assay a series 
of tests were performed as described below. Significantly more EB was found in the liver 
of EB injected wild-type mice than in uninjected controls (n = 4 per cohort, One-way 
ANOVA, p < 0.001).  No significant difference in EB amount was found in the retina of 
wild-type mice injected with EB and uninjected wild-type mice (n = 4 per cohort, One-
way ANOVA, p > 0.05) indicating an intact BRB in wild-type mice. In addition, wild-
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type mice show significantly more EB in liver than retina at both a young and old age 
(Figure 3.10 B, n = 4 per cohort, Two-way ANOVA, p < 0.005) but no significant 
reduction with age (Figure 3.10B, n=4 per cohort, Two-way ANVOA, p > 0.05). hq mice 
show a similar trend with significantly more EB in the liver than retina at both ages 
(Figure 3.10 C, Two-way ANOVA, p < 0.005) but no significant reduction with age 
(Figure 3.10C, Two-way ANOVA, p > 0.05). In order to account for technical variation, 
retina EB amount was normalized to liver EB amount and no significant difference in 
retina/liver ratio was found across all cohorts indicating a similar amount of EB is present 
in the retina across all cohorts. This evidence suggests that there is no degradation of the 
BRB in hq mice (Figure 3.10, Two-way ANOVA, p > 0.05).  
 
3.11 Pathway analysis reveals differential expression of focal adhesion, 
extracellular remodeling, cell stress and inflammation in the four-month hq retina 
 Four-month-old hq retinal gene expression microarray data (n=3 per cohort) 
previously performed by A. Laliberté (2010),
103
 was filtered using selection criteria set at 
a 1.75 fold change (mRNA transcript level) and a p-value less than 0.05. This revealed a 
total of 521 genes that were differentially expressed between retinal tissue from hqY 
mice and age-matched wild-type mice. A total of 182 genes were downregulated by 
greater than 1.75 fold, and a total of 339 were upregulated by greater than 1.75 fold. 
KEGG pathway analysis revealed pathways with significant proportions of differentially 
expressed genes. Significant pathways involved in extracellular remodelling, ABC 
transport, immune response, inflammation, cell cycle and p53 signalling were  
 
81 
 
 
 
 
 
82 
 
 
 
Figure 3.10.17hqY mice maintain a blood-retinal-barrier similar to that of age-
matched wild-type mice. (A) Evans Blue standards in formamide maintain a linear 
relationship between concentration and background-subtracted absorbance (r
2
 = 0.999, y 
= 7.87 x10
-6
x
 
+ 0.002). Standards were tested by three different people in triplicate and 
were virtually identical. (B) A significantly higher concentration of Evans Blue dye is 
present in the liver in comparison to retina in wild-type mice at both ages. (C) Similarly, 
a significantly higher concentration of Evans Blue dye is present in the liver of hqY mice 
in comparison to retina across both ages. (D) Liver-normalized retinal Evans Blue 
amount is not significantly different across any cohort indicating an intact blood-retinal 
barrier.   
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differentially expressed  in the hq retina (p < 0.01) (Table 3.1). Additional DNA repair 
and cancer pathways were also differentially expressed (p < 0.05) (Table 3.1).    
 KEGG pathway analysis allowed for a comprehensive overview of differential 
expression in the hq mouse retina. However, due to the nature of KEGG gene annotations 
(not retinal specific) and containing only single genetic isoforms, only 177 gene IDs out 
of the 521 were represented the software analysis. Therefore, well over 65% of genes 
differentially expressed in the expression microarray were not used by KEGG pathway 
software. To account for this bias, a manual annotation of all differentially expressed 
genes was performed (Appendix E). A thorough review yielded an alternative 
metabolism theme, common amongst AIF knock-downs including; the upregulation of 
glucose metabolism, lactate acidosis, and glycerol metabolism. Genes present in these 
pathways were selected for Taqman
®
 qPCR analysis (Table 3.2).  
 
3.12 Cerebellar and retinal RNA quality was assessed prior to transcriptional 
analysis 
 Spectrophotometry, gel electrophoresis and Bioanalyzer spectra all indicated the 
presence of high quality cerebellar RNA. Cerebellar samples were only chosen if they 
indicated a concentration greater than 140 ng/uL and a high absorbance ratio (A260/A280  
> 1.8) (Appendix B, Table B.7). Gel electrophoresis allowed quantification of the 28S 
and 18S ribosomal RNA (rRNA) subunits as well as the potential for gDNA 
contamination. Samples were only selected if they demonstrated distinct rRNA subunits 
with no gDNA contamination (Figure 3.12). Samples were also analyzed via Bioanalyzer 
spectra and selected if there was clear separation of 28S and 18S peaks (Figure 3.13A) 
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Table 3.1. KEGG pathway analysis based on microarray data of differentially 
expressed genes from retinal samples of four-month-old hq disease mice.*
,†
  
Pathway p-value
‡ 
Number of 
Differentially 
Expressed Genes 
Gene Enrichment 
Percentage (%) 
ECM-receptor 
interaction 
6.9 x 10
-6 
13 2.5 
ABC transporters 5.5 x 10
-5 
9 1.8 
Focal Adhesion 1.0 x 10
-4 
18 3.5 
Viral myocarditis 5.5 x 10
-4 
11 2.1 
p53 signaling pathway 4.9 x 10
-3 
8 1.6 
Cell cycle 5.7 x 10
-3 
11 2.1 
Complement and 
coagulation cascades 
7.8 x 10
-3 
8 1.6 
Tight junction 8.2 x 10
-3 
11 2.1 
Regulation of actin 
cytoskeleton 
0.015 14 2.7 
Pathways in cancer 0.02 18 3.5 
Small cell lung cancer 0.046 7 1.4 
* Microarray was performed by A. Laliberté (2010). 
103
 
† 
Pathway analysis was performed with the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) [National Cancer Institute at Frederick, Frederick, 
MD].
141,142
 
‡ Pathway is ordered by increasing p-value.  
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Table 3.2. Genes of interest from four-month-old hq mice selected from retinal 
microarray data for Taqman
®
 validation.  
Gene Name Symbol Function† p-value 
Fold 
Change 
Adenylate cyclase 
10 
Adcy10 
Key intracellular regulation of pH 
and bicarbonate buffering  
0.005 +2.858 
Glycerol-3-
phosphate 
dehydrogenase 2  
Gpd2 
Secondary step of glycerol 
metabolism, feeds into glycolysis  
0.04 +2.377 
Aldehyde 
dehydrogenase 2  
Aldh2 
Primary step for conversion of 
Acetyl-CoA to acetate 
0.045 +2.345 
Glycerol Kinase 5 Gk5 
Primary step of glycerol metabolism, 
feeds into glycolysis 
0.048 +1.998 
TBC1 domain 
family, member 4  
Tbc1d4 
Responsible for shuttling Glut4 to the 
plasma membrane from the 
endoplasmic reticulum  
0.03 +1.992 
Hexokinase 1  Hk1 
Initial step of glycolysis in the retina 
– drives glycolytic rate 
0.037 +1.964 
Glucose 
transporter, 
member 4
‡
  
Glut4  
Rapid, insulin dependent glucose 
transporter responsible for glucose 
intake in neurons 
0.023 +1.4 
Lactate 
dehydrogenase C
‡
  
Ldhc  
Responsible for reverse reaction of 
L-lactate to pyruvate 
0.018 -1.63 
Pyruvate 
dehydrogenase, 
component X  
Pdhx 
Structural component of pyruvate 
dehydrogenase complex  
0.016 -2.482 
Sodium 
bicarbonate 
transporter, 
member 10  
Slc4a10 
Bicarbonate transporter to remove 
excess CO2 from mitochondria 
0.027 -2.873 
Apoptosis-
inducing factor 1  
Aif 
Complex I efficiency and 
maintenance, apoptosis inducer.  
0.0002 -6.012 
† 
 Functional annotation was based on NCBI, GENE search annotation [National Institute 
of Health, Bethesda, MD] 
‡ 
Previous literature suggests increased glucose metabolism and lactate acidosis in hq 
mice, therefore Glut4 and Ldhc (p < 0.05, < 1.75 fold change) were added for 
examination.  
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Figure 3.11.18Agarose gel electrophoresis demonstrates high quality cerebellar 
RNA samples with distinct 28S and 18S ribosomal subunits. A representative gel of 
11 samples indicates the presence of high quality cerebellar RNA (distinct 28S and 18S 
bands) electrophoresed with a 1 kb+ DNA ladder [Life Technologies, Burlington, ON]. 
Sample 925.45 (lane 5) presented contamination with high molecular weight gDNA. A 
negative control of water was electrophoresed in the final lane (lane 13).  
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Figure 3.12.19Electropherograms indicate high RNA quality of both cerebellar and 
retinal samples. (A) A representative electropherogram of intact, high quality cerebellar 
RNA using the Agilent 2100 Bioanalyzer [Agilent Technologies Inc., Palo Alto, CA]. 
RNA quality is a measure of fluorescence (FU) and nucleotide (nt) size. An initial 
fluorescence peak at 25 nt represents a size marker, followed by a clear distinction of the 
18S (~1500 nt) and 28S rRNA subunits (~4000 nt). A representative agarose gel image is 
created (right hand side) based on fluorescence of rRNA peaks.  (B) A representative 
electropherogram of intact, high quality retinal RNA. Fluorescence is much lower due to 
a lower concentration, however a clear separation of the 18S and 28S rRNA subunits is 
still evident. (C) A retinal RNA electropherogram with gDNA contamination. Sheared 
gDNA and degradation products show similar properties to the 28S rRNA subunit and 
lead to skewing of the rRNA peak.  
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as well as an RNA integrity number (RIN) greater than 8.  Retinal samples were subject 
to the same spectrophotometric (concentration  > 16 ng/uL) and Bioanalyzer assessment 
(Figure 3.13B) (Appendix B, Table B.7). Gel electrophoresis was not performed with 
retinal samples as the RNA concentrations were too low. All retinal RNA samples used 
for transcriptome analysis were of high quality.  
 
3.13 Taqman
®
 quantitative PCR confirms metabolic and cell regulation changes in 
the hq mice retina and cerebellum  
 Aif was significantly downregulated (p < 0.001, fold change < 11.312)  in the hq 
retina at four months, three months, and two months (Table 3.3) of age as well as 
significantly (p < 0.001, fold change = -8.8183) downregulated in the four-month hq 
cerebellum (Table 3.4). Cyclin-dependent kinase inhibitor 1A (Cdkn1a), responsible for 
inhibiting cell cycle, was significantly (p < 0.05) upregulated in the hq  retina at four 
months, three months and two months of age (Table 3.3) as well as the four-month 
cerebellum (Table 3.4). Genes associated with metabolism were upregulated in the four-
month hq retina (Table 3.3) including; Adcy10 (p = 0.0013, fold change = +1.7995), 
Slc4a10 (p = 0.0024, fold change = 1.8102), Gk5 (p = 0.0021, fold change = +1.7995), 
Aldh2 (p = 0.017, fold change = +1.660), Gpd2 (p = 0.023, fold change = +1.274) and 
Pdhx (p = 0.027, fold change = +1.250).  No genes involved in metabolism were 
differentially regulated in the three-month hq retina (Table 3.3). However, Gk5 (p = 
0.022, fold change = +1.2688) and Aldh2 (p = 0.0465, fold change = +1.289) were found 
to be differentially expressed early in the two- month hq retina (Table 3.3).  One 
metabolism gene was found to be differentially expressed in the four-month hq 
cerebellum (Table 3.4); Adcy10 (p = 0.0265, fold change = +2.2422). 
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Table 3.3. Differential gene expression of selected genes in the hq retina at two, three 
and four months of age based on Taqman
®
 RT-PCR.
*
 
Gene 
Name 
Two months 
Fold change
‡ 
 (p-value
†
)
 
Three months 
Fold change
‡
  
(p-value
†
)  
 Four months  
Fold change
‡ 
 (p-value
†
) 
Aifm1 - 12.315 (<0.001) - 17.301 (<0.001) - 11.312 (<0.001) 
Adcy10  + 1.7285 (0.0878) + 1.5042 (0.6607) + 1.7995 (0.0013) 
Gk5 + 1.2688 (0.0219) + 1.0664 (0.60) + 1.8102 (0.0021) 
Slc4a10 + 1.1164 (0.1655) + 1.0728 (0.4052) + 1.4990 (0.0024) 
Cdkn1a + 2.2391 (0.0334) + 1.6654 (0.0053) + 3.2214 (0.0063) 
Aldh2 + 1.2889 (0.0465) - 1.0963 (0.5967) + 1.660 (0.017) 
Gpd2  + 1.2586 (0.1036) - 1.106 (0.6446) + 1.274 (0.023) 
Pdhx +1.1222 (0.1319) +1.0285 (0.6297) +1.250 (0.027) 
Hk1 + 1.1442 (0.1780) - 1.007 (0.997) + 1.286 (0.060) 
Rn18s + 1.4432 (0.3058) + 1.0531(0.7299)  + 1.361 (0.270) 
Tbc1d4 + 1.2331 (0.2442) n/a + 1.091 (0.344) 
Glut4  + 3.2467 (0.1107) - 2.8596 (0.3161) - 2.898 (0.832) 
Ldhc  n/a n/a n/a 
* Gene order was established by ascending four month p-value, bold genes indicate 
significance.  
† An ANOVA was used in Excel [Microsoft, Redmond, VA] to determine significance of 
the ΔCt values.   
‡ Fold change was determined with DataAssistTM software [Life Technologies, 
Burlington, ON] using the comparative Ct (ΔΔCt) method.140 
n/a - indicates late amplification.  
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Table 3.4. Differential gene expression of selected genes in the hq cerebellum at four 
months of age based on Taqman
®
 RT-PCR.
*
 
Gene Name p-Value
† 
Fold Change
‡ 
Aifm1 <0.001 - 8.8183 
Cdkn1a  0.0251 + 1.6291 
Adcy10 0.0265 + 2.2422 
Slc4a10 0.1409 + 1.4275 
Tbc1d4 0.1409 + 1.2278 
Glut4 0.1624 + 1.6189 
Gk5 0.1792 + 1.4212 
Pdhx 0.2217 + 1.1763 
Rn18s 0.2776 + 1.3111 
Hk1 0.4030 + 1.1589 
Gpd2 0.4065 + 1.1127 
Aldh2 0.4159 + 1.1105 
Ldhc n/a n/a 
* Gene order was established on ascending p-value, bolded genes indicate significance.  
† An ANOVA was used in Excel [Microsoft, Redmond, VA] to determine significance of 
the ΔCt values.   
‡ Fold change was determined with DataAssistTM software [Life Technologies, 
Burlington, ON] using the comparative Ct (ΔΔCt) method.140 
n/a - indicates late amplification.  
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3.14 hqY mice have a decreased total body mass but display hyperphagia at four 
months  
 The mean body mass of hqY diseased mice at four months (22.422 ± 0.9993g) was 
significantly lower (p < 0.001) than age-matched wild-type mice (29.512 ± 0.5362g) 
(Figure 3.13A) with a 24% reduction in total body mass. Although hqY mice exhibit 
smaller mean body mass, they display hyperphagia at four months with a significant 
increase (p < 0.001) in mean food consumption (0.1991 ± 0.01 grams of food/gram of 
body mass/day)  in comparison to the wild type. This overall increase is nearly 34.4% 
(0.1481 ± 0.002 grams of food/gram of body mass/day) in hqY mice (Figure 3.13B).  
 
 
 
 
 
 
93 
 
 
 
Figure 3.13.20Feeding study indicates hyperphagia in hq mice at four months of age. 
(A) hq mice demonstrate a significantly lower mean body mass in comparison to age-
matched wild-type mice. (B) Mean daily food consumption was significantly higher in hq 
disease mice indicating hyperphagia. Sample size was four per cohort, asterisks indicate 
significance (*p  < 0.001) and error bars represent ± 1 standard error of the mean. 
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Chapter 4. Discussion  
4.1 Early hq retinal dysfunction can be tracked to the inner retina through the 
study of oscillatory potentials   
 Previously, it was shown that OXPHOS dysfunction in the hq retina is associated 
with parainflammatory disease as early as 1.8 months of age, resulting in microglial 
migration to the ONL and subsequent ONL cells losses.
103,104
 To date, early mechanisms 
prompting retinal degeneration in the hq mouse have yet to be elucidated. It was 
predicted that oscillatory potentials could be used to track hq disease progression because 
of their association with hq hallmarks of the retinal disease including degeneration of the 
ONL, IPL, OPL as well as ganglion and amacrine cells. Herein, at the retinal 
physiological level, in vivo diagnosis of electrophysiological response in the hq retina 
was able to identify early, diagnostic candidates of retinal malfunction including OP 
frequency and initial latency. NMDS provided a thorough visualization of OP waveforms 
across multiple flash intensities and identified changes across all measured parameters of 
OP profiles. 
 Due to the highly metabolic nature (continuous transport) of the BRB, it was 
unknown whether the severe neurodegeneration in the hq retina was the result of BRB 
degradation or endogenous retinal stress caused by reduced AIF function. Loss of BRB 
integrity leading to exogenous antigens larger than the Evans Blue albumin complex 
traversing the BRB was rejected as a proposed mechanism for chronic microglial 
activation in the hq retina. Thus, triggers of chronic microglial activation are 
hypothesized to be the result of an endogenous cellular stress mechanism. Early 
transcriptome changes in the hq retina are consistent with partial compensating metabolic 
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mechanisms in an attempt to maintain production of ATP in vivo. Such as, glycerol 
metabolism to generate FADH2  which enters OXPHOS distal to NADH dehydrogenase. 
This study provides the first, in vivo, preliminary evidence for alternative metabolism in 
the retina of the hq mouse and is the basis for subsequent future examinations of hq 
retinal metabolism.     
 
4.2 Oscillatory potentials are relevant for the study of hq retinal degeneration  
 Oscillatory potentials (OPs) are the intermediate peaks on the ascending limb of the 
ERG b-wave. OPs are believed to correspond to inner retinal function of the ON-, OFF- 
and feedback mechanisms of the INL and GCL. OP subgroups, beginning with 
intermediate OPs represent the proximal action-potential independent (bipolar and 
horizontal cell graded potentials) and action-potential dependent mechanisms of ganglion 
cells and amacrine cells of the inner retina (Figure 4.1).
56
 Additionally, the interplexiform 
cell which spans the OPL and IPL may generate radial current flow (feedback) from 
lateral synapses of the OPL and IPL and may be responsible for oscillations.
54,55
 This is 
particularly beneficial for the study of hq retinal degeneration. Neurites of the OPL and 
IPL contain the synapse between dendrites and axons of adjacent neurons relaying 
electrochemical signal from the OS. They are the most energetic region of the neurons 
and hence hq mice exhibit considerable thinning of the neurites
93
 as well as upregulation 
of neurite remodelling and maintenance genes.
103
 These genes include; Sodium channel 
beta 4 subunit (Scn4b), and Sterile alpha motif domain containing 4 (Samd4) both of  
96 
 
 
 
 Figure 4.1.21Isolated oscillatory potentials (OP1-OP5) may correspond to retinal 
layer functionality. OP1 is associated with photoreceptor hyperpolarization (red). 
Intermediate peaks OP2-OP3 are believed to be the response of second-order horizontal 
(blue) and bipolar (purple) action-potential independent (graded) neurons. Subsequent 
late OP peaks are believed to be associated with action-potential dependent amacrine 
(green) and ganglion (orange) cells. Intermediate OP peaks are thereby generally 
associated with INL function and later OP peaks with GCL function. Radial 
electrochemical cycling is the result of feedback mechanism occurring across the IPL of 
the retina.  
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which are involved in maintenance of neurite function and synaptic health.
103
 In addition 
to neurite loss, the first histological hallmarks of retinal degeneration begin at three 
months of age, with retinal thinning of the ganglion and amacrine cells.
93
 Oscillatory 
potentials measure retinal health and signal transduction through the retina and can 
therefore assess the health of both the neurites and the ganglion cells prior to structural 
losses. OPs are capable of detecting early changes as a result of mitochondrial 
dysfunction prior to any functional losses in the hq retina as diagnosed by the ERG a-
wave and b-wave.  
 
4.3 The hqY mouse shows early neuronal functional deficits   
 In the longitudinal study of ERG OPs through the hq disease, OP profiles changed 
in both the time and frequency domain. The initial latency of OPs indicated that 
functional changes began as early as three months of age in hq mice. Simultaneously, 
changes in the major frequency of the OPs began at two months of age in the hq mouse 
and were followed by a steep reduction in OP frequency occurring between two and three 
months of age. Major frequency and initial latency are informative of periodicity and 
likely a response of radial current cycling through the inner retina and therefore are 
indicative of the speed of the graded potential changes in the INL and GCL as a result of 
photoreceptor synapsis leading to depolarization of the bipolar cells. Analysis in the 
frequency domain is advantageous when examining periodicity of OPs because it 
identifies significant changes across hq retina function prior to the time domain.  
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 Significant decreases in OP summed amplitude began at four months of age in the 
hq mouse and continued into later ages with diminished total OP amplitude. Analogous 
changes in the frequency domain demonstrate decreases in total OP energy occurring at 
four months of age. Both the summed amplitude and total energy are indicative of total 
energetic response of the OPs, and therefore the functionality and health of all cells in the 
inner retina. Decreases of both hq OP summed amplitude and total energy are likely due 
to neuronal cell loss of the ONL, INL and GCL as decreasing OP amplitudes have been 
implicated in structural retinal loss.
56
 Summed OP amplitude can therefore be used as a 
measure of overall inner retinal health as previously described in other models.
66,78,79
 
 In the hq  mouse, inner retinal functional deficits as a result of changes in OP 
frequency and latency occur prior to any documented structural losses at four 
months.
19,93,102
 These functional differences occur as early as two months of age and are 
consistent with a neuronal synaptic malfunction and microglial activation at 
complementing ages in the hq retina. The activation of microglial cells and OP functional 
deficits of the inner retina coincide at two months and indicate the loss of homeostasis 
and neuronal synaptic malfunction.  
 
4.4 The hqX mouse demonstrates slower disease progression of the inner retina 
 The hq carrier mouse phenotype displays a moderate, extended disease phenotype 
in comparison to the hemizygous or homozygous disease mice.
93,102,103
 The functionality 
of the inner retina, as measured by OPs of the ERG, demonstrate consistent moderate 
phenotypic results. In fact, no OP initial latency or frequency changes were observed in 
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the hq carrier mice at any age. This is indicative of no periodicity change in the retina of 
the hq carrier mice and sufficient responses of the synapsis between ONL: INL and 
INL:GCL neurons and overall vitality of the ONL photoreceptors. However, decreases in 
both amplitude and analogous energy and power indicate inner retinal cell losses and 
decreases in INL and GCL function at eleven months of age. Retinal thinning in the hq 
carrier retina is not evident until approximately fifteen months when structural losses of 
the INL and ONL occur.
103
 Therefore OPs identify physiological changes of the INL 
(bipolar and amacrine cells) prior to any structural cell loss and reveal a diagnostic 
parameter to assess retinal health before cell death has occurred.   
 
4.5 hqY OP functional losses mimic retinopathy and may help reveal the origin of 
OPs   
 Mammalian retinopathy begins with photoreceptor loss in the ONL. Retinopathy 
leads to hyperoxia in the inner retina caused by oxidative challenges, neovascularization, 
and inflammation.
143,144
 Recent studies, of both human and rat scotopic ERGs have 
demonstrated the functional disease progression of retinopathy and its effect on OPs. 
Retinopathy leads to decreases in all OP amplitudes, particularly that of early OPs, 
indicative of persistent dysfunction of photoreceptors.
66,78
 Deterioration of OP amplitudes 
and total OP energy in hq disease mice indicates similar disease mechanisms to that of 
retinopathy as health of photoreceptors is diminished. 
 Aging has been associated with nuclear losses in the INL and GCL leading to 
compromised retinal function with senescence.
66,145,146
 Aging leads to the progressive 
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loss in OP periodicity (initial latency and frequency) in wild-type rats and humans,
66,146
 
analogous to periodicity changes in the hq retina. The deficits in hq OPs demonstrate 
persistent effects of hypomorphic AIF on retinal function leading to mitochondrial 
dysfunction, photoreceptor cell death, retinal degeneration and an advanced aging 
phenotype. A thorough histological characterization of hq retina neuron losses indicates 
OP are generated in the INL and GCL and are helpful in the investigation of the source of 
OP production in the retina.
102,132
   
 
4.6 Non-metric multidimensional scaling offers a comprehensive visualization of 
inner retinal function with genotype and age 
 The measurement of each OP amplitude and latency in the time domain provided a 
total of eight measurements for each flash intensity (excluding OP1 due to 
inconsistencies and photoreceptor contamination). Four flash intensities (0.63, 4, 10 and 
25 cd •s/m2) were examined as they all contained strong and measureable OP responses. 
Across the four flash intensities 32 measurements were taken in the time domain and 12 
measurements in the frequency domain for each mouse.  
 NMDS computationally-derived coordinates fitted to 32 time-domain variables into 
two dimensions and 12 frequency-domain variables into two dimensions. The stress 
associated with modelling multiple parameters into two dimensions was low across all 
four analyses and demonstrates a valid, comprehensive evaluation of OPs across multiple 
stimulus intensities. NMDS analysis provided a valuable interpretable aid in examining 
disease progression and provides translational relevance in determining origins of disease 
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and potentially identifying drug targets. Pearson’s correlation coefficients were used to 
examine the correlation of each axis with each of the fitted variables to determine which 
variables participate most into axis determination. For example, flash eight OP2 
amplitude may be highly positively correlated with the x-axis and therefore any sample 
with high flash eight OP2 amplitude will receive a high ordination on the x-axis. NMDS 
of OP parameters both in the time domain and frequency domain provided a visual aid in 
examination of disease progress as well as an interpretation of OP parameters and their 
impact on disease.  
 
4.7 NMDS of hqY mice reveals distinct functional retinal changes by two months 
of age   
 NMDS of time-domain OP parameters reveals that young, hqY mice (two months 
of age) cluster distinctly from wild-type mice and demonstrate early characteristics of 
retinal dysfunction. Through axis interpretation with Pearson’s correlation coefficients it 
is evident that young, hqY mice (two months of age) cluster in regions of low, early OP 
amplitudes (OP2-OP3) as well as decreasing initial latencies across all flash intensities. 
Age-matched wild-type mice cluster in regions of high, late OP amplitudes (OP4-OP5) at 
all flash intensities as well as short initial latencies across all flash intensities. It is 
therefore apparent that mechanisms of the hq disease lead to early OP latency increases 
and amplitude loss followed by both latency increases and amplitude reductions across all 
OPs later in life. This is consistent with previous findings indicating that hq mice 
experience ONL losses at four months of age.
19,93
 However, this evidence suggests that 
functional changes may occur as early as two months in the hq photoreceptors and INL 
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cells. An interesting observation is that ten-month-old wild-type mice cluster similarly to 
that of two-month-old hq mice indicating that young hq mice show retinal functional 
losses similar to that of middle-age wild-type mice. Ageing has been shown to affect rod 
photoreceptor function leading to a 40% reduction in mouse rods.
147
 This suggests that hq 
mice exhibit ERG features similar to an advanced aging phenotype leading to 
photoreceptor losses and decreased INL and GCL function.  
 In the frequency domain, young two-month-old hqY mice cluster distinctly with 
reductions in power and frequency in comparison to wild-type mice across all flash 
intensities. Wild-type mice cluster in regions of high energy, power and frequency across 
all ages with minimal OP changes with age. Aging of the hq mouse demonstrates 
dramatic reductions in OP frequency, power and energy, particularly between two and 
three months of age. This is indicative of reduced radial current feedback in the hq retina 
due to reductions in periodicity and overall INL and GCL function resulting in reduced 
neural retina response and OP generation.  
 
4.8 NMDS of hqX mice reveals distinct retinal changes at eleven months of age 
 NMDS of time-domain parameters indicates that middle-aged (eleven months of 
age) hqX mice cluster distinctly with reductions in both early and later OP amplitudes 
(OP2-OP5) as well as shorter overall latencies. Age-matched wild-type mice indicate 
slight reductions in all OP amplitudes but shortened overall latencies across all flash 
intensities. These functional decreases would indicate that the hqX mice lose the 
functionality of the overall retinal response and likely experience neurite losses in both 
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the OPL and IPL. Cell loss and subsequent retinal thinning does not occur in the INL and 
GCL until fifteen months of age in the hqX mice,
103
 however functional changes are 
evident early through NMDS of time-domain OPs.  
 In the frequency domain, middle-aged hqX mice (eleven months of age) cluster 
distinctly with large overall reductions in OP power and energy across all flash intensities 
and increases in OP frequency with age. Wild-type mice of similar ages cluster in regions 
of sustained OP power and energy with increased frequency. Functional losses in total 
OP energy and power indicate a delayed and stunted response of the radial current 
feedback of the INL and GCL. This is prior to any structural losses and indicates an early 
functional diagnosis of the hqX retinal disease.  
 
 
4.9 The hq mouse retina maintains an intact inner and outer blood-retinal barrier 
 Assessments of the blood-retinal barrier via Evans Blue circulation indicate no 
increase in EB concentrations in the retina of hq mice when compared to age-matched 
wild-type mice. Although endothelial cells of the inner and epithelial cells of the outer 
retina (RPE) blood barrier are highly metabolic, they retain functional tight junctions 
with limited diffusion of exogenous EB from the vasculature into the sensitive inner 
retinal space. This is consistent with the alternate hypothesis of activation of hq retinal 
microglial cells from an endogenous source due to diminished AIF function leading to 
cell stress and loss of retinal neurons. Although retinal endothelial and epithelial 
vasculature are rich in mitochondria and highly metabolic, a probable explanation of 
integrity is due to maintenance by glia.
148
 Glial cells rely heavily on glycolytic ATP as 
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well as lactate and therefore a deficiency in OXPHOS will not compromise glial 
function.
119
 Glial cells have been shown to enhance blood-retinal barrier properties by 
increasing tight junction protein expression, endothelial-1,
149
 as well as  providing 
neuronal support
150
 for both the outer
151
 and inner
33
 retina. It would be expected that a 
reduction in complex I functionality and ATP production accompanying hq mice leads to 
a blood-retinal barrier malfunction but continued support from aerobic glial cells 
promotes the continued formation of tight junctions and maintenance of the blood-retinal 
barrier.  
 
4.10 Transcriptome changes demonstrate Aif downregulation 
 Gene expression analysis of hq Aif is consistent with previous findings suggesting a 
global downregulation of Aif mRNA transcript by over 80%.
93
 Contrary to previous 
findings downregulation of Aif in the retina surpasses an 80% reduction in the retina of 
four-, three-, and two-month-old mice to a downregulation by 91.16%, 94.22% and 
91.88% respectively. This finding is consistent with quantified protein expression in the 
hq  retina indicating minimal to nil endogenous AIF expression and complex I efficiency 
in the hq retina.
95,98
 Regulation of hq Aif gene expression occurs prior to transcription and 
specifies that the regulatory region of intron 1 is more vital in the retina than other 
tissues. The significant downregulation of Aif in the hq retina may explain the rapid onset 
of retinal degeneration preceding other tissue malfunctions. Functional retinal deficits 
begin at two months of age and an early reduction of Aif mRNA expression may be the 
catalyst to early retinal degeneration in the hq mouse.  
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4.11 The hq retinal transcriptome suggests alternative metabolism  
 As functional losses occur in the ONL of the hq retina, it is important to 
characterize endogenous activation of microglial cells and changes that lead to cell loss. 
The loss of Aif efficacy leads to reduced complex I function and expression resulting in 
reduced ATP yield across a variety of tissues.
95,98,118
 As predicted, the hq retina at two-, 
three- and four-months of age are unable to upregulate early, key enzymatic reactions of 
the glycolytic cycle as demonstrated by Hexokinase I (Hk1). Hk1 catalyzes the first 
regulatory, enzymatic reaction of glycolysis in the cytoplasm by phosphorylating glucose 
to glucose 6-phosphate (Figure 4.2A).
152
 Overexpression of Hk1 drives high rates of 
aerobic glycolysis, largely in cancers.
153
 Hk1 demonstrated no change in transcript levels 
in the hq retina even after microarray data suggested it may be upregulated.  
 Previous studies suggest the role of increased glucose uptake in hq 
mesodermal/endodermal tissues as a result of OXPHOS deficiency and a reliance on 
glycolytic ATP.
98,118
 Glycolytic flux is believed to be primarily controlled at the level of 
glucose uptake and phosphorylation of glucose by Hk1.
154
  In agreement with no 
glycolytic changes in the hq retina, the expression of Glucose transporter 4 (Glut4), a 
glucose transporter in the retina,
155
 demonstrates no significant changes in mRNA 
expression. Glut4 is a rapid, time-scale glucose transporter that translocates to the plasma 
membrane from the endoplasmic reticulum when insulin binds its receptors on the cell 
surface (Figure 4.2A).
156
 This translocation is mediated by TBC1 Domain Family, 
Member 4 (TBC1D4)
157
 which also showed no regulation changes in the hq retina at any 
age. The regulation of Glut and Hk1 exhibit the high control over glycolytic flux
154
 and  
106 
 
 
 
 
 
 
 
 
 
 
 
107 
 
 
 
Figure 4.2.22Proposed mechanisms of altered metabolism in the hq mouse based on 
significant alterations in the hq retinal transcriptome. Boxes coloured: blue indicate 
enzymes, yellow indicate substrates/metabolites and green indicate reducing equivalents. 
(A) Glucose metabolism in the hq retina, beginning with the uptake of glucose from the 
extracellular space by GLUT4 and followed by regulatory steps of glycolysis (HK1, 
PFKFP3) remain essentially unchanged.  Metabolism of glycerol in the hq retina is 
differentially upregulated beginning with the conversion of glycerol to glycerol 3-
phosphate by GK5. Mitochondrial bound GPD2 facilitates the conversion of glycerol 3-
phosphate to dihydroxyacetone phosphate by reducing FAD to FADH2. The glycerol 
shuttle shuttles FADH2 into the mitochondria. In addition, the formation of 
dihydroxyacetone phosphate from glycerol metabolism feeds into glycolysis and through 
the formation of glyceraldehyde 3-phosphate (G3P). The dysfunction of complex I in the 
hq retina causes an accumulation of NADH and decreased ATP production. (B) FADH2, 
produced by the glycerol shuttle, can donate electrons distal to complex I and allow 
improved functionality of OXPHOS in the hq retina.  
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show no differential expression in the hq retina (Figure 4.2A). These observations 
support no upregulation of transcript levels of glycolytic compensatory mechanisms for 
neuronal ATP deficits cause by AIF dysfunction. This further confirms that neurons may 
be unable to upregulate glycolysis as increased glycolytic rate leads to oxidative stress 
and apoptotic cell death.
45
   
 Neuronal and glial cells do not preferentially metabolize triglyceride components 
under healthy conditions.
158
 β-oxidation of fatty acids is not favoured in neurons because; 
1) it requires high levels of oxygen thereby increasing risk of becoming hypoxic 2) it 
leads to generation of superoxides and 3) has a slower ATP turnover in vivo.
158
 Glycerol 
however, can traverse the blood-brain-barrier
159
 and be utilized as a neuronal 
metabolite.
160
 A suspected similar mechanism may occur in the retina during periods of 
ATP depletion and metabolic need. Glycerol metabolism is highly energetic as it fuels 
ATP formation as well the ability to participate in the glycerol-3-phosphate (G3P) shuttle 
by transferring reducing agents into the mitochondrion and leading to the formation of 
FADH2 (Figure 4.2AB).
160
 The oxidative metabolism of glycerol leads to the formation 
of one FADH2 reducing molecule before forming 3-carbon, dihydroxyacetone phosphate 
which can enter the glycolytic pathway (Figure 4.2A). Glycerol-3-phosphate 
dehydrogenase (Gpd2) and Glycerol kinase 5 (Gk5) encode the primary and 
secondary enzymatic mediators leading to and facilitating glycerol metabolism in the 
brain (Figure 4.2A).
160
 Both Gpd2 and Gk5 transcript levels were upregulated in the hq 
retina at four months of age inferring neuronal metabolism of glycerol as a metabolic 
means for ATP and FADH2 production. GK5 facilitates the primary step of glycerol 
metabolism by phosphorylating glycerol to L-glycerol 3-phosphate and was upregulated 
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at two-months of age and suggests a potential link between early hq disease and glycerol 
metabolism.  
  Since OXPHOS of the hq mouse becomes dysfunctional, alternative mechanisms 
for generation of ATP must occur in order for neurons of the retina to remain viable. 
Excess glycerol fed into the later stages of glycolysis would lead to a bottleneck of 
pyruvate oxidation (pyruvate dehydrogenase) and as expected the Pyruvate 
dehydrogenase complex component X (Pdhx) of pyruvate dehydrogenase is upregulated 
at four months. Pdhx is a structural component of the pyruvate dehydrogenase complex 
that links the catalytic and regulatory subunits of the functional complex.
161
 Pyruvate 
dehydrogenase complex is the metabolic link between glycolysis and the Tricarboxylic 
(TCA) acid cycle by decarboxylating pyruvate to form acetyl-CoA (Figure 4.2A). 
Deficiencies in Pdhx cause pyruvate dehydrogenase malfunction and have been 
associated with neurological dysfunction and lactate acidosis.
161
 Although the 
directionality of Pdhx expression based on Taqman
®
 assay and microarray for Pdhx do 
not agree, dysregulation infers an intracellular mechanism that may lead to lactate 
acidosis in the hq retina and/or enhanced production of acetyl-CoA as a result of 
increased glycerol metabolism. In vivo examination of PDHX activity may help resolve 
its exact function in the hq retina.  
 OXPHOS complex I reduction in the hq mouse
98
 likely results in the inadequate 
processing and utilization of reducing agents (NADH and FADH2) produced by the 
mitochondrial TCA Cycle (Tricarboxylic Acid Cycle) (Figure 4.2). This is of particular 
importance for NADH, which is primarily oxidized by the NADH dehydrogenase 
complex (complex I) of the electron transport chain. A dysfunction of NADH 
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dehydrogenase may disrupt the NAD+ pool, increasing the NADH/NAD+ ratio thereby 
altering the redox state of the cell.
162
 In 80% of patients with complex I deficiency, high 
levels of lactate/pyruvate were evident with severe increases in NADH/NAD+ ratios.
163
 
Since it is likely that hq OXPHOS has compromised utilization of NADH, the 
mitochondria may compensate by decreasing the throughput of the TCA Cycle (high 
NADH concentrations decrease the activity of malate dehydrogenase, the primary step of 
the TCA cycle
164
) and increase glycerol metabolism as a means to increase FADH2 
production. FADH2 electrons enter the electron transport chain distal to complex I and 
therefore can be used as an alternative electron source for driving the electron transport 
chain in order to maintain its function.
165
  
 Severe increases in NADH/NAD+ are also associated with ketoacidosis and lactate 
acidosis as a result of acetyl-CoA being converted into acetoacetic acid and beta-
hydroxybutyric acid or lactate.
166,167
 Neuronal excitability is affected by intracellular 
acid-base homeostasis,
168
 where a rise in pH is associated with increased neuronal 
excitability, and a drop in pH reducing neuronal excitability.
169,170
 Acidic buffering to 
maintain pH,  decreases intracellular concentration of HCO3
-
 and further reduces 
buffering capabilities of the cell.
171
 Consequently, two key intracellular pH regulators and 
bicarbonate transporters are transcriptionally upregulated in the hq retina at four-months. 
Solute carrier family 4, sodium bicarbonate transporter, member 10 (Slc4a10) is a 
sodium-coupled bicarbonate transporter that exploits the transmembrane Na
+
 gradient in 
neurons to uptake HCO3
-
  and reduces acid load.
172
 Adenylate cyclase 10 (Adcy10) is 
believed to be a universal, evolutionarily conserved bicarbonate sensor.
173
 Unlike other 
intracellular pH regulators, Adcy10 functions as a bicarbonate sensor rather than a proton 
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sensor which allows a more direct regulation of bicarbonate to maintain pH 
homeostasis.
174
 Almost every cellular protein is sensitive to fluctuations in pH, however 
ADCY10 exhibits a unique ability to remain functional during extreme pH 
fluctuations.
173
 In addition, ADCY10 exhibits the ability to regulate the TCA cycle. 
Discrepancy between generation and utilization of reducing agents (NADH and FADH2) 
produced mainly by the TCA cycle, leads to ROS production and becomes harmful for 
the cell.
174
 Adcy10 uses CO2 produced by the TCA cycle to serve as a metabolic signal for 
TCA cycle turnover and can reduce the intra-mitochondrial cAMP concentration leading 
to reduced output of the TCA cycle.
174
 Adcy10 is upregulated in both the four-month hq 
retina and the four-month hq cerebellum inferring an increased cellular need for pH 
homeostasis and TCA cycle regulation. High NADH/NAD+ ratios will also push 
increased lactate production which has been observed in Aif-deficient cells and tissues of 
the hq mouse.
95,98,118
 Expression analysis of Lactate dehydrogenase C (Ldhc), which 
catalyzes the reverse reaction of lactate to pyruvate, was not examined due to low 
transcript levels of the gene (Figure 4.2A 
 Previous transcriptome studies of the hq-mouse retina performed by our laboratory 
are consistent with ammonia toxicity and protein degradation leading to amino acid 
metabolism as a source for ATP generation in vivo.
175
 The catabolism of amino acids is 
associated with the production of aldehyde by-products which can lead to glycation of 
amino-acids,
176,177
 and subsequent inflammatory responses. Thereby, Aldehyde 
dehydrogenase 2 (Aldh2) is likely transcriptionally upregulated in the hq retina to 
eliminate toxic aldehydes as a consequence of increased amino acid catabolism.
178
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4.12 The limitations of transcriptome analyses and future in vivo examinations   
 The transcriptome of the hq retina identifies many useful preliminary therapeutic 
targets and potential early disease mechanisms, however many limitations exist with 
transcriptome investigation. Transcriptional analysis occurs prior to post-transcriptional 
processing, translation and post-translational regulation and therefore does not reflect the 
quantity or functionality of the enzyme/protein in vivo. In addition, other interacting 
targets may be responsible for the phenotype observed. Further examinations at the level 
of the proteome are important for characterizing changes and complete interactions as a 
result of the Aif downregulation in vivo. One recommendation is the examination of key 
enzymatic factors of the glycerol pathway, GK5 and GPD2, to determine if increased 
neuronal glycerol metabolism is a feasible mechanism for FADH2 production. In addition 
to proteome analysis, gas-chromatography mass spectrophotometry could be used to 
determine the in vivo concentrations of metabolites such as NADH, NAD+, lactate, 
pyruvate, dihydroxyacetone phosphate, and FADH2 in comparison to the wild type. This 
will give us better insight into the mechanisms that occur in the hq retina to cope with 
NADH dehydrogenase dysfunction and reduced ATP production.     
  
4.13 Preliminary suggestions for hq mitochondrial dysfunction therapy  
 In addition to transcriptome quantification, a preliminary study of metabolic rate 
suggests that hq mice are hyperphagic and require increased food consumption. This is 
likely the result of reduced OXPHOS function causing a reduced ratio of ATP produced 
per molecule of glucose. hq mice are resistant to progressive weight gain and lipid 
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accumulation when fed a high fat diet inferring potential reliance and utilization of 
triglycerides as predicted.
118
 This is likely due to the fact that fatty acids and glycerol 
yield a much higher FADH2 and NADH than glucose and are commonly used for 
treatment of complex I deficiencies.
162
  
 From a therapeutic point of view, treatment of hq mice must take a direct approach 
to correcting mitochondrial dysfunction. Increased glycerol metabolism in the hq mouse 
predicts an increased reliance on FADH2 as the primary reducing agent in the 
mitochondria. The benefits’ of a high fat diet are likely to reduce the severity of the hq 
phenotype, although the benefits are unlikely to provide continued treatment due to 
NADH accumulation in the cell. Thereby, a probable treatment may be in the form of 
Riboflavin (vitamin B2). Riboflavin is a flavoprotein precursor and is the central 
component of FAD. Treatment with riboflavin will allow the cell to produce more 
FADH2 and facilitate the enzymatic reactions of the TCA cycle.
179
 Complex I and II 
deficiencies show betterment of symptoms and delayed disease progression following 
treatment with riboflavin.
180–182
   In addition, riboflavin has been used to treat human 
patients with OXPHOS deficiency caused by an Aif amino-acid deletion (R201 del).
183
 
Riboflavin treatment improves neurological symptoms and increases the functionality of 
OXPHOS in these patients.
183
 Although the hq disease is associated with a severe 
downregulation of Aif as opposed to a deletion of an amino acid, riboflavin 
supplementation demonstrates a promising preliminary therapeutic treatment for 
improving the hq disease. 
 
114 
 
 
 
4.14 Conclusions  
 Retinal degeneration in the hq mouse is characterized by mitochondrial dysfunction 
leading to parainflammation and closely mimics aging and mitochondrial-associated 
retinal degeneration. Early disease mechanisms resulting in degeneration of the hq retina 
are associated with early neurite losses and photoreceptor cell losses that can be 
characterized by diagnostic oscillatory potentials.  This study has developed a novel 
framework for the analysis of the entire OP profile across multiple stimuli, allowing 
functional examination of all retinal cell types and their health when combined with a-
wave and b-wave analyse. We have identified diagnostic ERG markers associated with 
the hq disease as well as a pipeline for identifying diagnostic ERG markers in other 
models of retinal disease. Parainflammation in the hq retina is more likely the result of 
endogenous retinal AIF deficiency and transcriptome alterations are consistent with 
compensatory mechanisms of ATP production such as glycerol metabolism. Studies 
aimed at a thorough characterization of glycerol metabolism as well as the accumulation 
of specific primary metabolites will help elucidate the role of AIF  and bring us closer to 
understanding mitochondrial-associated  retinal degeneration. 
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laboratory. Approved by The Canadian Council on Animal Care and The Animal Use 
Subcommittee of The University Council on Animal Care  
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
 
 
 
Appendix B. Supplementary Figures and Tables  
 This appendix contains figures and tables to assist with understanding of presented 
material.    
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Table B.1. PCR Primers used for Aif Genotyping  
Primer Position Sequence (5’ to 3’) 
Amplicon 
Length 
(bp) 
   
Forward AGTGTCCAGTCAAAGTACCGGG 537 (WT) 
Proviral Forward GAACAAGGAAGTACAGAGAGAGGC 725 (hq) 
Reverse CTATGCCCTTCTCCATGTAGTT  
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Figure B.1. A representative diagram of Taqman
®
 block design for 3 month mice. 
The 384-well plate is divided into columns of three for each mouse and genes assayed are 
represented by rows. A total of 13 genes were assayed per mouse in triplicate. A no-
template control (NTC) for each gene was assayed in rows O & P to ensure no false 
amplification and was also assayed in triplicate.  
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A Adcy10
B Gpd2
C Aldh2
D Gk5
E Aifm1
F Gapdh
G Rn18s
H Tbc1d4
I Hk1
J Glut4
K Ldhc
L Pdhx
M Slc4a10
N
O
P
Tbc1d4   NTC
Hk1 NTC Glut4  NTC Ldhc NTC Pdhx NTC Slc4a10 NTC
925.33 925.45925.12
Adcy10  NTC Gpd2  NTC Aldh2  NTC Gk5  NTC Aifm1 NTC Gapdh NTC Rn18s NTC
925.19 925.22 925.31 925.26 925.36
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Measurement Coordinate 1 Coordinate 2
F11 Latency OP2 -0.859006334 -0.151377761
F11 Latency OP3 -0.853657492 -0.15753476
F9 Latency OP3 -0.846274465 -0.169707181
F10 Latency OP2 -0.841057093 -0.193566945
F8 Latency OP3 -0.830526046 -0.065715862
F10 Latency OP3 -0.822981718 -0.208552355
F9 Latency OP2 -0.82194351 -0.125478715
F9 Latency OP4 -0.80694756 -0.298008836
F8 Latency OP4 -0.799695375 -0.207521146
F8 Latency OP2 -0.742677191 -0.101943569
F9 Latency OP5 -0.733660057 -0.250762361
F10 Latency OP5 -0.685039837 -0.356267863
F10 Latency OP4 -0.684617696 -0.529856532
F11 Latency OP4 -0.638909514 -0.589130854
F11 Latency OP5 -0.468400077 -0.541219708
F8 Latency OP5 -0.344040045 -0.265368694
F11 Amplitude OP2 0.424307269 -0.412374408
F10 Amplitude OP5 0.481785605 0.164778075
F10 Amplitude OP2 0.543878698 -0.644420042
F9 Amplitude OP2 0.560034669 -0.66660931
F11 Amplitude OP5 0.578306152 0.186810407
F8 Amplitude OP3 0.599566532 -0.557316795
F8 Amplitude OP2 0.618144453 -0.461141832
F9 Amplitude OP5 0.65045626 -0.111703757
F8 Amplitude OP5 0.672790759 -0.40557432
F8 Amplitude OP4 0.684464179 -0.552811113
F9 Amplitude OP4 0.728464308 -0.343319214
F9 Amplitude OP3 0.729042222 -0.615488338
F10 Amplitude OP4 0.748886709 0.043278448
F11 Amplitude OP4 0.799065572 0.162761807
F10 Amplitude OP3 0.812086192 -0.448484634
F11 Amplitude OP3 0.870065089 -0.178484534
Measurement Coordinate 1 Coordinate 2
F9 Amplitude OP2 0.560034669 -0.66660931
F10 Amplitude OP2 0.543878698 -0.644420042
F9 Amplitude OP3 0.729042222 -0.615488338
F11 Latency OP4 -0.638909514 -0.589130854
F8 Amplitude OP3 0.599566532 -0.557316795
F8 Amplitude OP4 0.684464179 -0.552811113
F11 Latency OP5 -0.468400077 -0.541219708
F10 Latency OP4 -0.684617696 -0.529856532
F8 Amplitude OP2 0.618144453 -0.461141832
F10 Amplitude OP3 0.812086192 -0.448484634
F11 Amplitude OP2 0.424307269 -0.412374408
F8 Amplitude OP5 0.672790759 -0.40557432
F10 Latency OP5 -0.685039837 -0.356267863
F9 Amplitude OP4 0.728464308 -0.343319214
F9 Latency OP4 -0.80694756 -0.298008836
F8 Latency OP5 -0.344040045 -0.265368694
F9 Latency OP5 -0.733660057 -0.250762361
F10 Latency OP3 -0.822981718 -0.208552355
F8 Latency OP4 -0.799695375 -0.207521146
F10 Latency OP2 -0.841057093 -0.193566945
F11 Amplitude OP3 0.870065089 -0.178484534
F9 Latency OP3 -0.846274465 -0.169707181
F11 Latency OP3 -0.853657492 -0.15753476
F11 Latency OP2 -0.859006334 -0.151377761
F9 Latency OP2 -0.82194351 -0.125478715
F9 Amplitude OP5 0.65045626 -0.111703757
F8 Latency OP2 -0.742677191 -0.101943569
F8 Latency OP3 -0.830526046 -0.065715862
F10 Amplitude OP4 0.748886709 0.043278448
F11 Amplitude OP4 0.799065572 0.162761807
F10 Amplitude OP5 0.481785605 0.164778075
F11 Amplitude OP5 0.578306152 0.186810407
Table B.2. Pearson’s correlation coefficients from nonmetric multidimensional 
scaling analysis of hqY time-domain OP parameters. Tables are ordered by 
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right 
chart) to assist with axis interpretation. 
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Measurement Coordinate 1 Coordinate 2 
F9 Gaussian Power -0.590242553 -0.770721391
F8 Gaussian Power -0.439755859 -0.745030923
F10 Gaussian Power -0.735730899 -0.563367817
F8 Total Energy -0.817230902 -0.292346888
F11 Gaussian Power -0.837221842 -0.260841987
F9 Total Energy -0.938426703 -0.236289954
F10 Total Energy -0.97963505 -0.080079919
F11 Total Energy -0.968656764 0.088457664
F10 Gaussian 
Frequency -0.821513771 0.543230455
F9 Gaussian 
Frequency -0.810590977 0.546777937
F8 Gaussian 
Frequency -0.784149192 0.563671382
F11 Gaussian 
Frequency -0.776138181 0.594753436
Measurement Coordinate 1 Coordinate 2 
F10 Total Energy -0.97963505 -0.080079919
F11 Total Energy -0.968656764 0.088457664
F9 Total Energy -0.938426703 -0.236289954
F11 Gaussian Power -0.837221842 -0.260841987
F10 Gaussian 
Frequency -0.821513771 0.543230455
F8 Total Energy -0.817230902 -0.292346888
F9 Gaussian 
Frequency -0.810590977 0.546777937
F8 Gaussian 
Frequency -0.784149192 0.563671382F11 Gaussian 
Frequency -0.776138181 0.594753436
F10 Gaussian Power -0.735730899 -0.563367817
F9 Gaussian Power -0.590242553 -0.770721391
F8 Gaussian Power -0.439755859 -0.745030923
Table B.3. Pearson’s correlation coefficients from nonmetric multidimensional 
scaling analysis of hqY frequency-domain OP parameters. Tables are ordered by 
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right 
chart) to assist with axis interpretation. 
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Measurement Coordinate 1 Coordinate 2
F10 Latency OP2 -0.8465227 -0.33263146
F9 Latency OP2 -0.84122833 -0.26833499
F10 Latency OP3 -0.8286985 -0.28526331
F11 Latency OP3 -0.7839018 -0.39646655
F9 Latency OP4 -0.78382521 -0.21714434
F10 Latency OP5 -0.77789174 -0.07591251
F8 Latency OP2 -0.75190675 -0.47672993
F8 Amplitude OP3 -0.74317829 -0.22739861
F11 Latency OP2 -0.73761625 -0.47558814
F8 Amplitude OP4 -0.73351111 -0.04430713
F9 Latency OP5 -0.72513157 -0.46055913
F10 Latency OP4 -0.67806932 -0.06781597
F11 Latency OP4 -0.63576058 -0.55236009
F9 Latency OP3 -0.61737348 -0.35646637
F8 Amplitude OP5 -0.59553985 -0.2987983
F11 Latency OP5 -0.27739875 -0.23479761
F10 Amplitude OP5 0.12469163 -0.71649367
F11 Amplitude OP5 0.1437659 -0.68752732
F9 Amplitude OP5 0.33357947 -0.71742454
F9 Amplitude OP4 0.37176222 -0.87729291
F10 Amplitude OP4 0.3800024 -0.8572363
F8 Amplitude OP4 0.42295653 -0.74131346
F11 Amplitude OP4 0.48735872 -0.64154307
F8 Amplitude OP5 0.50542379 -0.54592269
F9 Amplitude OP3 0.59040284 -0.36471528
F8 Amplitude OP3 0.61054609 -0.72685793
F10 Amplitude OP3 0.64286454 -0.50677443
F8 Amplitude OP2 0.65078245 -0.34984908
F9 Amplitude OP2 0.68950648 -0.52237812
F10 Amplitude OP2 0.76133209 -0.36759832
F11 Amplitude OP3 0.76840952 -0.57446596
F11 Amplitude OP2 0.78171173 -0.41812742
Measurement Coordinate 1 Coordinate 2
F9 Amplitude OP4 0.37176222 -0.87729291
F10 Amplitude OP4 0.3800024 -0.8572363
F8 Amplitude OP4 0.42295653 -0.74131346
F8 Amplitude OP3 0.61054609 -0.72685793
F9 Amplitude OP5 0.33357947 -0.71742454
F10 Amplitude OP5 0.12469163 -0.71649367
F11 Amplitude OP5 0.1437659 -0.68752732
F11 Amplitude OP4 0.48735872 -0.64154307
F11 Amplitude OP3 0.76840952 -0.57446596
F11 Latency OP4 -0.63576058 -0.55236009
F8 Amplitude OP5 0.50542379 -0.54592269
F9 Amplitude OP2 0.68950648 -0.52237812
F10 Amplitude OP3 0.64286454 -0.50677443
F8 Latency OP2 -0.75190675 -0.47672993
F11 Latency OP2 -0.73761625 -0.47558814
F9 Latency OP5 -0.72513157 -0.46055913
F11 Amplitude OP2 0.78171173 -0.41812742
F11 Latency OP3 -0.7839018 -0.39646655
F10 Amplitude OP2 0.76133209 -0.36759832
F9 Amplitude OP3 0.59040284 -0.36471528
F9 Latency OP3 -0.61737348 -0.35646637
F8 Amplitude OP2 0.65078245 -0.34984908
F10 Latency OP2 -0.8465227 -0.33263146
F8 Amplitude OP5 -0.59553985 -0.2987983
F10 Latency OP3 -0.8286985 -0.28526331
F9 Latency OP2 -0.84122833 -0.26833499
F11 Latency OP5 -0.27739875 -0.23479761
F8 Amplitude OP3 -0.74317829 -0.22739861
F9 Latency OP4 -0.78382521 -0.21714434
F10 Latency OP5 -0.77789174 -0.07591251
F10 Latency OP4 -0.67806932 -0.06781597
F8 Amplitude OP4 -0.73351111 -0.04430713
Table B.4. Pearson’s correlation coefficients from nonmetric multidimensional 
scaling analysis of hqX frequency-domain OP parameters. Tables are ordered by 
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right 
chart) to assist with axis interpretation. 
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Measurement Coordinate 1 Coordinate 2 
F8 Gaussian Power -0.778672152 -0.477976579
F9 Gaussian Power -0.852374157 -0.462860557
F10 Gaussian Power -0.936559689 -0.249515924
F11 Gaussian Power -0.947405504 0.019228962
F9 Total Energy -0.969372022 0.053267539
F8 Total Energy -0.925313065 0.134905804
F10 Total Energy -0.96440625 0.209308386
F11 Total Energy -0.898996534 0.364182853
F8 Gaussian 
Frequency -0.103790027 0.939471085
F9 Gaussian 
Frequency -0.088637167 0.951935284
F11 Gaussian 
Frequency -0.045683178 0.969829489
F10 Gaussian 
Frequency -0.062301485 0.980003901
Measurement Coordinate 1 Coordinate 2 
F9 Total Energy -0.969372022 0.053267539
F10 Total Energy -0.96440625 0.209308386
F11 Gaussian Power -0.947405504 0.019228962
F10 Gaussian Power -0.936559689 -0.249515924
F8 Total Energy -0.925313065 0.134905804
F11 Total Energy -0.898996534 0.364182853
F9 Gaussian Power -0.852374157 -0.462860557
F8 Gaussian Power -0.778672152 -0.477976579
F8 Gaussian 
Frequency -0.103790027 0.939471085
F9 Gaussian 
Frequency -0.088637167 0.951935284
F10 Gaussian 
Frequency -0.062301485 0.980003901
F11 Gaussian 
Frequency -0.045683178 0.969829489
Table B.5. Pearson’s correlation coefficients from nonmetric multidimensional 
scaling analysis of hqX frequency-domain OP parameters. Tables are ordered by 
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right 
chart) to assist with axis interpretation. 
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Figure B.2. A schematic representation of OP parameters elicited by a three month 
hqY and wild-type mouse (10 cd•s/m2 stimulus). (A) Time-domain representation of 
ERG OP parameters indicate functional changes as early as three months of age with 
changes in OP periodicity. (B) Frequency-domain representation of ERG OP parameters 
at three months indicate functional changes in OP frequency. It is evident that power, and 
total energy are decreased in this schematic representation.     
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Figure B.3. A schematic representation of OP parameters elicited by an eleven 
month hqX and wild-type mouse (10 cd•s/m2 stimulus). (A) Time-domain 
representation of ERG OP parameters indicate functional changes at eleven months of 
age with changes in OP amplitude. (B) Frequency-domain representation of ERG OP 
parameters at eleven months indicate functional changes in OP total energy and power. It 
is evident that OP frequency remains unchanged in this schematic representation.    
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Table B.6. Two-way ANOVA’s performed in Excel [Microsoft, Redmond, VA] on 
oscillatory potentials parameters both in the time and frequency domain to explore 
the effect of age on genotype. Significance is equal to p < 0.05. 
A.  hqY Time-Domain Parameters 
 
Initial Latency   Summed Amplitude 
 
Genotype (p < 0.001)   Genotype (p < 0.001) 
 
Age (p  = 0.07337)   Age = (p < 0.001) 
 
Interaction (p = 0.212)   Interaction (p < 0.01) 
          
          B.  hqY Frequency-Domain Parameters 
 
Peak Frequency Peak Power Total Energy  
 
Genotype (p < 0.001) Genotype (p < 0.05) Genotype (p < 0.01) 
 
Age (p  < 0.001) Age  (p < 0.01) Age  (p < 0.01) 
 
Interaction (p < 0.05) Interaction (p < 0.01) Interaction (p < 0.01) 
          
          C.  hqX Time-Domain Parameters 
 
Initial Latency   Summed Amplitude 
 
Genotype (p < 0.01)   Genotype (p < 0.001) 
 
Age (p  < 0.001)   Age  (p = 0.63994 ) 
 
Interaction (p = 0.212)   Interaction (p = 0.15089) 
          
          D.  hqX Frequency-Domain Parameters 
 
Peak Frequency Peak Power Total Energy  
 
Genotype (p < 0.01) Genotype (p < 0.001) Genotype (p < 0.001) 
 
Age (p  < 0.001) Age  (p < 0.01) Age  (p = 0.7796) 
 
Interaction (p = 0.88369) Interaction (p = 0.16913) Interaction (p = 0.13802) 
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Sample ID
Concentration 
(ng/µL)
A260/A280 RIN Sample ID
Concentration 
(ng/µL)
A260/A280 RIN
*924.3 33.9 2.06 9.6 *924.3 257.2 2.028 9.3
*925.16 41.7 2.04 9.6 *925.16 185.6 2.053 9.2
*925.77 44.9 2.03 9.5 *925.77 232 2.064 8.8
*925.83 72.2 2.21 8.9 925.83 287.6 2.043 8.7
925.89 n/a n/a n/a *925.89 231.2 2.141 8.8
925.90 24 2.1 9.1 925.90 n/a n/a n/a
*925.93 72.3 2.13 9.2 925.93 n/a n/a n/a
924.4 n/a n/a n/a *924.4 273.2 1.957 9.3
*924.5 16.3 2.43 8.9 924.5 n/a n/a n/a
*924.11 23.7 2.01 9.3 924.11 n/a n/a n/a
*925.14 34.1 2.02 9.2 *925.14 140 1.977 8.8
925.72 n/a n/a n/a 925.72 146 2.086 9.1
*925.73 29.1 2.18 8.8 *925.73 140 2.077 8.9
925.75 12.1 2.59 8.4 *925.75 210 2.315 9.2
*925.95 41.1 2.11 9.1 925.95 n/a n/a n/a
*925.19 32.7 2.15 8.8 *925.19 212 2.008 8
*925.22 16.2 1.85 8.2 *925.22 210 2.05 9.1
*925.26 32 2.04 9.6 925.26 216 2.050 7.5
925.27 35.6 2.05 9 *925.27 240 2.040 8.2
*925.33 33.6 2.02 9.8 *925.33 154 1.873 9.1
*925.12 43.9 2.05 8.9 *925.12 353.6 2.007 7.7
925.13 12.8 2.23 None 925.13 240 1.911 7.6
*925.31 53.4 2.03 9.8 *925.31 84 1.812 8.8
*925.36 29.6 2.1 9.4 *925.36 214 2.030 8.3
*925.45 47.1 2.18 9.9 *925.45 85 2.095 9.2
*925.53 26.6 2.12 9.5 *925.53 215 2.011 8.8
925.54 8.2 2.21 9.2 *925.54 182 1.97 8.8
*925.55 52.9 2.11 9.6 925.55 199.6 1.965 9.3
*925.69 27 2.13 9.2 *925.69 221.6 1.965 8.9
*925.70 50.2 2.1 9.6 *925.70 167.2 2.133 9.1
*925.39 44.4 2.1 9.8 925.39 110 2.202 8.9
*925.43 31 2.18 9.6 *925.43 310 2.102 8.5
*925.51 32.3 2.03 9.4 *925.51 194 2.008 9
*925.58 36.1 2.15 9.1 *925.58 188 1.983 8.6
925.57 17 2.36 8.6 *925.57 209.2 2.135 9
2 Month
hq
WT
4 Month
hq
3 Month
hq
WT
WT
Retina Cerebellum
Table B.7. Concentrations and quality assurance measures for extracted retinal and 
cerebellar RNA samples.  
 
 
 
 
 
 
 
 
*Indicates sample that was chosen for transcriptome analysis. In addition, light shadings 
indicate that the sample was not used. 
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Appendix C. MATLAB functions and Scripts  
This appendix contains MATLAB scripts for the isolation of oscillatory potentials from 
the original ERG waveform and fast Fourier transformation.  
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MATLAB Script A. “P3fit” function written into MATLAB for modelling 
photoreceptor contribution to the ERG.  
function err = p3fit(rktd) 
global datatofit timestofit 
options.MaxFunEvals=1000000; 
i = find(timestofit<rktd(3)); 
model(i) = 0; 
j = find(timestofit>=rktd(3)); 
model(j) = rktd(1)*(1-exp(-rktd(2)*(timestofit(j)-
rktd(3)).*(timestofit(j)-rktd(3)))); 
err = sum((model' - datatofit).^2); 
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MATLAB Script B. “P3driver” function written into MATLAB for modelling 
photoreceptor contribution to the ERG, followed by a fifth order Butterworth 
transformation (65-300Hz) for oscillatory potential waveform extraction.  
 
global datatofit timestofit 
 
options.MaxFunEvals=1000000; 
for icol = 16:19 
 
clear model 
 
%modelling the p3  
%details 
minval = min(data(:,icol)); 
imin = find(data(:,icol) == minval); 
iremain = data(imin+1:200,icol); 
timestofit = data(1:imin,1); 
datatofit = data(1:imin,icol); 
datatofit = datatofit - datatofit(1); 
 
initialguess = [ min(datatofit) 0.5 0]; 
 
rktd = fminsearch(@p3fit,initialguess); 
  
i = find(timestofit<rktd(3)); 
model(i) = 0; 
j = find(timestofit>=rktd(3)); 
model(j) = rktd(1)*(1-exp(-rktd(2)*(timestofit(j)-
rktd(3)).*(timestofit(j)-rktd(3)))); 
k = (find(iremain)+(imin)); 
model(k) = min(model); 
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timestoplot(i) = i; 
timestoplot(j) = j; 
timestoplot(k) = k; 
 
%Subtracting model from data to form p2  
  
p2(i) = ((data(i,icol)-data(1,icol)) - model(i)'); 
p2(j) = ((data(j,icol)-data(1,icol)) - model(j)'); 
p2(k) = ((data(k,icol)-data(1,icol)) - model(k)'); 
 
%Butterworth filtering the p2 
Wn = [65 300] / 500; 
[B,A] = butter(5,Wn); 
fildata = filter(B,A,p2); 
 
%Plots to see how things are going 
figure 
subplot(2,1,1),hold on, 
plot(data(:,1),data(:,icol)-data(1,icol)); 
plot(timestoplot,model,'r'); 
plot(timestoplot,p2,'g'); 
plot(timestoplot,fildata,'black'); 
subplot(2,1,2),plot(timestoplot,fildata,'black'); 
 
end 
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MATLAB Script C. “P3driverFFT” function written into MATLAB for modelling 
photoreceptor contribution to the ERG, followed by a fifth order Butterworth 
transformation (65-300Hz) and fast Fourier transformation (Gaussian).  
global datatofit timestofit 
  
options.MaxFunEvals=1000000; 
for icol = 16; 
  
clear model 
  
%modelling the p3  
 
%details 
minval = min(data(:,icol)); 
imin = find(data(:,icol) == minval); 
iremain = data(imin+1:200,icol); 
timestofit = data(1:imin,1); 
datatofit = data(1:imin,icol); 
datatofit = datatofit - datatofit(1); 
  
initialguess = [ min(datatofit) 0.5 0]; 
  
rktd = fminsearch(@p3fit,initialguess); 
  
i = find(timestofit<rktd(3)); 
model(i) = 0; 
j = find(timestofit>=rktd(3)); 
model(j) = rktd(1)*(1-exp(-rktd(2)*(timestofit(j)-
rktd(3)).*(timestofit(j)-rktd(3)))); 
k = (find(iremain)+(imin)); 
model(k) = min(model); 
timestoplot(i) = i; 
timestoplot(j) = j; 
timestoplot(k) = k; 
  
%Subtracting model from data to form p2  
  
p2(i) = ((data(i,icol)-data(1,icol)) - model(i)'); 
p2(j) = ((data(j,icol)-data(1,icol)) - model(j)'); 
p2(k) = ((data(k,icol)-data(1,icol)) - model(k)'); 
  
%Butterworth filtering the p2 
Wn = [65 300] / 500; 
[B,A] = butter(5,Wn); 
fildata = filter(B,A,p2); 
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fs = 1000;                          % Sample frequency (Hz) 
t = 0:1/fs:0.2-1/fs;                % 10 sec sample 
x = (fildata); 
  
b = fildata(1:128);          % Window length 
m = length(b); 
n = pow2(nextpow2(m));  % Transform length 
y = fft(x,n);           % DFT 
f = (0:n-1)*(fs/n);     % Frequency range 
p = sqrt(y.*conj(y)/n);   % Power of the DFT 
  
  
plot(f(1:floor(n/2)),p(1:floor(n/2))) 
xlabel('Frequency (Hz)') 
ylabel('Power') 
title('{\bf Periodogram}') 
  
A=((p(1)/2 +sum (p(2:end-1) + p(end)/2))/2) % area under 
the curve 
  
%Plots to see how things are going 
%figure 
%subplot(2,1,1),hold on, 
%plot(data(:,1),data(:,icol)-data(1,icol)); 
%lot(timestoplot,model,'r'); 
%plot(timestoplot,p2,'g'); 
%plot(timestoplot,fildata,'black'); 
%subplot(2,1,2),plot(timestoplot,fildata,'black'); 
 
 
g = fit(f.',p.','gauss2') 
 
plot(g) 
  
end 
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Appendix D.  Non-metric multidimensional scaling R code. 
 This appendix contains R code for performing non-metric multidimensional scaling 
on oscillatory potential parameters in both the time and frequency domain.  
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NMDS R-code A. Non-metric multidimensional scaling performed by calculating 
Euclidean distances between samples followed by subsequent correlation analysis.  
 
> getwd() 
# This will list the location that R will read files from 
 
> list.files() 
#List of all files in the working directory 
 
> data <- read.csv(“ZSCORES HQY&XY FFT DATA.csv”) 
# Information in file will become a variable named “data” 
 
> data 
# View “data” variable  
 
> (D <- dist(data)) 
# This will calculate Euclidean distance between each 
sample based on input z-scores. Presented as a 
#dissimilarity matrix, assigned as variable D.  
 
> summary (D) 
# Displays dissimilarity matrix 
 
> library (“MASS”)  
# Reads in library package to perform NMDS 
# Install the HSAUR2 package  
 
> data_mds <- isoMDS(D) 
# This will perform NMDS on the dissimilarity matrix (D) 
based on 50 iterations. Assigns NMDS as #data_mds 
 
> x <- data_mds$Points[,1]  
# Assigns the first coordinate of the NMDS variables to the 
variable x  
 
> y <- data_mds$Points [,2] 
# Assigns the first coordinate of the NMDS variables to the 
variable y 
# Variables plotted in excel  
# NMDS coordinates put into a new z-score file and read 
into excel for correlation analysis  
 
> x <- read.csv("ZSCORES (Coorelation) HQY&XY FFT DATA 
(ERIC DOLINAR).csv") 
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# Assigns variable x to z-score file with NMDS coordinates  
 
> cor(x, use = "complete.obs", method = "pearson") 
# Performs a Pearson’s correlation on the variable x  
 
# Shepard plots 
 
> MDS.sh <- Shepard (D, data_mds$points) 
 
> plot(MDS.sh, pch =".") 
 
> plot(MDS.sh, pch =".", xlab = "Dissimilarity", ylab = 
"Distance") 
 
> lines(MDS.sh$x, MDS.sh$yf, type="S") 
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Appendix E. Functional annotation of differentially expressed retinal genes  
 This appendix contains functional annotations based on NCBI Gene searches
184
 of 
521 retinal genes differentially expressed in hq mice at four months of age. Differential 
expression is based on a retinal gene expression microarray [Affymetrix, Mouse Gene 1.0 
ST Array, Santa Clara] previously performed by the Hill laboratory.
102
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Table E.1. Functional annotation of 521 differentially expressed retinal genes  based 
on microarray data from four-month-old hq disease mice.
*
   
Gene Symbol p-value‡ Fold 
Change 
Annotation/Function† 
Aifm1 0.000163 -6.01196 
Mitochondrial intermembrane flavoprotein involved in 
OXPHOS and apoptosis 
Cyp3a25 0.0307866 -4.68949 
Cytochrome P450 variant involved in metal binding and 
oxidoreductase activity  
Hc 0.0116071 -3.90775 
Complement activation (C5) and innate immune 
response  
Ttc18 0.0024609 -3.43071 
Extracellular vesicular exosome important to ciliated 
cells  
Trim36 0.0275573 -3.41135 
Ubiquitin ligase activity with zinc-binding protein 
activity 
Abca6 0.0450953 -3.09029 
ATP-binding cassette involved in macrophage lipid 
metabolism and homeostasis  
Iqgap2 0.0440039 -3.01678 
Regulates cell morphology and mobility through 
interaction with the cytoskeleton 
Myh6 0.0058866 -2.90362 
Encodes heavy chain of myosin, an intracellular motor 
protein 
Slc4a10 0.0266117 -2.87259 
Neuronal intracellular bicarbonate transporter and pH 
regulator 
Robo3 0.0008035 -2.81071 Controls neurite outgrowth and axonal navigation  
Olfm4 0.015151 -2.77354 Antiapoptotic protein and facilitates cell adhesion 
Haus6 0.0362302 -2.70602 Microtubule and kinetochore assembly  
Atm 0.0358792 -2.69275 Cell cycle checkpoint kinase protein  
Nbr1 0.0227154 -2.64043 Peroxisome autophagic degradation 
BC030307 0.0060405 -2.62532 Unknown 
Slc26a4 0.0160909 -2.60606 Sulfate and chloride transporter 
Dpy19l1 0.0274067 -2.54374 Unknown 
Ppp1r9a 0.0149737 -2.53199 Phosphatase I involved in cytoskeleton organization 
4930519F16Rik 0.0061143 -2.51977 Unknown 
Wdr60 0.0071325 -2.51121 Cell cycle regulator and formation of cilia  
D19Ertd652e 0.0298091 -2.50222 Unknown 
Pdhx 0.0161061 -2.48204 
Structural component of pyruvate dehydrogenase, binds 
subunits together 
Aqp4 0.0018312 -2.47148 Neuronal aquaporin to allow water-selective transport 
Pkd1l2 0.0066857 -2.46823 Cation channel pore, cation transport 
Siglece 0.0321588 -2.46084 
Sialic acid binding protein involved in immune cell 
response 
BC055324 0.0449079 -2.40619 Unknown 
Garnl1 0.0495052 -2.38863 Activation of Ral GTPase  
Smc1b 0.0466303 -2.3795 
Mitotic and meiotic DNA recombination and chromatid 
formation 
Klra5 0.0094125 -2.36588 
Membrane protein involved in cellular adhesion during 
immune response 
Pear1 0.0419941 -2.35637 Responsible for platelet aggregation  
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Trio 0.0159855 -2.345 Promotes leukocyte transendotheial migration  
Adal 0.0032844 -2.3368 Purine, drug and small molecule catabolism 
Kmo 0.0428267 -2.32506 
Mitochondrial protein involved in NADH oxidase 
activity and FAD binding 
4922505G16Rik 0.0380333 -2.30153 Unknown 
Mansc1 0.03965 -2.28514 Plasma membrane component 
Rbms3 0.0109571 -2.27729 Cytoplasmic RNA metabolism 
Golga3 0.0392264 -2.27699 
Golgi apparatus transport of proteins and lipids to 
nucleus during mitosis 
Car1 0.0257676 -2.2678 Catalyzes to reversible hydration of carbon dioxide 
Hdc 0.0008771 -2.23775 
Conversion of L-histidine to histamine involved in 
neurotransmission 
Ankfy1 0.0015828 -2.23773 Cytoplasmic protein and vesicle transport  
Msh3 0.0048097 -2.2069 Initiates post-replication DNA mismatch repair 
Dnahc2 0.0235939 -2.20618 Involved in axonemal microtubule formation  
Apaf1 0.0367202 -2.19996 
Cytoplasmic initiator of apoptosis through formation of 
apoptosome 
Col7a1 0.0174913 -2.19387 Component of collagen and extracellular remodelling 
Sall2 0.0137244 -2.18272 
Involved in transcriptional regulation during growth and 
development of neurons  
Katnal2 0.0307008 -2.1754 Microtubule severing through ATPase activity 
Slc38a11 0.0438682 -2.17502 Plasma membrane amino acid and sodium transporter 
Col4a2 0.02681 -2.16956 
Component of collagen involved in inhibiting 
angiogenesis 
Npy2r 0.0213178 -2.16915 Neuropeptide signalling activity  
Rad50 0.0452278 -2.16269 
DNA double-stranded break repair and cell cycle 
regulation 
Nmbr 0.039171 -2.15422 Binds neuromedin B to promote mitosis  
Tada3l 0.0106471 -2.15409 Promotes DNA-binding of transcriptional factors  
Nlrp3 0.0341535 -2.15371 
NF-kappa B signalling to regulated inflammation and 
immune response 
Dhx29 0.0398495 -2.15276 Involved in mRNA translation initiation 
Col9a2 0.0063438 -2.14271 
Component of collagen involved in extracellular 
remodelling and axon guidance 
Abca16 0.0127381 -2.13578 ATP-binding cassette, function unknown 
Duox2 0.0052049 -2.11419 NADH oxidase activity and cytokine release  
Wrn 0.0050367 -2.1116 RNA and DNA helicase  
Pard3b 0.0249889 -2.10666 Involved in cell cycle and tight junction formation 
Ptpru 0.0008582 -2.10598 
Protein binding regulation of cell growth, differentiation 
and mitosis 
Clasp2 0.048169 -2.08765 Microtubule end binding and anchoring  
Grin2b 0.0422529 -2.0848 
Glutamate receptor for prominent neurotransmitter in the 
retina 
Dnahc11 0.0020171 -2.06752 Ciliary dynein protein from microtubule motor activity 
4921528I07Rik 0.0376126 -2.06285 Unknown 
Ms4a4c 0.0019349 -2.06017 Unknown 
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Tg 0.0232324 -2.06013 Thyroglobin (thyroid hormone) 
Nudt13 0.0313719 -2.05882 Unknown 
Oca2 0.0226697 -2.05639 Integral membrane protein - tyrosine transport 
Itgal 0.013379 -2.05613 
Integrin expressed in leukocytes for intracellular 
adhesions 
Scn5a 0.0192309 -2.04663 Sodium channel, voltage-gated 
Spna1 0.0108579 -2.04024 Actin cytoskeleton organization  
Dpp10 0.0499214 -2.03872 
Serine protease and binds K+ channels and alters 
functionality 
Coq7 0.0001781 -2.03198 Coenzyme Q involved in ubiquinone biosynthesis 
Rfc1 0.0063545 -2.02704 DNA replication factor C for DNA replication 
Telo2 0.008154 -2.00621 S-phase checkpoint protein 
Nlrc5 0.0164919 -2.0028 Inhibits NF-kappa-B activation and interferon signalling 
Brca1 0.021531 -2.00024 
Tumour suppressor acts as a DNA damage sensor and 
mediates repairs 
Casc5 0.0081067 -1.99927 
Microtubule-kinetochore attachments and chromosome 
separation  
L3mbtl 0.0497075 -1.99779 Chromatin modification and cell cycle regulation 
2310033E01Rik 0.0307551 -1.98669 Phospholipidase inhibitor  
Lctl 0.00774 -1.96934 Glycosidase 
Tcp10b 0.0271985 -1.96595 Unknown 
Mfn1 0.0067646 -1.96589 Mediates mitochondrial fusion  
Pfkfb3 0.0191326 -1.96108 
Activator of the glycolysis pathway through early 
primary steps 
2610034M16Rik 0.0169822 -1.96036 Unknown 
Lars2 0.0062127 -1.95613 Aminoacyl-tRNA synthetase 
Aox4 0.0361653 -1.94431 
Aldehyde oxidase involved in biosynthesis of retinoic 
acid 
Cdh23 0.0006493 -1.94368 Intracellular adhesion glycoprotein  
Ptbp2 0.0088319 -1.94299 Neuronal RNA regulatory protein 
Pla2g4d 0.0325627 -1.94056 Phospholipidase, liberates fatty acids  
Wdr52 0.0464484 -1.93782 mRNA processing and/or cytoskeleton assembly 
Csmd1 0.0052928 -1.93496 Integral membrane protein  
Txndc3 0.0474444 -1.93491 Unknown 
BC059842 0.0456172 -1.93344 Unknown, potential for CNS development 
Scnn1b 0.0456916 -1.93172 
Sodium channel, voltage-gated control of electrolytes 
across epithelia 
C1qtnf5 0.001318 -1.92401 Basement membrane and cell adhesion 
Ift140 0.0364322 -1.91511 Microtubule formation of cilia 
Cdx4 0.0260372 -1.9096 RNA polymerase core promoter binding protein 
Hephl1 0.006727 -1.90675 Copper ion transport 
Slc5a4a 0.0281977 -1.90241 Unknown, transporter protein 
9030420J04Rik 0.0062036 -1.90156 Unknown 
Nphp4 0.0382606 -1.89934 Microtubule development and function 
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Kif2c 0.0299502 -1.89863 
Kinesin-like microtubule motor protein, mitotic 
chromosome segregation 
Hkdc1 0.0242806 -1.8967 Hexokinase activity and glucose metabolism 
Nbeal2 0.0373284 -1.89554 Regulates neurotransmitter receptor trafficking  
Pole 0.019369 -1.89426 DNA polymerase subunit 
Gucy2c 0.0005898 -1.89361 Enterotoxin receptor  
Acot12 0.0272659 -1.89312 Acetyl-CoA hydrolase activity  
Lhx8 0.0443032 -1.89031 DNA binding transcription factor 
1700040L02Rik 0.0025767 -1.88678 Unknown, important for cilia function 
Abcc5 0.0410045 -1.88581 
ATP-binding cassette involved in export of cyclic 
nucleotides  
Cep152 0.0360524 -1.88357 Microtubule centrosome function 
Gm6190 0.0055903 -1.87934 Unknown 
Lrp2 0.0249245 -1.8778 
Uptake of lipoproteins, sterols, hormones and vitamins 
from extracellular space 
Stag3 0.0005808 -1.87163 Cohesion of sister chromatids during mitosis  
4930555F03Rik 0.0406336 -1.8666 Unknown 
Prkdc 0.0292855 -1.86298 
Protein kinase mediates double-stranded break DNA 
repair 
Vps13c 0.0425298 -1.85981 Unknown 
Optc 0.0157026 -1.85973 
Binds collagen fibrils and regulations fibril formation 
and morphology 
Col27a1 0.0486116 -1.85899 Component of structural extracellular matrix  
Enoph1 0.0344511 -1.85735 Unknown, amino-acid metabolism 
Cd2ap 0.0110717 -1.85617 
Scaffolding protein involved in organization of actin 
cytoskeleton 
Mcm5 0.0444294 -1.85324 Facilitates cell cycle and mitosis initiation  
Usp33 0.0228026 -1.85306 Deubiquinating enzyme 
Lcp2 0.0018684 -1.85165 T-cell receptor and immune response  
Senp6 0.0247478 -1.85165 Ubiquitin-like molecule  
Hsd17b3 0.0295071 -1.84551 Conversion of androstenedione to testosterone  
2010204N08Rik 0.0058221 -1.84151 High carbohydrates induces histone acetylation 
Setdb1 0.0326697 -1.83627 Mediates gene silencing and transcriptional repression 
Lef1 0.0049875 -1.8353 Transcription factor for T-cell receptors 
Kndc1 0.0267347 -1.8341 
Regulates Ras GTPase activity and dendrite 
morphogenesis 
Gm6986 0.0120064 -1.82782 Unknown 
Col6a2 0.020632 -1.8273 
Component of collagen binds extracellular matrix 
proteins 
Ippk 0.0300244 -1.82475 
Mediates DNA repair and endocytosis through inositol-
phosphate signalling 
Timeless 0.0430905 -1.82091 
Involved in DNA polymerase activity, telomere 
maintenance and cell morphology 
C730048C13Rik 0.0126639 -1.82063 Unknown, solute carrier 
Slc9a10 0.0313326 -1.82026 Na+ transporting carboxylic acid decarboxylase 
Enah 0.011655 -1.81313 Axon guidance and T-cell receptor signalling 
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Zfp597 0.0215991 -1.81127 Unknown 
Mbd2 0.0030594 -1.81122 Binds methylated DNA and represses transcription 
4430402I18Rik 0.0030179 -1.80948 Unknown 
B3galtl 0.0208824 -1.80685 Beta 1,3-galactosyltransferase 
Vps13b 0.0355605 -1.80646 Intracellular vesicle protein transport of CNS 
Lgr5 0.0418022 -1.8045 G-protein-coupled receptor  
Chd1l 0.039933 -1.80225 DNA helicase for DNA repair  
Rnf10 0.0066076 -1.80152 
Ring finger protein DNA binding and transcription 
regulation 
Hmcn1 0.0369989 -1.79986 
Immunoglobin, involved in anchorage of neurons to 
epidermis 
Wdr90 0.0235019 -1.79898 Unknown 
Ccdc33 0.032919 -1.79699 Unknown 
Pcsk5 0.0191332 -1.79594 Protein trafficking through the endoplasmic reticulum  
Htr3b 0.049761 -1.79425 Ion channel for fast, depolarizing response in neurons 
Myh7b 0.000595 -1.79347 Heavy chain of myosin (transport) 
F11 0.0400904 -1.79324 Factor 11 in blood coagulation 
Col4a3 0.0341158 -1.79188 Component of collagen  
Zbtb17 0.0187941 -1.78929 Regulation of c-myc (transcription factor) 
Srrt 0.031086 -1.78731 Regulation of transcription 
Chkb 0.0003588 -1.78714 
Formation of phosohocholine or phosphoethanolamine 
by kinase activity 
Tecrl 0.0019138 -1.7857 Unknown 
Alg13 0.0429268 -1.78543 Lipid oligosaccharide biosynthesis  
Ank3 0.0474462 -1.78453 Ankyrin, cytoskeleton anchoring and cell mobility 
Hnf1a 0.0046702 -1.78376 Liver transcription factor 
Clic6 0.0270728 -1.78355 Chloride channel, intracellular transport 
Myo7a 0.01778 -1.78178 Myosin component, compromised in retinal degeneration 
Ubr2 0.0197904 -1.78082 Ubiquitin protein ligase, targets proteins for degradation  
Clcn1 0.0254486 -1.77847 Chloride channel, voltage-sensitive (muscle) 
Cdkl4 0.0059487 -1.777 Cyclin dependent kinase, cell cycle regulation 
Hdac7 0.0285512 -1.77682 
Histone deacetylase, transcription and cell cycle 
regulation 
Eme2 0.0158106 -1.77538 Endonuclease involved in DNA repair 
Myh15 0.0186594 -1.77466 Myosin component, motor activity 
Myo15 0.0261537 -1.77444 Myosin component, motor activity 
Lypd6b 0.0207377 -1.77414 Unknown 
Reg3d 0.0443465 -1.77411 Enhances glucose tolerance, unknown function 
Vti1a 0.0191915 -1.76861 Vesicle transporting, SNARE interactions  
Tyr 0.035644 -1.76852 Facilitates conversion of tyrosine to melanin  
Morc1 0.0141049 -1.76743 Potential in regulating apoptosis 
Ciz1 0.0417301 -1.76299 Zinc-finger protein for CDKN1A interaction  
Itgb2l 0.0265953 -1.76047 Integrin, intracellular adhesions  
C8a 0.0459502 -1.76019 C8 of complement system  
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Cenpk 0.0417527 -1.75707 Kinetochore assembly and mitosis progression 
Ahctf1 0.0486254 -1.75615 Transcription factor for mitotic gene transcription  
Ltbp2 0.0023953 -1.75599 Growth factor, involved in cell adhesion  
Dnahc12 0.0032213 -1.75459 Dynein, microtubule motor activity  
Chd4 0.0391803 1.75029 DNA helicase, histone modifications  
Plg 0.0028306 1.75042 Inhibitor of angiogenesis  
Fras1 0.0203383 1.75069 Extracellular matrix protein for cell adhesion  
Rbl2 0.0395343 1.75129 Retinoblasma-like involved in cell cycle regulation 
Steap3 0.0263896 1.75146 Ferrireductase 
Ldlr 0.0340576 1.75369 
Low density lipoprotein receptor, endocytosis, 
cholesterol metabolism  
Ostf1 0.0028003 1.75443 Cell adhesion, unknown function 
Nusap1 0.0061925 1.75444 Nucleus spindle microtubule formation and integrity 
Esyt1 0.0333224 1.75465 Unknown  
Cdh19 0.0447529 1.75584 Cadherin, glycoprotein involved in cell adhesion 
Ptpn14 0.0377965 1.75649 Mitosis, microtubule associated  
Plbd2 0.0444493 1.75824 Phospholipase B, lipid metabolism 
Trim37 0.0419797 1.75946 Protein-protein interactions  
Mov10l1 0.0119256 1.76008 RNA helicase (testis) 
Asap3 0.0050632 1.76035 Promotes differentiation, cell morphology and mobility 
Plcb2 0.0048519 1.76224 Phospholipase C, lipid metabolism, synaptic function 
Rictor 0.0231411 1.76235 Component of MTOR, growth factor 
Arfgap3 0.0098453 1.76245 GTPase activity, promotes vesicle transport 
Col5a3 0.0262117 1.76265 Component of collagen  
Scn11a 0.0163679 1.76309 Sodium channel, voltage gated, ion regulation  
Lbp 0.0303646 1.76368 Immune response, binds lipopolysaccharides 
Aire 0.0118822 1.76399 Binds CREB, regulates expression of immunity genes 
Dkc1 0.0101854 1.76501 DNA damage repair 
Hepacam2 0.0296601 1.76551 Promotes mitosis and metaphase 
Mmp14 0.0165032 1.76592 Extracellular matrix remodelling 
Nln 0.02361 1.76613 Formation of neurotensin  
Plcb3 0.0120545 1.76731 Phospholipase C, lipid metabolism, signal transduction  
Ubash3b 0.0103796 1.7674 Ubiquitin domain inhibits endocytosis of growth factor 
Psat1 0.0206356 1.77061 
Phosphoserine aminotransferase involved in 
schizophrenia 
Skap2 0.0081311 1.771 Responsible for src signalling pathway 
Strc 0.0479517 1.77119 Stereocilin involved in stereocilia formation 
Atf5 0.0004549 1.77199 Transcription factor inhibiting astrocyte differentiation  
Fam83b 0.0452632 1.77223 MAPK activation and epithelial cell transformation  
Vwf 0.0212629 1.77274 Glycoprotein involved in blood coagulation  
Irak3 0.0261513 1.77409 
Interleukin receptor, inhibits Toll-like receptors in glial 
cells 
Cchcr1 0.0388618 1.77477 Cellular organization and proliferation  
Pls3 0.0403178 1.77554 Plastin involved in actin-binding 
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Ifih1 0.0230229 1.77892 
RNA helicase to remove secondary structure, ribosomal 
formation  
Patz1 0.0384599 1.77933 
DNA binding transcription factor and chromatin 
remodelling  
Siae 0.0263821 1.78277 Deacetylation of sialic acids  
Qk 0.0243801 1.78342 RNA binding protein for oligodendrocyte differentiation 
Ctnna3 0.0031298 1.7871 Intercellular interactions, cell adhesion 
Plin3 0.0392788 1.78726 
Mannose receptor  for transport of lysosomal hydrolase 
to endosome 
Col3a1 0.0050813 1.78733 Component of collagen  
Dock9 0.0227907 1.78862 Mediator of cytokinesis  
Cdkn1a 0.0200694 1.7907 Cell checkpoint cell, mediates DNA damage repair 
Cd53 0.0165928 1.7919 
Cell growth and mobility, recruits T cells and 
macrophages  
Fam129b 0.0432193 1.79195 Junction protein, can inhibit apoptosis processes in vivo 
Mtmr12 0.0174133 1.79408 Lipid phosphatase  
Trpv5 0.0410751 1.79854 Calcium channel involved in ion regulation  
Cbx1 0.0095426 1.80234 Heterochromatin protein to maintain chromatin structure  
Unc93b1 0.0204658 1.80241 
Regulates Toll-receptors trafficking from endoplasmic 
reticulum, immune response 
Clic4 0.038684 1.80258 Chloride channel, intracellular pH and transport 
Nsun2 0.0348147 1.80296 mRNA translation, ensures codon/anti-codon matching 
Trpm5 0.0190737 1.80627 Cation channel, ion homeostasis  
Tmem2 0.0164632 1.80853 Extracellular organization  
Dpyd 0.017076 1.80883 
Uracil and thymidine metabolism, rate-limiting 
pyrimidine metabolism 
Slc4a4 0.0342031 1.80922 Bicarbonate transported for intracellular pH maintenance  
Slc25a30 0.0216791 1.81068 Small molecule inner mitochondrial matrix transporter 
Spef2 0.011715 1.81131 Unknown 
Slamf7 0.0089023 1.81231 Inhibits production of inflammatory cytokines 
Rap1gap 0.0231372 1.81419 GTPase activity  
Atp5g1 0.0464895 1.81564 
Mitochondrial ATP synthase for proton transport during 
OXPHOS 
E030010N08Rik 0.0221112 1.81575 Unknown 
Rbl1 0.0417279 1.81876 Retinoblasma-like involved in cell cycle regulation 
Brip1 0.0323628 1.81949 
Interacts with BRAC1 to mediate double-stranded DNA 
break repair 
Gbp10 0.0079526 1.82162 Immune response via interferon activation  
Erbb2 0.0414782 1.82236 Epidermal growth factor involved in mitosis activation 
Ano5 0.0304613 1.82246 Anoctamin calcuium-cholride channel 
Atp13a5 0.025178 1.82328 ATPase, unknown function 
Ifltd1 0.0465649 1.8238 Unknown 
Depdc1b 0.0204587 1.82578 GTPase activation 
Rnf213 0.0016575 1.82609 Zinc-finger protein for inter-protein interaction  
Lrp2bp 0.0483587 1.82778 Unknown 
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Klhl4 0.037315 1.82864 Actin binding, unknown function 
Dapk2 0.0441918 1.82947 Regulator of pre-programmed cell death  
Ddx60 0.0002651 1.83023 RNA helicase to remove secondary structure 
Fyttd1 0.0002602 1.83227 Unknown 
Lcp1 0.0305862 1.83464 B-cell and T-cell activation and cell migration  
Sh3pxd2a 0.0016584 1.8374 Regulates invadopodia (extracellular protrusions)  
Ccnb3 0.0017382 1.838 Cyclin involved in cell cycle regulation 
Cfb 0.0018594 1.83836 
Complement factor B for complement activation and 
leukocyte recruitment  
Tmc3 0.0438492 1.84376 Ion transport, unknown function 
Nmt2 0.0001749 1.84398 N-myristoyltransferase 2 
Naip5 0.0364918 1.84443 
 Apoptosis inhibitory protein, inhibits proteins involved 
in apoptosis   
Plcg2 0.0092755 1.84448 
Phospholipase C, signal transduction and cellular 
messaging  
Dock1 0.0133594 1.84479 
Dedicator of cytokinesis, induces cell migration and 
phagocytosis   
Gbp5 0.0440096 1.84668 Stimulates inflammation response to foreign antigens  
Cyp27a1 0.0372999 1.84918 Cytochrome P450 variant, drug metabolism  
Zfp330 0.0358616 1.85066 Zinc finger protein, unknown function  
Ttc12 0.0098723 1.85072 Unknown 
Wdr64 0.0307521 1.85187 Unknown 
Cadps2 0.0171056 1.85342 Calcium secretion, synaptic function in neurons 
Itga8 0.0114879 1.85524 Integrin, intracellular adhesions, cytoskeleton formation   
Atp1a4 0.0212119 1.85636 
 ATPase, Na+/K+ transporter, neuron electrochemical 
gradient maintenance  
Tmem77 0.007951 1.85869 Cellular apoptosis inducing  
Slc25a13 0.0030538 1.86195 Mitochondrial glutamate/aspartate transfer 
Parp12 0.018547 1.86243 mRNA post-translational modifications, ADP ribose 
Hydin 0.0313929 1.86592 Cilia formation  
Oprm1 0.0181287 1.87057 Opioid receptor, neuronal G-protein 
Rps6ka1 0.0374657 1.87268 Ribosomal protein kinase, controls cell differentiation 
Gpr64 0.025621 1.87376 G protein-coupled receptor, transmembrane  
Mthfd2 0.0019253 1.87397 Nuclear mitochondrial NAD sequestering 
Nid2 0.0172362 1.87464 Binds collagen, involved in cell adhesion 
Lsp1 0.0468358 1.8747 
Immune cell expression, involved in cell adhesion and 
extracellular remodelling 
Ppfia4 0.0098483 1.87761 
Protein tyrosine phosphatase, receptor type, tyrosine 
phosphorylation 
1700003E16Rik 0.0106796 1.88475 Unknown 
Btk 0.0300985 1.88622 Formation and functionality of B-cells 
Maged1 0.0174606 1.88731 Programmed cell death, cancer antigen presentation 
Slc22a4 0.0382704 1.89398 Solute carrier, cations and zwitterion transport 
Egfr 0.0279557 1.89959 Epidermal growth factor receptor, cell proliferation 
Fanci 0.0060002 1.90404 Fanconi anemia, complementation group I activation 
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Muc5b 0.0041903 1.90453 
Mucin 5B, glycosylated protein involved in mucus 
formation 
Sympk 0.0036757 1.90828 
Post-transcriptional processing, involved in 
polyadenylation 
Meox1 0.019515 1.9114 Developmental signalling 
Atp2c2 0.0266884 1.91293 ATPase, cation transporter, neuron function  
Ano1 0.0409161 1.91376 
Anoctamin 1, calcium activated chloride channel, 
epithelial repair 
Padi2 0.0202878 1.91377 
Post-translational modifications mediated by calcium, 
CNS  
Apoe 0.0235635 1.9157 Apolipoprotein E, metabolism of triglycerides (liver) 
Ncf2 0.0177262 1.91758 Oxidoreductase activity, neutrophil specific  
Map3k6 0.0247556 1.91763 Mitotic activated protein kinase 
Dock11 0.0036392 1.91909 Dedicator of cytokinesis 11, extracellular remodelling 
BC057079 0.0142697 1.92342 Focadhesin, cell adhesion, unknown function  
Col6a3 0.0133423 1.92357 Component of collagen, extracellular matrix binding 
Ppp1r12c 0.0066925 1.92469 
Protein phosphatase 1, cytoskeleton formation and 
organization 
Elmo3 0.0392572 1.92727 Engulfment of apoptotic cells, inflammation  
Ccdc88c 0.0496785 1.93007 Developmental interactions, wnt signalling 
Abca8b 0.0061563 1.9319 ATP-binding cassette, unknown function 
Dnahc17 0.0288871 1.93335 Dynein, microtubule motor activity  
Lrrfip1 0.026914 1.9367 DNA, RNA binding, regulation of transcription 
Slc7a7 0.0483406 1.94032 
Solute carrier, amino acid transporter (cationic and 
neutral)  
4833423E24Rik 0.0361036 1.94104 Unknown 
Sytl1 0.0258357 1.94714 GTPase activating protein  
Rtkn 0.0205158 1.9493 Rhotekin scaffold protein inhibits GTPase Rho 
Orc6l 0.0257836 1.95019 Initiates DNA replication in the nucleus  
Sec24d 0.045669 1.95193 Vesicle transporting in vivo 
Pnldc1 0.0114914 1.95203 Binds poly-A tail of mRNA, unknown function 
Ppp2r1b 0.0226536 1.95427 
Protein phosphatase, regulates protein function in vivo, 
cancer associated 
Abca14 0.0374404 1.95828 ATP-binding cassette, unknown function 
Grhl3 0.0425524 1.96065 
Developmental transcription factor, endothelial cell 
migration  
Sorbs2 0.0308871 1.96262 Cytoskeleton modifications  
Hk1 0.0367158 1.96385 
Hexokinase, glucose metabolism and glycolysis 
regulation 
Itpr3 0.0090388 1.96463 
Inositol 1,4,5-trisphosphate receptor, regulates calcium 
homeostasis 
Pyroxd2 0.0302111 1.96623 Unknown 
Soat1 0.0179412 1.96706 Formation of fatty acids and cholesterol  
Eng 0.043215 1.97004 Vascular endothelial glycoprotein receptor 
Slc7a1 0.0123391 1.97223 Solute carrier, cationic amino acids  
Trim6 0.0210848 1.9726 Unknown 
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Fbxl13 0.0324725 1.97696 Cleave ubiquitin from ubiquitination products  
Spata6 0.0456238 1.9815 Spermatogenesis, cell differentiation, unknown function 
Lrrc9 0.0356599 1.9848 Unknown 
Myh3 0.0268801 1.98504 Myosin component, motor activity, cell transport  
Zfp599 0.0370838 1.9856 Zinc finger protein, unknown function  
2310008H04Rik 0.0400248 1.98643 Unknown 
Cacna1h 0.0118042 1.98808 
Calcium channel, voltage-dependent, maintenance of 
membrane potentials  
Tbc1d4 0.0315198 1.99166 
Mediates transport of GLUT4 from endoplasmic 
reticulum to plasma membrane 
Dhx40 0.0420537 1.99427 RNA metabolism, helicase  
Cep250 0.0243675 1.99597 Centrosome formation and function during mitosis 
Gk5 0.0480136 1.99773 Primary, regulatory step of glycerol metabolism 
Slc12a1 0.0416418 1.99777 Solute carrier, unknown function 
Abca9 0.0438495 1.99907 ATP-binding cassette, unknown function 
Klk1b16 0.0251047 2.00083 Unknown 
Lama2 0.01227 2.0026 
Laminin component, extracellular component for 
remodelling and organization 
Atp8b1 0.0192593 2.00292 Aminophospholipid transporter  
Baiap3 0.0003945 2.00342 
Angiogenesis regulator in the brain, involved in synaptic 
function  
Igfbp3 0.0358018 2.00685 Insulin-like growth factor binding protein  
Lmna 0.0164179 2.00747 Nuclear lamin, nucleus stability and chromatin structure 
Ephx1 0.0429007 2.00765 
Conversion of epoxides to trans-dihydrodoils for 
excretion  
Scn4b 0.0418185 2.0079 Sodium channel, voltage-gated  
Samd4 0.0318405 2.00926 RNA-binding, postranscriptional regulation  
Cyfip1 0.0210452 2.0136 Regulates cytoskeleton and axon growth/formation 
Fbln2 0.0057021 2.01365 Extracellular, neuronal structure development 
Ankrd26 0.0291523 2.02058 Ankyrin, protein-protein interactions 
Eya4 0.0268545 2.02241 Eye development, transcription activation  
Mx2 0.0307161 2.02348 
Dynamin and GTPase activity, heterochromatin 
formation 
Ifnar2 0.0370614 2.02687 Interferon receptor, activates Janus kinases  
Wdr62 0.0108659 2.03409 Cerebral development, function unknown   
Kif14 0.0261951 2.03591 Kinesin, microtubule motor protein for transport 
Aldh1l1 0.0205617 2.03926 
Aldehyde dehydrogenase for removal of cytotoxic 
aldehydes 
Syk 0.0130348 2.04443 
Tyrosine kinase involved in cell proliferation, 
differentiation and phagocytosis 
Ddb2 0.0142656 2.04721 DNA damage repair from UV light damage 
Flnc 0.0458499 2.04823 Filamin involved in anchoring of actin cytoskeleton 
4930452B06Rik 0.0425945 2.05001 Unknown 
Kntc1 0.0116476 2.05073 Mitotic chromosome separation during anaphase 
Arhgef10 0.0173248 2.0533 Rho GTPase, stimulates G-proteins 
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Lamc2 0.0297158 2.05539 
Laminin component, extracellular component for 
remodelling and organization 
Stab1 0.0215188 2.05942 
Stabilin, receptor that endocytoses AGES, bacteria and 
lipoproteins 
Notch1 0.0027652 2.06196 Intracellular signalling pathway mediator 
BC006779 0.0150289 2.06524 DNA helicase, transcriptional activation  
Klf4 0.0404938 2.06701 Transcription regulation and activation  
Sfmbt2 0.0316905 2.07112 Regulation of transcription 
Rgs22 0.0449781 2.0731 Regulator of G-protein signalling 
Atp8b4 0.0050661 2.07605 Cation ATPase channel for phospholipid transport 
Pde2a 0.0162072 2.07675 
Phosphodiesterase, regulates endothelial cell 
proliferation and angiogenesis   
Col25a1 0.0282262 2.07705 Component of collagen, brain specific   
Tmbim1 0.0386395 2.07758 Inhibits apoptosis by reducing FAS trafficking   
Abcc3 0.0025065 2.07795 ATP-binding cassette, transport of anions  
Msn 0.0492673 2.07988 
Moesin, links plasma membrane to actin as well as 
filopodia formation  
Sult5a1 0.0181227 2.08116 Unknown 
Baiap2l1 0.0451011 2.08365 
Remodelling of the plasma membrane and cytoskeleton 
pedestal formation  
Col19a1 0.0015986 2.08366 
Component of collagen, maintenance of extracellular 
matrix 
Pnpla7 0.0413459 2.08459 Lipid metabolism, function unknown  
Col5a2 0.0343231 2.08489 Component of collagen  
Tap2 0.0128675 2.08507 
ATP-binding cassette, transport of peptides to 
endoplasmic reticulum  
Fgfr2 0.0317797 2.08935 
Fibroblast growth factor receptor, mitosis and 
differentiation  
Fblim1 0.0248279 2.10192 Cell-cell adhesion modifications  
Ecm2 0.0480193 2.10255 Extracellular matrix protein, function unknown  
Dock2 0.0211604 2.10412 Cytoskeleton modifications for lymphocyte mobility  
Taf1d 0.0085981 2.11135 RNA transcription regulation  
Col1a2 0.0138499 2.11752 Component of collagen  
Magt1 0.023233 2.12737 Magnesium transporter, N-glycosylation associated  
Nckap1l 0.0115969 2.12884 Cell morphology regulation (hematopoietic)  
Ccdc150 0.0115571 2.12925 Unknown 
Cd68 0.0202543 2.13446 
Glycoprotein in microglial cells, promotes activation of 
macrophages 
Svep1 0.0457553 2.13766 Unknown 
Frem2 0.0232823 2.13927 Basement membrane epithelia protein  
Vwa1 0.008256 2.14086 Extracellular matrix protein 
Pebp4 0.0195098 2.14353 Lipid binding, unknown 
Lrrk1 0.0116593 2.14701 Unknown  
Gbp4 0.0277205 2.15078 Guanylate binding protein, interferon induced  
Plcl2 0.009802 2.152 Phospholipase C, modifications to GABA receptors  
Sgsm1 0.0143354 2.15698 G-protein signalling, GTPase activity  
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Ccl24 0.0205018 2.15907 Cytokine CC, activates T-lymphocytes  
Kitl 0.0309238 2.16085 
Tyrosine-kinase receptor, neural cell development, cell 
mobility 
Kif20a 0.0312462 2.16108 Kinesin, microtubule motor protein for transport 
Dnahc1 0.0089948 2.17058 Dynein, microtubule motor activity  
Calcrl 0.0195045 2.17483 Calctonin receptor 
Abcc4 0.0495595 2.18036 ATP-binding cassette involved in anion cycling 
Abca13 0.0068074 2.18061 ATP-binding cassette, transport (unknown function)  
H2-D1 0.0232616 2.1838 Major histocompatibility component  
Hpse 0.0361428 2.18872 
Heparanase, component of extracellular matrix and cell 
mobility 
Nt5dc1 0.0014142 2.19853 5'-nucleotidase protein 
Abca12 0.0210858 2.20527 ATP-binding cassette, small molecule transport 
Ecm1 0.0133792 2.20762 Cell structure interaction for extracellular remodelling  
Pth1r 0.0414317 2.21192 Parathyroid hormone receptor  
Mertk 0.0157256 2.21711 
MER/AXL/TYRO3 receptor kinase, involved in RPE 
phagocytosis  regulation 
Myom2 0.0104973 2.21919 Myomesin 2, muscle cell component 
Clca1 0.0381724 2.22377 Chloride channel accessory protein  
Pappa2 0.0093243 2.22752 
Regulates intracellular insulin-like growth factor 
availability  
AW551984 0.0204154 2.23252 Unknown 
Nrap 0.0457788 2.23485 Nebulin-related anchoring protein, actin binding  
Myo5c 0.0035317 2.23524 Myosin component, actin motor activity  
Pld2 0.0463916 2.23549 
Hydrolysis of phosphatidylcholine, cell cycle and 
transcription regulation 
Serpina3a 0.0458079 2.23824 Serine peptidase inhibitor  
Iqgap3 0.0152522 2.23908 GTPase activation  
Ermp1 0.026493 2.24009 Endoplasmic reticulum metallopeptidase 
Tnxb 0.0431861 2.24326 Tenascin, reduces cell adhesion 
Fut8 0.0406937 2.24542 Transfers fucose to glycopeptides  
4933428G20Rik 0.0347269 2.24603 Unknown 
Mpa2l 0.0362691 2.24733 Macrophage activation like, GTPase activity  
Trpm4 0.0428844 2.25314 Calcium ion channel, non-selective  
Myof 0.0059642 2.27105 Membrane vesicle formation, membrane fusion 
Pkhd1l1 0.0083783 2.2745 Potential role in immune response 
Poln 0.0388691 2.2817 DNA polymerase subunit 
Fn1 0.0160342 2.2906 Fibronectin glycoprotein, cell mobility  
Sfrp4 0.0167618 2.29162 Regulates Wnt signalling, receptor protein   
Myh11 0.02687 2.30494 Myosin, microtubule motor activity  
Plin1 0.0405267 2.30902 Lipid storage, lipolysis regulation and inhibition 
Ccdc46 0.0344049 2.31067 Unknown 
Efcab7 0.0026008 2.32595 Unknown 
Scml2 0.033619 2.33493 Transcription regulation (inhibition), polycomb protein 
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Myo15b 0.0067032 2.33608 Myosin, microtubule motor activity  
Cd93 0.0376391 2.33913 Immune response to apoptotic cells, cellular migration  
Aldh2 0.0450249 2.34462 
Aldehyde dehydrogenase for removal of cytotoxic 
aldehydes 
Kynu 0.0160715 2.34696 
Amino acid metabolism of tryptophan, NAD 
regeneration  
C920025E04Rik 0.0365824 2.34911 Major histocompatibility binding protein 
Galnt3 0.0292916 2.35444 Polypeptide N-acetylgalactosaminyltransferase  
Dse 0.0420728 2.36637 Induces immune response  
Gpd2 0.0399365 2.37661 Secondary step of glycerol metabolism, glycerol shuttle  
Pdzrn4 0.0249827 2.39325 Zinc-ring finger protein, unknown function  
Adhfe1 0.0358737 2.39843 Alcohol dehydrogenase 
Vipr1 0.0160948 2.40598 Activation  of adenylate cyclase  
Fxyd5 0.0435462 2.40968 
Ion transport regulator, functions during high chemokine 
production  
B2m 0.0238666 2.42012 
Major histocompatibility complex heavy chain 
associated, microglial activation 
Renbp 0.0156324 2.42411 N-acetylglucosamine metabolism 
Dlec1 0.0277845 2.4261 Deleted in cancer progression, unknown function 
Itpr2 0.039317 2.43982 Inositol 1,4,5-trisphosphate receptor, cell signalling 
Slc44a5 0.0399251 2.44105 Solute carrier, unknown function 
Igtp 0.0366583 2.44422 Interferon gamma subunit 
Fas 0.0160064 2.45018 TNF receptor for cell apoptosis  
Mvp 0.0233917 2.45571 Regulates MAP kinase for drug metabolism 
Ncapd2 0.0265338 2.46031 Binds histones during mitosis 
Sec16b 0.0451595 2.46535 
Endoplasmic reticulum organizational transport of 
mature proteins  
Tspan12 0.0455787 2.47621 Cell surface tetraspanin for cell growth and mobility  
Slc15a1 0.0488859 2.48534 Oligopeptide transporter for protein metabolism 
Osmr 0.0118207 2.49015 Interleukin receptor for inflammation response 
Gm7298 0.0104095 2.49301 Unknown 
Thsd7b 0.0234948 2.51864 Unknown 
1700011F14Rik 0.0159698 2.53491 Unknown 
Clic5 0.0454731 2.54845 Chloride intracellular channel 
Diap1 0.038375 2.54863 Axon guidance and elongation 
Nup133 0.0421358 2.54899 Formation of nuclear envelope during mitosis 
Mmel1 0.0193461 2.56265 Endopeptidase for phosphate homeostasis 
Atp10d 0.0486888 2.57034 
ATPase ion transport across concentration and 
electrochemical gradients 
Obfc2a 0.0140833 2.57695 
Single-stranded DNA binding protein for replication, 
repair and recombination 
Nos2 0.0316639 2.58763 Nitric oxide synthase for regulation of nitric oxide 
F3 0.0378579 2.58869 Factor 3 in blood coagulation  
Dnahc8 0.0312568 2.60645 Dynein, microtubule motor activity  
Sdk2 0.0422683 2.60932 Immunoglobin, synaptic maintenance 
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Pola1 0.0082495 2.61239 
Subunit of DNA polymerase involved in initiation of 
DNA replication  
Myo1e 0.0024885 2.61773 Non-muscle myosin for actin motor activity 
Dysf 0.0130688 2.64452 Membrane repair and regeneration 
Zfp748 0.0486775 2.67676 Unknown, zinc-finger protein 
Csmd2 0.00496 2.68896 Unknown 
Mllt4 0.0447334 2.70289 
Organization of cell junctions and extracellular 
interactions 
Cast 0.0018883 2.71118 
Calpain inhibitor which is involved in neuronal vesicle 
trafficking 
Aox3l1 0.0153934 2.71173 Retinol and amino-acid metabolism  
Asah2 0.0132518 2.71609 Production of sphingosine, induce apoptosis 
Fndc3c1 0.0074993 2.72731 Fibronectin 
Lama3 0.0032464 2.78592 Extracellular remodelling and migration  
Rassf2 0.0486192 2.78738 Tumor suppressor gene, Ras associated 
Mug1 0.0151463 2.80096 Unknown 
Cps1 0.0242031 2.81088 
Primary, regulatory step of urea cycle and ammonia 
removal 
Il18r1 0.0389371 2.81156 
Interleukin receptor for microglial activation and 
cytokine release 
Myh9 0.0255247 2.82263 Non-muscle myosin for cell mobility and morphology 
B230120H23Rik 0.0352319 2.82642 Unknown 
Utp20 0.0292205 2.84246 Small nucleolar RNA for 18S assembly 
Abca15 0.0133014 2.84975 ATP-binding cassette  
Adcy10 0.0050507 2.85833 Intracellular bicarbonate sensor and pH regulator 
Dock10 0.0090131 2.89996 Directs cytokinesis  
Hhip 0.0086926 2.91551 Involved in hedgehog recruitment for development 
Nrk 0.0136839 2.94234 Activates JNK pathway 
Clspn 0.0035071 2.94334 Cell cycle checkpoint protein, arrests cell cycle 
Gmnn 0.0215492 2.99088 Inhibits DNA replication, cell cycle checkpoint protein 
Cd97 0.0149192 2.99546 
Intercellular interactions, involved in leukocyte 
activation and recruitment  
Xdh 0.0064959 3.00028 Metabolism of purines, involved in microglial activation  
Myo1c 0.0374662 3.00731 Myosin component for actin motor transport 
Als2cl 0.0282106 3.0433 Protein localization and transport  
Myo1f 0.0001664 3.04358 Myosin component for microtubule transport 
H2-K1 0.0371741 3.06774 Major histocompatibility component  
Nfkbil2 0.0214434 3.14832 Inhibits NF-kappa-B activation  
F13a1 0.0234937 3.21301 Factor 13 in blood coagulation  
Plec1 0.0253006 3.22776 Unknown 
Kif4 0.0073226 3.3724 Kinesin microtubule motor activity 
Trpm6 0.0435942 3.47521 Ion channel for magnesium transport in epithelial cells 
Csmd3 0.0211546 3.53038 Unknown 
Bub1b 0.0050054 3.78249 
Spindle checkpoint to inhibit cell cycle until proper 
chromosome separation 
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Dpp4 0.0179589 4.02866 T-cell activation, involved in immune response  
Muc5ac 0.0183852 4.03264 Extracellular remodelling 
* Microarray was performed by A. Laliberté (2010).
103
 Cut-offs set at: Fold change > ± 
1.75, p < 0.05. 
† 
Annotation based on NCBI Gene
184
 [National Center for Biotechnology Information, 
U.S. National Library of Medicine, Bethesda MD] 
‡ Pathway is ordered by increasing p-value.  
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